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Abstract 
This study examines the impact of general anaesthesia, surgery and perioperative atorvastatin 
on Alzheimer's disease pathology in mice.  A progressive neurodegenerative condition of complex 
aetiology, Alzheimer's is a common cause of dementia in humans but has no disease modifying 
treatment.  Its long pre-symptomatic phase and lack of known biomarkers means asymptomatic 
individuals are exposed to modifiable risk factors in early life that influence disease progression 
and trajectory in the long term.  Anaesthesia with surgery may be a modifiable risk factor.   
Neuroinflammation is a common feature of anaesthesia with surgery and Alzheimer's.  
Atorvastatin has potent anti-inflammatory pleiotropic effects that may be a useful perioperative 
intervention to modulate any acute on chronic neuroinflammatory interaction.   
The effects of the anaesthetic agents, isoflurane, nitrous oxide and xenon, were observed in 
immortal human cell lines that over-express APP and also in primary mouse hippocampal 
neurones incubated with βAmyloid.  Altered distribution of APP, BACE-1 activity and differing 
expression of cleaved caspase-3 and BCL-2 were observed post exposure, with no change in -
secretase expression. 
The effects of anaesthesia, unilateral nephrectomy surgery and atorvastatin on pre-symptomatic 
and older APP23 mice (a murine model of Alzheimer's) were examined using behaviour 
techniques including Trace Fear Conditioning, Morris water maze and Y maze.  Genotype 
dependent differences in learning were detected in different paradigms, as well as a post 
modifiable risk factor deficit in novel learning that was not seen after introduction of atorvastatin.  
Y maze performance showed changes in exploratory drive and working memory after the 
modifiable risk factor. 
Markers of neuroinflammation, synaptic function and A pathology were quantified, showing a 
neuroinflammatory response and altered A pathology, but no detectable change in synaptic 
marker after the modifiable risk factor.   
Anaesthesia with surgery does affect Alzheimer's neuropathology in mice, with perioperative 
atorvastatin changing both novel learning and working memory after anaesthesia with surgery.   
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“Eine Frau von 51 Jabren zeitge als erste auffällige Krankheitserscheinung Eifersuchtsideen gegen 
den Mann.  Bald machte sich eine rasch zunebmende Gedächtnisschwäche bemerkbar, sie fand sich 
in ihrer Wohnung nicht mehr zurecht.  Schleppte die Gegenstände hin und her, versteckte sie, 
zuweilen glaubte sie, man wolle sie umbringen and begann laut zu schreien. 
In der Anstalt trug ihr ganzes Gebaren den Stempel volliger Ratlosigkeit.  Sie ist zeitlich und ortlich 
ganzlich desorientiert.  Gelegentlich, macht sie Äußerungen, daß sie alles nicht verstehe, sich nicht 
auskenne.. “ 
 “One of the first disease symptoms of a 51-year-old woman was a strong feeling of jealousy 
towards her husband.  Very soon she showed rapidly increasing memory impairments; she could 
not find her way about her home, she dragged objects to and fro, hid herself, or sometimes thought 
that people were out to kill her, then she would start to scream loudly. 
  
During institutionalization her gestures showed a complete helplessness.  She was disoriented as to 
time and place.  From time to time she would state that she did not understand anything, that she 
felt confused and totally lost..” 
Alzheimer A.   
Über eine eigenartige Erkrankung der Hirnrinde.   
Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin. 
 1907 Jan;64:146-8.   
Translated by Dr Katherine L. Bick.   
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Statistical analysis 
Details of tests used for statistical analysis are provided in the figure descriptions.   
All tests for normality were performed using D'Agostino & Pearson omnibus normality test. 
Where data were collected longitudinally linear mixed model was used to derive time-adjusted 
changes in outcome over time since baseline.  MIXED procedure in SAS was used by fitting 
values of the outcome from all time-points as a dependent variable.  Independent variables 
included the fixed effects of intervention, study time-points and intervention by time 
interaction.  An unstructured covariance matrix was used to model the within patient errors.  Data 
are presented as mean of the estimate of the outcome at each time point. 
Longitudinal analysis was performed using SAS v9.3 and all p-values presented are two tailed. 
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Chapter 1 Introduction 
1.1 General introduction 
Alzheimer’s disease (AD), a progressive neurodegenerative condition, is the most common cause 
of dementia.  Its incidence is predicted an imminent exponential growth1 due to an ageing global 
population.  Although primarily driven by pathology within the brain, AD causes a progressive 
cognitive and physical decline, and is ultimately fatal.   
Its aetiology is complex; current treatment options only partly mask symptoms and offer no 
disease modifying potential.  A disease under close scrutiny for decades, despite global research 
efforts, no therapeutic options to stop or reverse the process have been found, and few look 
promising.  The cost of AD on those affected and their families is beyond estimate.   
The main risk factor for AD is ageing, and an understanding of the complex interplay of 
pathological factors affecting neuronal and glial health that converge to drive the disease process 
are only starting to emerge.  An established understanding of AD pathogenesis revolves around 
three key players:  
1. Amyloid beta (A), the product of sequential cleavage of the transmembrane signalling 
molecule Amyloid Precursor Protein (APP) by - and  secretases, which function in 
cholesterol rich membrane micro-domains.   
2. Hyperphosphorylated Tau (), a key molecule of intracellular trafficking.   
3. Neuroinflammation, the innate but distorted inflammatory response of the Central Nervous 
System (CNS).   
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase antagonists (statins) are 
cholesterol-lowering drugs that possess a range of potent anti-inflammatory pleiotropic effects 
and may modulate the interplay between these factors in the chronically inflamed AD affected 
brain.   
An anaesthesia, surgery and AD link was first suggested after clinical observation noted a 
worsening of neurocognitive deficits in patients after surgery.2  In NHS hospitals, an estimated 
2.9 million patients undergo anaesthesia with surgery each year.3  Most receive volatile 
halogenated ethers; a group of drugs increasingly recognised to cause structural and functional 
brain changes that are protective or damaging, both in the short and long term.   
 
23 
Interplay between several patient and surgical factors during the perioperative period contribute 
to the overall effect that anaesthesia with surgery has on the brain and its function in the long 
term.   
With this in mind, and in light of longer life and increased survival of high-risk patients after major 
anaesthetic and surgical interventions, strategies to preserve cognition during the perioperative 
period becomes a high priority.   
This investigation attempts to clarify the impact of anaesthesia, and anaesthesia with surgery, on 
cognitive functions affected by molecular components of AD, how neuroglial activity and 
interaction is affected, and if the statin drug atorvastatin offers therapeutic potential.   
1.2 Cognition and the brain 
The brain is home to the resources that enable the instinctive, innate and learnt behaviours 
necessary for the survival of an animal; it is the home of cognition.   
1.2.1 Cognition 
The fundamental mental activities involved in acquiring and processing information, applying 
knowledge and changing preferences - such mental processes required for everyday living, are 
described as cognition.4   
Cognition and intelligence are very different things.  Cognition enables the individual to reason at 
a basic level, problem solve (such as the manoeuvres needed to put on a shoe), make plans 
(such as how to map and follow a memorised route out of a building), to understand and use 
language (to recognise the significance of the sound and its order) and can be both conscious 
and unconscious processes.  It is a basic function needed to support an individual’s independent 
survival.  As such, cognitive failure holds significant consequences to both the individual, those 
that care and are responsible for them, and the community and society at large.   
1.2.2 Cognition and ageing 
Normal healthy ageing includes mild changes in memory and the rate of information processing 
that are not progressive and do not affect daily function.  This may include a decline in the rate of 
learning new information, but is without impairment in memory retention.   
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1.3 Cognitive change: neurocognitive disorders 
Cognitive changes are common in all age groups preceding, during and after anaesthesia, 
surgery and acute illness, but are more commonly recognised at the extremes of age.  
Despite evidence linking new cognitive change following anaesthesia with surgery with poorer 
outcomes and increased morbidity and mortality,5,6 it is often unrecognised.   
Strong risk factors for neurocognitive disorder in the perioperative setting are: increasing age, 
level of patient education and the severity and duration of anaesthesia with surgery.7   
Neurocognitive disorders are categorised into three distinct clinical conditions depending on time 
course and reversibility: delirium, postoperative cognitive decline (POCD) and dementia.  Each 
are diagnostically distinct but can be triggered and exacerbated by physiological stress 
associated with illness, hospitalisation, anaesthesia and surgery.   
1.3.1 Delirium 
Delirium is defined as any acute, fluctuating mental disturbance, characterised by a disturbance 
of attention, cognitive deficit and reduced awareness of the environment.8   
Delirium is common9,10 but under diagnosed11 and manifests as hypoactive,11 hyperactive or 
presenting with mixed psychomotor behaviours.  Often transient (typically up to 7 d in duration), 
symptoms include a disturbed sleep wake cycle, emotional disturbance, hallucinations, 
perceptual distortion (typically visual) and impairment of memory.  Perioperatively, symptoms of 
delirium are fluctuant (often worse at night) and emerge after a period of initial lucidity.   
Delirium is common in older adults after surgery, but estimates of incidence vary from 0 – 82%.12  
The already more vulnerable ageing brain more frequently decompensates in the context of the 
controlled traumatic event of surgery, regardless of the mode of anaesthesia.13   
Surgery does not occur alone, and often the perioperative period introduces several factors that 
each contribute independently to delirium risk.  Predisposing factors in perioperative patients 
include dehydration and electrolyte imbalance (notably hypernatremia and hypomagnesaemia), 
substance withdrawal, severe acute or chronic illness, drug effects,14 immobility15 and restraint, 
perioperative blood loss, transfusion and infection.  These are exacerbated by the stress response 
to surgery.   
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Anticholinergic burden is also implicated.  Elderly patients are already at increased risk due to 
existing brain pathology16 and long term polypharmacy17 in the community.  Anticholinergic effects 
are frequent in drugs used during anaesthesia, both as routine parts of a balanced anaesthetic 
e.g. steroids as anti-emetics, and to treat physiological responses to surgery and improve 
operative conditions.   
Delirium is associated with raised levels of pro-inflammatory cytokines during the perioperative 
period, including Interleukins (Il) Il-6 and Il-8,18 and those who develop delirium show distorted 
inflammatory and cholinergic balance.14  Likewise, raised levels of cerebrospinal fluid (CSF) Il-1 
are detectable before the onset of delirium symptoms in elderly patients with traumatic hip injury,19 
postoperative stress markers being linked to delirium risk.20   
In hospitalised patients, delirium is associated with poorer outcomes6 and predisposes persistent 
neurocognitive deficit.21   
1.3.2 Postoperative cognitive decline (POCD) 
POCD describes a postoperative change in cognition that is subtle but long lasting, and 
sometimes permanent.  Affecting learning, concentration, memory, and speed of mental 
processing, symptoms include changes in ability to focus on a task, inability to multitask, difficulty 
with word finding and recall of recently acquired information.  These occur in the context of recent 
anaesthesia with surgery, even after minimally invasive surgery,22 and resolve over weeks to 
months, but can be permanent.   
POCD affects surgical patients of any age.  Strong risk factors include increasing age (over 60 
years), depth of anaesthesia,23 pre-existing cognitive decline24 and the severity of surgical 
trauma.25  Reported incidence rates vary depending on patient factors and are different for 
cardiac26 and non-cardiac surgery.7,27  Symptoms emerge days or weeks after anaesthesia with 
surgery and show faster resolution in younger individuals25 who are less vulnerable in terms of 
their brain.  Anticholinergic burden is again implicated.27   
Delirium and short term POCD are linked.28  Inflammation after major sterile surgery29 is 
adequate, particularly for the vulnerable brain, to trigger neuroinflammation linked to POCD.30  
Anti-inflammatory strategies have been effective in animal models of POCD, where an intra-
cisternal injection of Il-6 antagonists during laparotomy in aged rats attenuated both learning 
deficits in the Morris water maze (MWM) and up-regulation of several pro-inflammatory cytokines 
in their brain, 24 hours after surgery.31   
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1.3.3 Dementia 
Dementia, or major neurocognitive disorder, is described as an "impairment of memory and of 
abstract thinking, often with other disturbances of cognitive function and with personality 
change".32  This is severe enough to interfere with daily function, with relationships and 
independence, occurs in the absence of delirium and is not better explained by another mental 
disorder.  The Diagnostic and statistical manual of mental disorders V8  modified the diagnostic 
criteria in 2013 to include significant acquired cognitive impairment in at least one of the six 
cognitive domains including learning and memory, language, executive function, complex 
attention, perceptual-motor function and social cognition.  Memory impairment is always present.  
Cognitive change in dementia occurs longitudinally, presenting as a decline when compared to 
previous function.  Serial examinations and assessments reveal a progressive condition of 
insidious onset.  Although primarily a disorder of the CNS, dementia is a syndromic disease with 
multiple organ systems affected over time, secondary to a global loss of function.  Extra CNS 
symptoms may feature more strongly in some syndromes than others and dementia frequently 
has more than one cause as the disease progresses.   
The causes of dementia include: Alzheimer’s disease (AD); vascular (multi-infarct) dementia; 
dementia with Lewy bodies; Parkinson’s dementia; Pick's disease, alcohol-related dementia; 
Fronto-temporal dementia; Chronic traumatic encephalopathy; HIV encephalopathy; Progressive 
supra nuclear palsy; Huntington’s disease and Creutzfeld-Jacob disease.  Each have similar, but 
different pathological hallmarks.  Many are associated with amyloidopathy and tauopathy, 
although the nature and distribution of these aggregates varies with the diagnosis.   
Risk factors for dementia include positive family history, the risk factors for cerebrovascular 
disease (including hypertension in middle age, Type 2 diabetes, hypercholesterolemia and 
obesity), depression, chronic psychological stress and traumatic brain injury.  Both delirium and 
POCD are associated with an increased risk of dementia in the long term,33 and an accelerated 
rate of functional decline is seen in patients with dementia who suffer an acute delirium of any 
cause.34   
1.3.4 The link between acute and chronic neurocognitive disorders 
Acute physiological stress on any organ system can precipitate decompensation and organ 
failure.  The relationship between the neurocognitive disorders is possibly but another example.  
A strong neuroinflammatory stimulus from the periphery can cause acute decompensation and 
brain failure in an organ already responding to an on-going but subclinical chronic disease 
process.  This raises the question of whether the underlying pathophysiology of the three 
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neurocognitive conditions described here, delirium, POCD and dementia, are linked.4  
Neuroinflammation is a feature common to all three.30,35,36  However, evidence for a unifying 
mechanism that transforms the self-limiting neuroinflammatory response seen in delirium and 
transient POCD into one that is persistent in dementia, as in Figure 1-1, is yet to be established.   
1.3.5 The scope of the clinical problem 
The burden of perioperative cognitive change is likely to increase in the future, as ageing 
individuals become the greatest consumers of surgery,37 notably in the context of better surgical 
survival of older people with more complex health problems.   
Estimates of POCD incidence are consistently reported at 10 – 15 % at 3 months, increased in 
those over 60 years of age, and in those with pre-existing neurodegenerative brain pathology.  
Consequently, the proportion that proceeds to develop permanent neurocognitive deficit after 
surgery is set to increase.   
Given the evidence that postoperative cognitive change is linked to dementia,33,38 the hunt for 
effective perioperative cognoprotective strategies is a priority.   
1.4 Alzheimer’s Disease 
AD derives its name from Alois Alzheimer (1864 – 1915), the German neuropathologist and 
psychiatrist who first published a clinical and pathological account of the disease in 1907.39   
The disease typically presents with clinical symptoms of amnesic declarative memory impairment, 
confusion and disorientation, progressing to a loss of insight, personality change, impairment of 
language function and visuospatial skills.  However, presenting symptoms differ with age of 
disease onset.40  Neuropsychiatric symptoms, including delusion and paranoia, develop with 
disease progression, as do motor deficits.   
The prominent feature of AD is a loss of cognitive ability, leading to dementia.  Incidence rates 
vary widely, but consensus is achieved on the fact that incidence increases with age,41 is going 
up, and that the burden of the disease lies in developing countries.42   
With an ageing population, a global epidemic of AD is anticipated,43 making AD a major public 
health concern.   
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1.4.1 AD risk factors 
Age 
Increasing age is the strongest risk factor for sporadic AD.  Prevalence and incidence rates 
increase exponentially with age, most notably over the age of 70 years.41   
Chronic disease 
Several comorbidities are common to AD and vascular dementia, including chronic hypertension, 
diabetes and hypercholesterolemia; improvements in the management of cardiovascular risk may 
modify this.   
Familial mutations of A 
Several risk factor genes are directly or indirectly involved in A production or processing.  These 
include several genes encoding mutant APP44 and -secretase (PSEN1 and PSEN2).45,46  These 
mutations favour A1-42 production, a more amyloidogenic isoform of A.  
Trisomy 21 is also a causative factor for early onset dementia, as APP is encoded on 
chromosome 21 and over expressed in trisomy.   
Genetic 
Genetic risk factors are known to play a role in AD independent of the autosomal dominant 
familial forms.  Genome-wide studies show that several risk genes are associated with higher 
incidence, but not with earlier or more severe pathology.  These include the gene Apo E 4, 
associated with a 3 – 10 fold increase in AD, depending on gene dose.47  Also, loci influencing 
biological pathways including endocytosis (BIN1 and PICALM), immune, complement and 
inflammatory responses as well as cholesterol metabolism (CR1, CLU, HLA-DRB1 and 5), have 
each been identified as having significant associations.48  The risk due to each single risk gene 
is small but combinations of 'risk alleles' may be significant in risk profiling.  Emerging gene data 
suggest they may account for an estimated 70% of the risk of AD.49   
Familial mutations of  
The relationship between  mutations and AD is complicated in that, although tauopathy is seen 
in AD, major tauopathy causing mutations of  are associated with dementia but without amyloid 
deposition50 and therefore are not AD.  However, polymorphisms of phosphokinases (enzymes 
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that catalyse phosphorylation) such and DYRK1A and GSK3-, which also contribute to amyloid 
pathology,51 may be associated with AD.   
Other vulnerable individuals 
It is suggested that AD is a disease continuum where subtle, subclinical AD-related brain changes 
begin decades before the manifestation of any memory symptoms.52  Individuals with AD 
phenotype early in the continuum have measurably altered levels of AD-related biomarkers in 
CSF and blood, but are entirely asymptomatic.  Some may progress to develop mild memory 
symptoms (Mild Cognitive Impairment), whereas others (approximating 50%) will see disease 
progression towards more severe and end stage AD.  Conceivably, a cohort of individuals with 
AD phenotype outlive the subclinical disease, dying in old age of unrelated causes, whilst their 
disease remains preclinical.   
Individuals with AD phenotype and preclinical AD are therefore exposed to disease modifying risk 
factors throughout life, potentially altering disease trajectory in the long term.   
1.4.2 Pathological hallmarks of AD 
The core pathological hallmarks of AD are a disordered expression of A (as soluble and 
aggregate forms), neurofibrillary tangles of hyperphosphorylated 53 and neuroinflammation.   
1.4.2.1 Amyloid Precursor Protein 
Upstream of A is APP, a 677 – 770 amino acid residue in length transmembrane protein encoded 
on chromosome 21.   
 APP is a cell surface protein with receptor function that features in the regulation of cell adhesion, 
neurogenesis and neuronal growth.  Found as 10 isoforms in humans (due to alternative splicing), 
isoform 695 predominates in the brain.  Expressed in all tissues, including blood cells, plasma 
and CSF, regional differences in APP expression are found in the brain, with the highest levels in 
the cortex and lowest in motor cortices.   
APP plays a complex role in the response to oxidative stress and is microtubule-associated, 
mediating the intracellular transport of secretase enzyme components.  It plays a role in cell and 
neurite growth through binding components of the extracellular matrix including collagen.  APP is 
also linked with apoptosis inducing pathways and neuronal death.  Products of cleavage include 
A and other molecules that regulate activation of transcription.  APP mutations cause autosomal 
dominant familial AD and cerebral angiopathy.   
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1.4.3 A 
A is a small peptide molecule of 39 – 43 amino acid residue length and 5 kDa atomic weight.  
(Sequence A1-42: Asp – Ala – Glu – Phe – Arg – His – Asp – Ser – Gly – Tyr – Glu – Val – His 
– His – Gln – Lys – Leu – Val – Phe – Phe – Ala – Glu – Asp – Val – Gly – Ser – Asn – Lys – Gly 
– Ala – Ile – Ile – Gly – Leu – Met – Val – Gly – Gly – Val – Val – Ile – Ala – OH (N-terminus are 
residues 1 – 28, C-terminus 29 – 40)).  The structure of A1-42 in aqueous solution derived by 
solution NMR consists of two helical domains (residues: 10 – 22 and 28 – 32) connected by a 
turn (residues: 25 – 26).54   
1.4.3.1 BACE-1 and -secretase 
A is produced by the sequential cleavage of APP in a two-step cleavage by non-specific 
secretases,53  BACE-1 and -secretase.  Secretase enzymes are predominantly found in the 
cholesterol rich micro-domains of the cell membrane.   
Firstly, BACE-1, a -site APP-cleaving transmembrane aspartic protease (BACE), cleaves at the 
amino terminus of the APP molecule.  At the carboxyl terminus a second cleavage is performed 
by -secretase complex, an aspartyl protease of 4 subunits (presenilin 1 or presenilin 2, nicastrin, 
anterior pharynx-defective-1 (APH-1) and PS-enhencer-2 (PEN-2)), all of which are necessary for 
its activity.   
A heterogeneous population of A isoforms is produced.  In health, this is mainly as a 40 amino 
acid long molecule (A1-40).  However in AD, production of A1-42, the most highly 
amyloidogenic A isoform, predominates.   
1.4.3.2 A in health 
A are neuronal morpho-regulatory molecules and a physiological cell product found in small 
amounts in a healthy brain55,56 where they display several physiological roles.57  Although poorly 
understood these include roles in cell signalling and growth, oxidative stress and cholesterol 
handling.  A plaque is found in healthy older individuals without AD58 but the severity of the 
pathology is much milder than in AD.   
1.4.3.3 A in AD 
First purified in 198459 from cerebrovascular amyloid isolated from a brain diseased with 
Alzheimer’s, A function is intrinsically disordered in AD.  Currently, the amyloid cascade 
hypothesis provides the most widely accepted explanation53,60 of AD neuropathology.   
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In AD, A appears to act as a potent neurotoxin, acting both directly at neuronal and synaptic 
level, and indirectly by promoting pathological responses in cells that function to support and 
maintain neuronal and brain homeostasis and health.  Direct effects include: perforation of 
neuronal membranes causing calcium influx and destabilisation of calcium homeostasis;61 
impairment of inhibitory GABA receptor activity;62 alteration of glutamate uptake leading to 
receptor hyperstimulation;63 the release of synaptic vesicles; synaptic failure due to vesicle 
depletion;64 and, a failure of hippocampal Long term potentiation (LTP)65-67 (a process central to 
the long lasting enhanced synaptic activity fundamental to new learning and recall of memory).  
Indirect effects include the pathological activation of microglia68 and astrocytes,69 the propagation 
of a chronic neuroinflammatory state and of neuronal death (by both necrosis and apoptosis), all 
being synonymous with neurodegeneration.70   
1.4.3.4 A isoform interaction and spontaneous oligomerisation 
A molecules undergo spontaneous conformational transformation and molecular aggregation 
into soluble small oligomers, larger insoluble fibrils and insoluble amyloid plaque.   
Plaques are extracellular aggregates of A intensely stained with Thioflavin-S and Congo red and 
characterised by their cross-beta sheet quaternary structure.  ‘Diffuse plaques’ of A are often 
seen in cognitively normal elderly and potentially may be physiologic safe storage of A pending 
its clearance.  Conversely, ‘neuritic plaques’ are histologically pathognomonic of AD and are 
closely associated with altered cognitive function.  They consist of a mixture of fibrillar A1-40, 
A1-42 and other soluble isoforms surrounded by degenerative neurones (dystrophic neurites), 
inflammatory microglia and may contain hyperphosphorylated aggregates of  (neurofibrillary 
tangles).  Cerebral amyloid angiopathy56 describes the infiltration of blood vessel walls with A 
and is associated with perfusion deficits, but not infarction.  These consist of more diffusely 
distributed soluble and small A aggregates.   
The poor clinicopathological correlate of hippocampal A plaque load and cognitive function71,72 
triggered a change in academic thinking regarding its neuropathological significance.  The 
quantity of A plaque correlates poorly with the clinical degree of dementia,73 with tissue quantities 
of soluble A oligomer isoforms better correlating to both synaptic loss74 and the severity of the 
clinical disease75 than total plaque load.  Research focus has consequently moved from A 
plaque, pathognomonic of AD, to the smaller oligomers of soluble A that are highly diffusible and 
neurotoxic.76  Small, soluble oligomers of A are now considered the most neurotoxic isoforms, 
 
32 
with different isoforms showing different toxic potency.  The propensity of A to aggregate is linked 
to neurotoxic potential, implicating disordered protein folding in AD pathogenesis.77   
1.4.3.5 A clearance from brain 
In health, A is cleared from the brain in one of 4 ways: through endocytosis by glia, enzymic 
breakdown by insulin-like peptides and several other peptidases, clearance via the peri-arterial 
spaces and also via extrusion through the BBB to the periphery.  Brain lymphatics, only recently 
described, may provide a further route.78  Abnormalities of clearance can lead to an accumulation 
of A, and may be one cause of its accumulation in disease.   
1.4.4 Tau () 
 is a family of proteins produced by alternate mRNA splicing of a single gene on chromosome 
17 to form six isoforms.   
 functions to regulate the assembly and stability of microtubules, as is a significant member of a 
group of soluble filamentous microtubule associated proteins (MAPs).  Found predominantly in 
neurones and mainly localised in axons,79  is a heat stable molecule that forms cross bridges 
between microtubule fascicles to stabilise the structure.80   
Microtubules are created by tubulin polymerisation and form a dynamic cytoskeletal network, 
particularly abundant in neurones.  These maintain cell structures and are able to create force 
through association and disassociation, providing transport for organelles, chromosomes, cell 
motility, growth and intracellular transport of cargo.  In neurones, microtubule function is essential 
both during neuronal development and throughout its long lifespan.  Neurogenesis also depends 
on their function to mobilise the growth cone, the growing tip of neurones.   function is governed 
by phosphorylation state, being inhibited by phosphorylation.   
Accumulation and hyperphosphorylation of  causes neurodegeneration and abnormalities of  
protein play a key role in several neurodegenerative diseases, both sporadic and familial, which 
are collectively termed tauopathies.  These include AD, fronto-temporal dementia, corticobasal 
degeneration and dementia associated with Down’s syndrome.   
1.4.4.1 Hyperphosphorylated  
In AD, hyperphosphorylated  forms insoluble intraneuronal neurofibrillary tangles81 and neuropil 
threads of paired helical filaments whose major antigenic component is .82  It is over expressed 
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in post mortem AD affected brains83 and the balance of phosphorylation and dephosphorylation 
is disturbed.84  Neuroinflammation facilitates hyperphosphorylation85 of  which, in AD, is thought 
to be downstream of A pathology and triggered by A.86  Indeed, the clinical manifestations of 
AD can be better related to the extent of tauopathy (described using Braak staging)87 than to that 
of amyloidosis.   
1.4.5 Neuroinflammation 
Neuroinflammation describes the process of inflammation within the brain.   
A pathology alone cannot explain the progressive nature of synaptic and neuronal loss seen to 
correlate with clinical dementia in AD, and examination of neuritic plaques revealed within them 
elements in addition to A and dystrophic neurites.  These include activated, pro-inflammatory 
glia,88,89 known to be cytokine secreting.90  Further immune system involvement was 
demonstrated by the recognition of immune cell recruitment91 and the activation of  complement92 
in AD human brain tissue.  Similar neuropathology was triggered in young animal brain by infusion 
of lipopolysaccharide (LPS) intraventricularly93 and after activation of the peripheral innate 
immune system by the intra-peritoneal (IP) injection of LPS.94  Here the effect on neuropathology 
was long lasting95 and exaggerated in aged animals.94   
These findings underlie the hypothesis that a core feature of AD pathogenesis is a repeated local 
neuroinflammatory response to local CNS injury that becomes chronic, self-sustaining and 
dysregulated,96 exacerbated by the effects of ageing and by inflammatory signals originating 
outside the CNS.   
1.5 Anaesthesia, surgery and cognition 
Anaesthesia and surgery was described as having lasting effects on cognition in 195597 but our 
understanding of why and how this occurs is far from complete 60 years later.  Indeed, we 
continue to discover the lasting impact systemic illness and critical care has on long term cognitive 
function.98  Acute cognitive changes are common during periods of illness and perioperatively at 
any age, but most are recognised only in the young (when the brain is undergoing intense periods 
of cell activity and of synaptic re-modelling) and the old (when the brain continues to regenerate 
but has reduced reserves to compensate for problems that cause cellular and organ dysfunction).4   
Anaesthesia alone, at clinical doses, causes reversible learning deficits in animal models, 
detectable using several behavioural models including Trace Fear Conditioning (TFC)99 and 
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MWM.  Performance deficits are persistent100 and show age101 and anaesthetic dose 
dependence.102  These animals show altered protein expression in hippocampus,103 with raised 
hippocampal levels of pro-inflammatory cytokines.104  However conflicting data can also be 
found105.   
In experimental models of anaesthesia with surgery, behaviour deficits are associated with glial 
activation and increased cytokine transcription30 in the early postoperative period.  The data 
shows that deficits are of greater magnitude and are longer lasting in animals with pre-existing 
brain vulnerability, as imposed by advanced age or transgene.  Post-surgical deficits are 
detectable even after minor surgery in old mice.35   
In humans, where control for anaesthetic and surgical effect is more difficult, Ballard et al. show 
that depth of anaesthesia is a major contributing factor in POCD incidence in older adults 1 year 
after surgery,23 where a protocolised optimisation of anaesthetic depth and cerebral oxygen 
saturation reduced the incidence of POCD.   
1.5.1 Anaesthesia, surgery and AD 
Evidence from cell free and tissue culture in vitro work, animal studies and human data106,107 
suggest a link between exposure to anaesthesia with surgery and AD related dementia.108   
1.5.2 In vitro A cell free assay 
The hydrophobic C-terminus of A isoforms determine its aggregation potential (kinetic 
solubility),109 the kinetics of dimer and small oligomer formation having been explored recently 
using several molecular dynamic simulation110 techniques.  Oligomerisation of molecules relies 
on the disorder and hydrophobic properties of the peptide monomer, to drive molecular interaction 
towards a state that is energetically favourable and stabilised by the formation of hydrogen bonds 
and hydrophobic interactions.  Small hydrophobic inhalational anaesthetic molecules can bind to 
peptide molecules, distorting the molecular structure in a way that alters their disorder and 
hydrophobic properties, changing the availability of free energy and therefore changing the 
potential for molecular interaction.   
Nuclear magnetic resonance spectroscopy (NMR) data shows that anaesthetic agents interact in 
a concentration-dependent manner with critical residues in the A molecule, altering the chemical 
dynamics of an inter-helical hinge region of the molecule.  Putatively, this might approximate the 
two -helical regions of the molecule and alter the likelihood of oligomerising interaction.  This 
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was initially described, using NMR spectroscopy, at supra-physiological concentrations of A111 
(approximately 0.5mM), but later at the more clinically relevant concentration of 0.2mM.112   
Eckenhoff et al. demonstrated in 2004, the concentration-dependent effect of inhalational 
anaesthetic agents, including halogenated ethers, on A oligomerisation in an in vitro system.113  
They showed that halothane (a haloalkane, 2-bromo-2-chloro-1,1,1-trifluoroethane) and 
isoflurane (a haloether, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane) caused an 
enhancement of A1-42 oligomerisation.  Conversely, propofol (di-isopropyl-phenol), a widely 
used intravenous anaesthetic agent, only showed enhancement of A oligomerisation at 
concentrations 100-fold above those in clinical use.   
A better understanding of the nature of A molecule-to-molecule interaction and the impact of 
other and more novel anaesthetic agents such as nitrous oxide and xenon, is essential in enabling 
progress in the field.   
1.5.3 In vitro tissue culture  
The exploration of anaesthetic agent effects on AD pathogenesis at a cellular level has been 
investigated pre-clinically using several in vitro systems.  These use cultured cell lines exposed 
to anaesthetic agents in highly controlled environments that lack the complexity and confounding 
factors inherent in animal and clinical studies.  Investigators, including Eckenhoff et al.113 and Xie 
et al.,114 have produced a body of work exploring the effects of anaesthetic dose, duration of 
exposure, interval since exposure and cell type (immortal and primary, neuronal and non-
neuronal and A gene transfected).  Their models also include simultaneous co-exposure to 
multiple agents and exogenous A, and introduce variables such as hypoxia.115  These studies 
examine mechanistic hypotheses, specific cellular vulnerabilities and agent specific properties.   
Eckenhoff el at.113 demonstrated enhanced A1-42 cytotoxicity, as reflected in lactate 
dehydrogenase release (LDH), in rat phaeochromocytoma cells co-exposed to A and halothane 
or isoflurane.  This enhanced cytotoxicity occurred at clinically relevant anaesthetic agent 
concentrations, appeared dose-dependent, counteracted the slight reduction in LDH release seen 
with isoflurane alone and was not seen with propofol.   
Mechanisms of neurotoxicity were explored by Xie et al. who began their investigation using H4 
neuroglioma cells stably transfected with full-length human wild type (WT) APP.  In H4 cells over-
expressing APP, 6 h exposure to 2% isoflurane induced the activity of apoptotic executor protein 
caspase-3 and reduced cell viability, as assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) assay.114  They showed this to be associated with a reduction 
in - Carboxyl terminal fragment (-CTF) production (the cleavage product of APP by BACE-1) 
and that caspase-3 induction was independent of the amount of A secreted.114  In 2007, the 
same group demonstrated that the increase in A production seen after isoflurane exposure was 
dependent on the induction of caspase-3,116 that isoflurane caused an increase in BACE-1 and 
-secretase (nicastrin subunit) expression, and that the caspase-3 activation observed was 
blocked by agents that prevent A oligomerisation.  From this they postulated a potential pathway 
of isoflurane-induced neurotoxicity mediated by caspase activation and apoptosis, promoting a 
BACE-1 and -secretase expression that enabled APP processing and enhanced synthesis of 
A.117   
Independently, Wei et al.118 showed isoflurane-induced apoptosis in immortal eukaryotic cells, 
identifying a mechanism involving cytosolic calcium dysregulation and implicating Inositol 
trisphosphate receptor (IP3R) over-activation in its release from the endoplasmic reticulum.118  
This was prevented by a reduction in extra- and intracellular calcium levels and by silencing the 
IP3R by RNA interference.119   
Other apoptotic regulators modulated by isoflurane exposure include members of the BCL-2 
family, regulators of the intrinsic mitochondrial pathway of apoptosis.  Both in H4-APP immortal 
cells and WT mouse primary neurones, a reduction in anti-apoptotic BCL-2 expression, at mRNA 
and protein level, were quantifiable following 6 h exposure to 2% isoflurane.120  This was 
concurrent with increased pro-apoptotic BAX mRNA and protein expression.  Mitochondrial 
increase in reactive oxygen species (ROS) was detectable, an increase attenuated by calcium 
chelation, as was an isoflurane-induced leakage of cytochrome c protein from mitochondria to 
cytosol.120   
Similar in vitro characterisation work has been repeated using several anaesthetic agents 
including sevoflurane,121 another hoaloether in common use, producing data similar to that of 
isoflurane.  However, evidence of A interaction and mitochondrial stress was absent in normoxic 
conditions when the authors repeated the work using newer holoether anaesthetic agent 
desflurane.115   
These interesting findings are open to criticism in that most data are the work of one laboratory 
alone.  Furthermore, similar work examining the effects of xenon, a novel anaesthetic gas 
appearing clinically organoprotective, remains outstanding.   
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1.5.4 In vivo  
Although exclusively a human disease, animal models have been extensively used in the field of 
AD laboratory work and in exploring the effects of anaesthesia and surgery on cognition.  These 
studies have examined both brain function (through animal behaviour studies) as well as 
neuropathology.   
Using the AD mouse model Tg2576, Perucho et al.,122 showed reduced exploratory behaviour 
after isoflurane anaesthesia, associated with increased hippocampal cell death by apoptosis, 
differing glial response and increased A deposition, effects that were not present in WT mice.   
Bianchi et al., who exposed mice to volatile anaesthetics repeatedly, described behaviour deficit 
in WT mice.123  The change seen in their A burden was anaesthetic agent dependent, but the 
behavioural deficits in MWM were independent of poorer A pathology.   
Using a WT mouse model of abdominal and orthopaedic surgery, Wan et al. similarly found A 
expression after isoflurane was increased, associated with neuroinflammation and impaired 
performance in the MWM.124   
1.5.5 Potential dual effects of single agents and their combination 
The reproducibility of laboratory findings in this field, both in vitro and in vivo, is confounded by a 
lack of consistency in experimental protocol between investigators.  However, the data suggest 
that the effects of individual anaesthetic agents appear dependent on dose and duration of 
exposure, and are modified when different agents are combined, as would occur in typical clinical 
practice.  These are described as ‘dual’ effects.   
This is exemplified in vitro in immortal and primary neuronal cells exposed to isoflurane at sub-
toxic concentrations, in combination with the anaesthetic gas nitrous oxide.  Neither agent causes 
apoptosis nor modulates A biosynthesis alone, but do so in combination.125  Similarly, using the 
same in vitro model, neither desflurane nor hypoxia alone appear adequate, but are when 
combined.115   
Data from animal models are further complicated by apparent species, sex, genotype, age at 
exposure and interval since exposure effects.   
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1.5.6 AD mouse models 
The discovery of familial AD-causing mutations allowed their introduction into other species to 
enable the development of several animal models of AD for use in the laboratory, despite the fact 
that no equivalent diagnosis occurs naturally in most rodents.  These models express human 
mutations of APP,  and presenilin, which cause intrinsic human A1-42 production.  The strength 
of pathology and its speed of onset can be amplified by introducing two or more mutations into a 
single model.  Recently, non-AD mouse models bearing mutations for other chronic human 
diseases including diabetes, obesity and hypertension, have been employed in AD animal 
studies.   
Most mouse models investigated are back-crossed on a C57BL/6 background, a strain with 
particularly high visual acuity, making them good candidates for behavioural work.   
The APP23 model used in this investigation bears the APP751Swe gene driven by the Thy1 
promoter, over expressing APP 7-fold only in neuronal tissue.  The strength of this model lies in 
its spontaneous hyperphosphorylation of , the development of neuritic plaques, synaptic 
degeneration and cerebral amyloid angiopathy, all being associated with strong gliosis and 
neuroinflammation.  These pathologies closely match human disease.  APP23 mice develop 
behavioural deficits in several paradigms including the MWM from 3 months of age,126-128 and A 
plaque is detectable in cortex and hippocampus from 6 months.   
No one model expresses all neuropathological and behavioural features of AD.  Some lack A 
plaque, and neurofibrillary tangles are absent in all but one.  All APP transgenic mice have 
increased mortality when compared to WT, display myoclonic movement, low seizure threshold 
and abnormal limb reflexes.  These suggest hindbrain involvement in their pathology.128   
1.6 Inflammation: Its role and mechanism 
1.6.1 Sterile Inflammation 
Inflammation is a fundamental, complex protective response to threatened or actual tissue 
damage, which can be sterile or infectious.  Elective surgery causes sterile inflammation, where 
tissue damage caused by mechanical injury triggers a response that protects the body from 
potential pathogenic invasion, activates the inflammasome and apoptosis,129 and attempts to 
optimise conditions for healing.   
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Several cellular and humoral mediators are involved, the effects being both local and systemic.  
Cellular mediators are leukocytes (capable of phagocytosis) and endothelial cells (lining blood 
vessel and lymphatic walls to form an interface and semi-permeable barrier).   
Leukocytes (including monocytes) can penetrate tissue through interaction with endothelium.  
Monocytes become resident within tissue and are long lived, retaining their ability to phagocytose 
and secrete signalling molecules.  These include small, short-lived, locally acting molecules (such 
as nitric oxide), lipid based compounds (such as prostaglandins) and more complex proteins 
(such as circulating cytokines and chemo-attractant chemokines).   
Cytokines are signalling proteins that mediate peripheral and neuroinflammation, and can be pro- 
or anti-inflammatory.  Pro-inflammatory cytokines include Il-1, Il-6 and tumour necrosis factor- 
(TNF-), whilst others, including Il-4, are largely anti-inflammatory.130  Chemokines constitutively 
have very low physiological concentrations within the CNS but show up-regulation during 
inflammation, a chemokine gradient guiding effector cells to their site of action.   
An excessive, dysregulated inflammatory response can cause or contribute to tissue damage.  
This occurs after activation of cellular mediators that target not only the initial trigger site, but also 
remote sites, in a similar defensive manner.  Neuronal function, as reflected in spatial memory 
assessed by means of the MWM, is impaired by Il-1 injection IP131 and by other pro-inflammatory 
mediators, including cytokines and ROS.  These inhibit LTP and impair cognitive function.132-135   
1.6.2 Neuroinflammation 
Neuroinflammation occurs after both anaesthesia alone99 and anaesthesia with surgery.30,35   
Microglia are brain resident macrophages that, after detecting pro-inflammatory signals, transform 
from a ramified, inactivated state to an activated phagocytic one capable of the synthesis and 
release of pro-inflammatory mediators.  Microglia are long-lived and remain activated for 
extended periods, releasing quantities of cytokine and neurotoxic molecules that contribute to 
long-term neurodegeneration.136   
Astrocytes are a second form of glia that play an important role in modulating neuronal energy 
supply, detoxification, synaptic function and regulation.  They police cerebrovascular endothelial 
barriers and ventricular walls, where they respond to blood or CSF borne stimuli, becoming 
capable of pro-inflammatory signalling molecule release.137  Although microglia show much 
greater capacity for cytokine release,138 a combined glial response is likely central to disease 
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pathology as crosstalk exists between BBB endothelial cells, glia and neurons,139 and the activity 
of one cell type directly affects another.   
Gliosis describes the activation of glia into a reactive phenotype, characterised by up-regulation 
of Ionised Calcium Binding Adapter molecule-1 (IBA-1) expression in microglia, and Glial fibrillary 
acid protein (GFAP) in astrocytes.  Gliosis is a common hallmark of neuroinflammation, and is 
seen after sterile peripheral surgery.124   
1.6.3 Endothelium and the blood brain barrier 
The blood brain barrier (BBB), a highly specialised form of endothelium, was previously thought 
to completely isolate the CNS from the peripheral immune system.  However, not only is the BBB 
permeable to peripheral pro-inflammatory mediators, it can also be stimulated to release and 
transmit these mediators itself, and allow leukocyte migration into the brain, drawn by humoral 
factors produced by activated glia.   
Breakdown of the BBB is key in understanding how peripheral inflammation can enter the CNS.  
Previously thought to be impermeable to the large pro-inflammatory cytokines, active transport 
systems have been observed to facilitate their delivery into the brain.140  Circumventricular organs, 
such as the area postrema, posterior pituitary and pineal gland, are particular areas of 
concentrated cytokine transport.141   
Cytokines interfere with BBB integrity by altering the resistance of tight junctions between 
endothelial cells of the capillary wall,142 and up-regulating inflammatory cytokine and Cox-2 
transcription in the endothelium.143  (Cyclooxygenase (Cox, or prostaglandin-endoperoxide 
synthase) convert arachidonic acid to pro-inflammatory prostaglandins.  Two isoenzymes are 
found, Cox-1 and -2, both expressed by neurones in physiological and pathological conditions.)144   
1.6.4 Effects of neuroinflammation 
Neuroinflammation is a physiologically normal response to actual and threatened tissue damage.  
It is part of normal ageing, caused by the accumulation of DNA and protein damage, impaired 
oxidative phosphorylation and calcium handling.   
The long post-mitotic lifespan of neurones, their high basal energy requirement, dependence on 
oxidative phosphorylation, need for energy reserves when firing and their sensitivity to energy 
crisis, make the brain vulnerable to the effects of chronic neuroinflammation.  This is true in the 
context of normal, healthy ageing and in disease.   
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An older brain is more susceptible to acute decompensation and aggravated neuroinflammatory 
response following any inflammatory trigger.  Chronic, low level inflammation may promote an 
age dependent ‘acute on chronic’ neuroinflammatory response, driven by peripheral inflammatory 
stimuli.  The response triggered is disproportionate, dysregulated and persistent.   
A failure of resolution of neuroinflammation, driven by the accumulation of trigger factors that 
persist within the CNS through defective elimination of toxins (including A) and on-going tissue 
injury, is ultimately damaging and contributes significantly to the neurodegeneration associated 
with neurocognitive disorders.   
1.6.5 Neuroinflammation and the role of A 
A over production and failure of clearance both contribute to its dysregulation in neuroinflammed 
brain, through a self-perpetuating cycle of cause and effect.   
Chronic, low level A1-42 exposure (as oligomers and fibrillar material) in the ageing brain 
stimulate microglia to produce pro-inflammatory cytokines that drive neuroinflammation.  
Increased local A production (through the induction of BACE-1 expression in activated 
astrocytes, and through other mechanisms responding to local inflammatory stress), along with 
reduced A clearance by activated glia, all contribute to an increased A load.  A positive 
feedback loop is created.   
In disease driven by A over-expression, progressive pathology means A production chronically 
exceeds clearance, driven by the underlying disease process.   
In both situations, inflamed BBB becomes permeable to peripherally synthesised A, with several 
mechanisms of A transport into the brain described, including via the Receptor for advanced 
glycation end products (RAGE).145   
Despite neuronal resilience and robustness, in the persistently toxic conditions of A excess, 
neuronal functions fail, they ultimately undergo cell death, and neurogenesis is reduced.   
1.6.6 Neuroinflammation: effects on synapses and neurones 
1.6.6.1 Synaptic dysfunction 
AD is a synaptopathy.  Synaptic impairment is a feature of the early progression of dementia146 
and synaptic loss is a strong correlate of cognitive decline.73,147  Neuronal apoptosis is likely to 
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be an inadequate measure of neurodegeneration, as neuronal function is compromised long 
before cell death.  Synaptic dysfunction manifests in various ways including, complete loss of 
synaptic function, such as loss of post-synaptic density proteins (PSD-95), and dysregulation of 
pre-synaptic transport proteins (including synaptophysin, synapsin and synaptobrevin).   
1.6.6.2 The role of glia in synaptic function 
The tripartite synapse model describes the synapse as a trinity consisting of pre- and post-
synaptic terminals with astrocyte interaction.148  Astrocytes interact intimately with neurones and 
synapses in their vicinity, potentially regulating their maintenance and development.  Astrocyte 
mediated inflammatory responses, including cytokine release and astrogliosis, can cause 
detrimental long-term effects on synaptic function.   
The net effect of microglial interaction with synapses alters as they change their morphology to 
assume an activated phenotype.  Ramified microglia exert a protective influence over synaptic 
excitotoxicity.149  Activated microglia, however, potentially promote synaptic damage and 
neurodegeneration, via pathways such as Nuclear factor-B (NF-B) signalling.   
Recent studies have suggested that synaptic dysfunction features in the very early stages of 
neuroinflammatory brain pathology.  For example, Vizcaychipi et al.150 report down-regulation of 
hippocampal synapsin within 24 h of unilateral nephrectomy surgery in mice, suggesting that pro-
inflammatory processes modulate the change from healthy, physiological synaptic transmission 
to impaired network functioning.   
1.6.6.3 Neuronal death 
Neuronal death can be necrotic or apoptotic.  Necrotic death occurs after cellular damage, but 
apoptosis is a physiological programmed cell death that is part of healthy homeostasis.  Apoptotic 
death also occurs as part of an inappropriate response to inflammation in acute and chronic 
neurodegeneration.   
Molecules released during the inflammatory response are capable of initiating and sustaining 
individual neuronal death pathways.  However, the true extent of apoptotic neurodegeneration 
depends on the balance of pro- and anti-apoptotic signalling molecules released from glia, the 
existing pathology, and numerous other factors that make up the complex interplay of 
inflammation within the human brain.  Although both apoptosis and necrosis feature in a range of 
neurodegenerative conditions, there is little evidence at present for outright neuronal death at 
early time points following surgery.  For example, even following a severe peripheral procedure 
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(renal transplant) in a rat model, hippocampal neuronal numbers were preserved in this 
laboratory.   
Neurogenesis 
Neurogenesis (the differentiation of neural progenitor cells (NPCs) to neurons) in adults occurs in 
the subgranular layer of the dentate gyrus (DG) of the hippocampus, as well as other areas such 
as the subventricular zone of the lateral ventricles and the amygdala.151  Neurogenesis is reduced 
in AD and is modulated by neuroinflammation, being impaired by pro-inflammatory cytokines 
including Il-6 and TNF- through death of NPCs and an inhibition of cell differentiation.152   
1.6.7 Microglial priming - neurodegeneration from peripheral inflammation 
Microglia may play a key role in accelerating and propagating neurodegeneration in response to 
repeated peripheral inflammatory signals through a process termed priming.  Priming occurs 
when acute or chronic inflammatory insults sensitise immune cells, producing an exaggerated 
pro-inflammatory response when triggered by a repeated or secondary stimulus.   
Well described in the periphery, notably in macrophages,153 microglia also display evidence of 
priming.154  Acute peripheral inflammatory challenges induce exacerbated cytokine responses 
from microglia following priming associated with neurodegeneration.  Cunningham et al. showed, 
in a mouse prion model of chronic neurodegeneration, worse working memory deficits after 
peripheral LPS challenge, and prolonged transcription of pro-inflammatory mediators in the CNS, 
but equal peripheral circulating levels of cytokine.155   
Age is a critical risk factor in determining brain functional response to inflammatory signalling from 
the periphery.  Low levels of pro-inflammatory mediators156 present in the CNS for decades during 
pre-symptomatic AD, potentially prime microglia.  This promotes a distorted response to 
inflammatory stress caused by peripheral infection, surgical trauma and inflammation.157  Such 
distorted, chronic neuroinflammatory response contributes to neuronal damage, synaptic 
impairment, neurodegeneration and worsening AD pathology, in a self-perpetuating cycle.   
The translation of the inflammatory signals across the BBB may be exaggerated in the conditions 
of chronic neuroinflammation seen in AD, as suggested by recent data from Japan using a novel 
live-animal microdialysis technique.  In this study, live APP23 mice showed massively 
exaggerated Il-6 levels in the brain after IP LPS when compared to WT,158 whereas there was no 
genotype dependent difference in the levels of cytokines measured peripherally.   
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1.6.8 The balance of inflammation and anti-inflammation 
Pro- and anti-inflammatory signalling are equally active during inflammation.  Anti-inflammation is 
mediated by cytokines including Il-4, Il-10, stress hormones such as cortisol, and cholinergic 
activity from the CNS, including vagal stimulation.  These systems are often disrupted during the 
perioperative period by the stress response to anaesthesia with surgery.  An imbalance of pro- 
and anti-inflammatory cytokine responses is a predisposing factor for delirium.159   
The failure of anti-inflammatory signalling, such as the surge in anti-inflammatory cytokines seen 
later after anaesthesia with surgery,160 which aims to resolve brain inflammation, may play a role 
in bridging acute to chronic neuroinflammation in disease.   
1.6.9 Modulating neuroinflammation 
Understanding how a normally self-limiting and protective physiological response transforms into 
one that is damaging remains at an early stage.  However, therapeutic interventions targeting 
inflammation may prevent the onset and propagation of early neuroinflammatory processes that 
ultimately drive neurodegenerative disease.  Several strategies have been attempted, aiming to 
limit inflammatory impact and to regain control of over-reactive glia.  Potential strategies are:  
1. Anti-inflammatory  
2. Anti-cytokine 
3. Anti-cholinesterase161 and 
4. Pro-cholinergic162,163  
Anti-inflammatory strategies in the both the laboratory and clinical setting have involved the use 
of inhibitors of Cox (using Non-Steroidal Anti Inflammatory Drugs (NSAIDs)) and HMG-CoA 
reductase (using statins).  As modulators of inflammation such agents present several therapeutic 
potentials in AD.   
In cDKO mice, (a double presenilin knockout model where APP CTFs accumulate but A is 
reduced, the number of apoptotic neurons is elevated and progressive gliosis occurs in neocortex 
and hippocampus), long term ibuprofen reduced learning deficits,  hyperphosphorylation and 
cleaved caspase-3 expression, proving more effective in older adult mice.164  Selective Cox-1 
inhibition reduced spatial learning deficit in a triple AD mouse model, where it improved learning 
and memory, reduced A deposition and  hyperphosphorylation.165  It also blocked LPS induced 
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working memory deficit in a prion-based model of neurodegeneration.166  Cox-2 inhibition 
prevented the suppression of LTP by A in Tg2576 mice,167 restoring memory function.   
Clinically, advances have been limited and conflicting, as effective intervention in one outcome 
measure proves damaging in another.   
Considering delirium, several commonly used NSAIDs can worsen delirium,168 while trials to 
boost cholinergic anti-inflammatory signalling with the AD drug rivastigmine (an 
acetylcholinesterase inhibitor) were halted prematurely due to higher mortality and longer duration 
of delirium.169  Mixed effects have been observed with statin but this is confounded by inconsistent 
study design, methods of delirium assessment and data recording.  Prospective trials of 
perioperative statin show mixed results, statins appearing to reduce delirium after cardiac surgery 
by 46% in one study,170 but showing no benefit in another.171  Of note, statins may be 
cognoprotective if used early in critically ill patients with sepsis,172 but neurocognitive outcome is 
worse in septic patients on long-term statins who have their treatment discontinued.172   
Considering dementia, both NSAIDs173 and statins174 show benefits in reducing dementia 
incidence in observational studies but lack benefits in randomised control trials, highlighting the 
need for further well controlled prospective studies.   
Anti-cytokine therapy using Il-1 receptor antagonists  (such as the recombinant Il-1 receptor 
antagonist anakinra), have shown great promise as biological response modifiers for a wide range 
of inflammatory conditions, including traumatic brain injury175 and subarachnoid haemorrhage.176  
However, it remains to be determined whether their abiliity to attenuate acute brain injury extends 
to long-term protection of cognitive function.   
1.7 Cholesterol and statins 
1.7.1 Cholesterol 
Cholesterol, a sterol isoprenoid molecule produced via the mevalonate pathway, is an essential 
structural component of all animal cell walls and the precursor of several biosynthetic pathways.  
Its hydroxyl group interacts with polar groups of phospho- and sphingolipids while its steroid and 
hydrocarbon chain are embedded in the membrane alongside non-polar fatty acids and other 
lipids, enabling cholesterol to stabilise membrane structure and its fluidity.  With roles in 
endocytosis, intracellular transport, cell signalling and nerve conduction, cholesterol is a precursor 
molecule in several biosynthetic pathways including those for steroid hormones, bile acids and 
Vitamin D.   
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Within the cell wall, cholesterol forms a major component of lipid rafts in all eukaryotic cells.  These 
rafts are micro-domains that harbour protein molecules and enable cells to interact, assuming 
important roles in cell signalling.  Lipid rafts enable segregation of inactive signalling molecules 
but allow them to associate and coalesce during protein-to-protein interaction.177-180  About 50nm 
in diameter, rafts float on the exoplasmic part of the cell membrane lipid bi-layer, selectively 
binding to proteins with glycosylphosphatidylinositol anchor and acyl moieties.  Cholesterol is 
believed to stabilise raft micro-domains, which renders the platform less fluid and more ordered.   
1.7.2 Cholesterol in brain 
The brain is cholesterol-enriched compared to other body organs (15-20 mg / g vs. 2 mg / g 
tissue), operating its own lipoprotein transport system independent of the periphery, as the BBB 
is impermeable to lipoprotein.  The brain contains 25% of total body cholesterol, mostly as myelin 
sheath.181  During active neuronal myelination, when brain-derived cholesterol synthesis is at its 
peak; its synthesis is mainly in oligodendrocytes.  In an adult brain cholesterol biosynthesis 
continues at a lower rate, predominantly in astrocytes.182  Brain cholesterol has a long half-life in 
rodents (4-6 months) and humans (up to 5 years),181 and is metabolised by cholesterol 24-
hydroxylase (CYP46) enzyme, a highly conserved cytochrome P450 expressed in a subset of 
neurons including hippocampal and cortical.  The 24-hydroxycholesterol produced can cross the 
BBB and is eliminated in bile.183   
1.7.3 Cholesterol in AD 
In common with several neurodegenerative conditions, disordered cholesterol metabolism is seen 
in AD,184,185 although it remains unclear if the relationship is causal or consequential and an 
explanatory molecular mechanism is lacking.   
In vitro, reduction of membrane cholesterol affects APP cleavage186 and A processing187 and 
cholesterol depletion reversibly inhibits A production in hippocampal neurones.188  
Epidemiological evidence is inconsistent,189 but hypercholesterolemia in middle age may be a risk 
factor for AD.  However, de novo cholesterol synthesis appears reduced in the AD affected 
brain.190   
1.7.4 Statins 
Statins are HMG-CoA reductase inhibitors that inhibit cholesterol synthesis in the liver, the source 
of 70% of the body’s total cholesterol.  So far, their main therapeutic role has been in the treatment 
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of cardiovascular disease, including stroke, where they are effective at both primary and 
secondary prevention.   
Statins are structural analogues of HMG-CoA, but have much greater affinity for the catalytic site 
of HMG-CoA reductase enzyme, at approximately 1000-10,000 times that of the natural 
substrate.  This causes competitive inhibition of the enzyme, blocking production of mevalonate 
within the mevalonate pathway, which reduces terpene and sterol synthesis from which 
cholesterol is derived.  Several intermediate molecules of the pathway, including isoprenoids and 
their derivatives, farnesyl pyrophosphate (a substrate for Coenzyme Q10, part of the electron 
transport chain in mitochondria) and geranylgeranyl pyrosphosphate, can modulate 
inflammation.191   
Although generally free of severe side effects, the most often reported adverse effects of statins 
are muscle pain and myositis, impaired glucose regulation and derangement of liver function.  
Less frequently reported are reversible effects on mental state, memory function and cognition.192  
Synaptic193 and behavioural194,195 effects are also reported in mice.   
Both laboratory and clinical data suggests that the benefits of statin treatment are not related to 
cholesterol reduction alone, and that they possess several cholesterol independent ‘pleiotropic’ 
effects.196  These are anti-inflammatory, immunomodulatory and endothelial function 
enhancing.191   
Statins exhibit strong anti-inflammatory and immunomodulating effects in several effector cells.  
In particular, they affect monocyte activity,197 where they attenuate Toll-like receptor up-regulation 
in response to inflammatory challenge.  Through multimodal effects that stabilise endothelium, 
including increased fibrinolysis, statins help maintain BBB integrity in the face of inflammation, 
limiting monocyte migration into the CNS.  They also reduce glial activation and the production of 
inflammatory cytokines.   
Statin effects may occur without their penetrating the BBB, as lipophylicity of different statins vary.  
Although long debated, the balance of evidence suggests that atorvastatin is capable of 
penetrating the BBB.198,199   
1.7.5 Statins in AD 
Statins are being investigated for a potential therapeutic role in the prevention and treatment of 
AD.200   
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In vivo, statin reduced A and  pathology and improved behavioural memory after long term 
administration to Tg2576 mice, without affecting serum lipid levels.201  Atorvastatin was 
neuroprotective against A effects in an A intra-cerebro-ventricular injection model using albino 
mice,202 where it reduced inflammatory and oxidative stress markers but did not show 
preservation of memory deficit in the MWM.  However, in the same model using object place 
recognition, memory deficits were attenuated.203   
In the perioperative setting, a reduction in surgery-induced neuroinflammation and preserved 
memory was shown in WT mice treated acutely with atorvastatin during the perioperative 
period.150   
The clinical evidence for statin effect on AD is mixed204-211 with several studies, including a 
Cochrane review on the subject, having failed to confirm any benefit.212  Early laboratory213 and 
clinical214 data suggest that the efficacy of statins in preventing AD and reversing neuronal 
damage may be age dependent, effective only in the early preclinical stages of the disease.  Statin 
use in symptomatic AD may indeed be harmful.215   
1.8 Rationale and hypothesis 
Although mixed clinical effects are reported in AD trials where disease progression was advanced, 
the therapeutic potential of statins to prevent neuroinflammation and modulate behavioural deficit 
in the acute, perioperative setting has shown early promise in a WT mouse model of POCD.150  
Both Cox-2 induced cerebrovascular inflammation and hippocampal neuroinflammation were 
dramatically reduced in WT mice after anaesthesia with surgery, suggesting the ability of statins 
to stabilise the endothelium was key to preventing neuroinflammation and preserving memory 
performance.   
The current programme of work therefore set out to establish the impact of anaesthesia and 
surgery on Alzheimer’s disease and the potential therapeutic role of atorvastatin.   
Concepts explored in this thesis are summarised in Figure 1-2.   
My hypothesis states that general anaesthesia with surgery triggers or interacts with early AD 
pathology and perioperative atorvastatin may modulate this.   
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Chapter 1  Figures 
Figure 1-1: Do acute and chronic causes of cognitive change share a common pathology?   
 
This schematic illustrates fundamental questions that underlie this investigation: Do acute and 
chronic causes of cognitive change share a common pathology?  Does the physiological and 
inflammatory stress experienced during the perioperative period modulate this disease process?4   
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Figure 1-2 Potential interactions between modifiable risks and AD pathogenesis 
 
Over decades, preclinical AD causes a chronic, low-level inflammation within the brain.  Long- 
term inflammatory stress injures the BBB, its function becomes impaired, exposing the brain to 
inappropriate inflammatory signals form the periphery.  Microglia become primed and respond in 
an exaggerated manner to such inflammatory stimuli.  Regulation of the inflammatory response 
is blunted, A synthesis and clearance dysregulated, and  irreversibly phosphorylated.  
Neurodegeneration occurs, caused by synaptic impairment, impaired neurogenesis and perpetual 
neuronal apoptosis.   
Acute inflammation, triggered by anaesthesia with surgery, may interact with chronic inflammation 
within the CNS, and the pleiotropic effects of atorvastatin may modulate this.   
Adapted from a figure conceived by Lyman, Lloyd et al.216 
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Chapter 2 Cell free assay and in vitro study 
2.1 Introduction 
The effect of 3 anaesthetic agents were investigated in this part of study:  isoflurane, nitrous oxide 
and xenon.  Each is used clinically, although xenon remains an emerging anaesthetic agent and 
is only rarely used.   
This study built on a body of work produced in the Academic Anaesthetics Laboratory at Imperial 
College London and elsewhere.  These showed that in AD cell culture models, fundamental 
processes governing the processing and production of A, cell viability and apoptosis are each 
modulated by anaesthetics, with different agents producing differing effects.   
2.2 Aims of the cell free assay and in vitro study 
1:   To examine the spontaneous oligomerisation behaviour of A in cell free assay and to 
determine the effect of anaesthetic agents upon this.   
2:   To examine cell viability of primary neuronal culture exposed to A and to determine the 
effect of exposure to anaesthetic agents.   
3:   To examine the expression of several proteins of interest (POI) linked to AD, cell injury and 
apoptosis in immortal cell in vitro culture, and to determine the effect of exposure to 
anaesthetic agents.   
2.3 Effect of anaesthetic agents on A protein in solution:  Cell free assay 
A cell free assay technique was used to assess the effects of different anaesthetic agents on the 
oligomerisation behaviour of synthetic A monomer in solution, by quantifying different molecular 
species present after 24 h exposure using western blotting (WB).   
Mitul Patel performed this work.   
2.3.1 Materials and methods 
All conditions were at RT unless stated.  All consumables, apparatus and equipment required for 
the performance of any work described in this thesis are listed in the materials catalogue in the 
appendix, as are instructions for the preparation of all reagents. 
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Reagents 
NuPAGE MES SDS running buffer for WB x1 
TBST for WB 
TBS for WB  
Electrotransfer buffer for A WB 
2.3.2 Preparation of the A monomer 
Synthetic A protein (1-42) hydrochloride salt 0.5 mg was removed from – 80 ºC storage and 
thawed on ice.  To monomerise, the protein was dissolved in 110.8 μl 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) on ice in a fume hood.  The solution was vortexed to ensure complete dissolution, 
producing an A solution of concentration 1 mM.   
Following incubation for 60 min, the solution was held ice for 10 min before aliquoting into non-
siliconised microcentrifuge tubes at 25 μl per tube, containing 112.8 μg monomerised A per 
aliquot.   
The HFIP was allowed to evaporate from the open tubes ON in a fume hood and dry film aliquots 
were stored at – 80 ºC until used.   
2.3.3 Preparation of A monomer solution for anaesthetic exposure 
A film was thawed on ice and dissolved in 5 μl Dimethyl sulfoxide (DMSO) by vortexing, producing 
a 5 mM A monomer solution.  This was further diluted in 495 μl 1x MEM (without phenol red) to 
a working solution of A monomer of 50 μM.   
Two starting solutions were used:   
-  A monomer solution:  The 50 μM solution produced as described above and used immediately. 
-  ADDL solution:  A monomer solution incubated on ice for 24 h prior to centrifugation at 16464 
g for 10 min at 4 ºC before use.  (This solution contains a higher amount of low and high molecular 
weight (LMW and HMW) A oligomers, termed amyloid derived diffusible ligands (ADDL)). 
Each solution was used in separate experiments using the same protocol described here.   
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2.3.4 Spontaneous oligomerisation behaviour 
50 μl aliquots of the solution were aliquoted into microcentrifuge tubes and loaded into anaesthetic 
chambers.  These chambers were closed, filled with anaesthetic agents and sealed airtight, as 
described in the protocol detailed in 2.5.3.  The contents of the chamber during each condition 
are described in Table 2-1.   
Sealed chambers were incubated at 37 ºC for 24 h prior to opening and vortexing the sample for 
10 sec.  10 μl of the solution was collected and held on ice.   
The remaining solution was centrifuged at 16434 g for 30 min at 4 ºC to sediment fibrillar material 
and the solution then held on ice with minimal agitation.   
Protein quantification was performed on 10 μl samples of both the pre- and post-centrifugation 
solutions, as described in 2.7.2.  The difference in protein concentration of the pre- and post- 
centrifugation samples represents large fibrillar material sedimentation by centrifugation and is 
described as ‘Fibrillar material removed by centrifugation’ in the results.   
WB was performed on the solution using the amyloid specific protocol described in 2.7.  Prior to 
WB the solution was further centrifuged at 16434 g for 10 min at 4 ºC to ensure sedimentation of 
fibrillar material.   
Mean pixel intensity (MPI) during chemiluminesence was determined at specific molecular 
weights and used in analysis.  Data from each molecular weight of interest was normalised to the 
total protein content determined during the protein quantification of each sample.   
2.4 Effect of A on primary neuronal cell viability 
Primary WT mouse neuronal cultures were prepared and used in a set of experiments to 
determine any differences in cell viability after exposure to A supplemented media both with and 
without anaesthetic agent exposure.   
Olar Adeyi performed this work.   
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2.4.1 Materials and methods 
Reagents 
PBS 1x for in vitro work 
Primary cortical neurones were used in experiments to determine the effect of supplemental A 
on their cell viability, determined by colorimetric assay using the tetrazolium dye MTT.  Metabolic 
activity, considered an index of cell viability and apoptosis, is quantified in MTT by measuring the 
amount of colour change caused by the reduction of yellow coloured MTT to its insoluble purple 
coloured formazan (EZ-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan) by NADH-dependent 
cellular oxidoreductase enzymes.217  
2.4.2 Preparation of A oligomers 
Synthetic A was monomerised as described in protocol 2.3.2, to produce a 400 μM solution in 
phosphate buffered saline 0.9% (PBS) (1 mg in 0.55 ml), and incubated at 37 °C for 72 h to create 
a mixture of LMW and HMW oligomers and fibrillar material.  This was diluted to working 
concentrations at the time of use.   
2.4.3 Preparation of primary neuronal cultures 
Mouse primary hippocampal and cortical neurones were prepared in culture as described in 2.6.1 
and used in experiments d 7 ex vivo.   
2.4.4 Concentration response of cell viability to A concentration 
A concentration response experiment was performed to assess the effect of supplemental A 
concentration (range 0 – 10 μM) on cell viability of primary cortical neurones after 24 h exposure.  
The concentrations of A in each of the conditions are detailed in Table 2-2.  At the end of 
exposure cell viability was determined using MTT assay.   
2.4.5 MTT cell viability assay 
Immediately after exposure each well was aspirated to dryness and media replaced by 600 μl 
MTT solution (0.5 mg MTT / ml MEM without phenol, with L-Glutamine (2 mM)).  After 2 h 
incubation at 37 °C with 5 % CO2, the MTT solution was removed and replaced with 1 ml DMSO 
and the floor of the well scraped using a glass Pasteur pipette.  After thorough scraping the 
solution was divided equally between 2 wells of a 96 well plate.  Spectrophotometric measurement 
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of each well was performed immediately using a microplate reader at 540 nm and the data 
expressed as % measured compared to Control.   
2.4.6 Anaesthetic exposure in A supplemented media 
Primary neuronal cells were exposed to anaesthetic agents for 24 h in media supplemented with 
0.8 μM A, to determine their effect on cell viability.  Isoflurane, nitrous oxide and xenon were 
examined at different concentrations, all exposures being in 21 % O2 with 5 % CO2 at 37 oC.  The 
conditions used are described in detail in Table 2-3 and the setup detailed in 2.5.3.  
At the end of the 24 h incubation cell viability was determined using MTT assay as described in 
2.4.5.   
2.5 Effect of anaesthetic exposure on immortal cells 
H4 naïve, H4-APP and N2aSwe cells were exposed to 3 anaesthetic agents, in order to determine 
the effect of these agents on the expression of several POI linked to AD pathogenesis and 
apoptosis.  The chamber contents during each condition, and the cell type used, are described in 
Table 2-4.  Exposure time for all experiments using immortal cells was 6 h.   
2.5.1 Materials and methods 
Reagents 
H4 cell working media 
H4 cell media serum free 
H4-APP cell working media 
H4-cell media serum free 
2.5.2 Preparation of immortal cells for experiments 
Cells were grown in culture (as described in section 2.6.2) for up to 3 weeks post resuscitation 
from cryostorage.   
Anaesthetic exposure was performed on ‘n numbers’ of 3 - 4 in these experiments.  In this context, 
n means cells that originate from a different flask to the other n in the same experiment.  These n 
were isolated by subculturing cells into separate flasks as early as possible after resuscitation, 
meaning the cells used in each experiment were of the same passage and post resuscitation age.   
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The day before an experiment a viable cell count was performed on several 175 cm2 tissue culture 
flasks of cells at 90 – 100 % confluence, one for each n, as described in 2.6.  Experiments were 
carried out in a sterile 6 well cell culture plate labelled with one of the 5 experimental condition 
(detailed in Table 2-4).  A well in the same position on each plate e.g. A1, B3 etc, was labelled 
with an n number, and used to hold cells from that specific n on all the plates used in that 
experiment e.g. A1 holds n1, B3 holds n4 etc.   
All wells were seeded at a density of 7 x 105 cells in their appropriate working media and allowed 
to incubate overnight, as detailed in 2.6.2 and illustrated in Figure 2-1.  The morning of the 
experiment cells were examined under an inverted microscope for confluence and cell health, the 
working media was removed and substitute with 2 ml serum free media (appropriate to the cell 
line) at 37 oC.  For A work, a minimum amount of serum free media was used, enough to cover 
the cells only.   
2.5.3 Anaesthetic gas exposure 
Gas exposure was performed in purpose built, airtight 1.5 l steel gas exposure chambers with 
inlet and outlet pipes that could be occluded.  Chamber contents was unchanged after 24 h in 
these airtight chambers, once established and sealed as per protocol.218  Incorporated into the 
chamber was a fan to circulate internal gases and vapours throughout the exposure time.  The 
chamber design is illustrated in Figure 2-2.   
Loading the chamber with cell culture plates 
Chambers were warmed to 37 oC prior to loading the cell culture plates and closing the chamber 
within a laminar flow hood.  During gas exposure the plate lids were removed.  Humidity was 
maintained within the chamber by placing a petri dish containing sterile water within the chamber 
during exposures, to minimise evaporation of media.  The chamber opening was sealed using a 
rubber O-ring and secured closed with a spring-tensioned clamp.   
Filling the closed chamber with anaesthetic agent 
Chambers were filled with anaesthetic agent mixtures following a protocol detailed in  Table 2-5.  
Contents of the chamber were sampled via a fine-bore tube fed through the gas outlet to confirm 
achieving steady state.  Continuous sampling occurred from within the chamber, being analysed 
by either a medical anaesthetic gas analyser or xenon gas analyser.  Gas sampling rate was 200 
ml / min.219    
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Flow rates and duration of flow to achieve steady state composition within the chamber were 
determined previously using:   
flow time constant (t) = (3 x volume of chamber ( l )) / fresh gas flow (l / min),  
where time to 95 % steady state gas composition within the chamber = 3 t  
CO2 ± N2 was injected into the sealed chamber once at steady state (The rubber tubing of the gas 
inlet and outlet were expansive and would neutralise the pressure change).  Inlet and outlet pipes 
were sealed during experiments by clamping.   
During exposure, sealed chambers were housed within an incubating chamber at 37 oC.  At the 
end of the exposure, for a random number of experiments, the chamber contents was again 
analysed via the outlet pipe.  Analysis confirmed that the steady state anaesthetic gas mixture 
was maintained until the end of the exposure time for all samples analysed.   
Opening the chambers 
Chambers were opened within a laminar flow hood, samples removed, lids replaced and plates 
immediately transferred onto ice.   
Processing of the cells and media would proceed according to the analytical method used, either 
WB for POI (described in section 2.7), immunoprecipitation (described in section 2.8) for WB, 
Enzyme-linked immunosorbent assay (ELISA) for A (described in section 2.9) or 
immunochemistry (described in section 2.10).   
2.6 Cell culture protocols 
2.6.1 Primary neuronal culture 
Reagents 
Dissecting media 
Neurobasal media 
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Preparation of cultures 
WT foetal C57BL/6 cell cultures were prepared from 16-d gestation mouse pups in a method 
adapted from Choi et al.220  A 16-d gravid female WT C57B/6 mouse was euthanized with 
pentabarbitone, as detailed in 3.8.3.  Dissection was performed rapidly under aseptic conditions.   
Briefly, isolated mouse pup brain was placed in ice-cold dissecting media.  The meninges were 
completely removed under a dissecting microscope and the cortices and hippocampus dissected 
away from the remainder of the brain.  The hippocampus was isolated by careful dissected from 
the inferior surface of the cortex, hippocampal neurones being grown in separate culture to 
cortical.   
Following thorough maceration using sterile vannas scissors the tissue was trypsinised in 0.25 % 
trypsin-EDTA in dissecting media, for 20 min at 37 °C, before trituration using a sterile Pasteur 
pipette and centrifugation at 164 g for 10 min at 4 °C.  The supernatant was discarded and the 
cells re-suspended and washed in ice-cold neurobasal media.  Centrifugation and washing was 
repeated a total of three times.  The pellet was re-suspended and a cell count performed.  Cells 
were plated in neurobasal media at a density of 5 x 105 cells / well in 24 well plates coated in poly-
L-lysine.   
Cells were incubated at 37 °C in 5 % CO2, media being replaced every 48 – 72 h.  48 h before 
the experiment, 10 μl / ml of cytarabine was added to the media (to halt glial proliferation and 
produce a pure neuronal cell culture).   
Experiments were performed on cells d 7 ex vivo.   
2.6.2 Immortal cell lines 
Two immortal cell lines were used in this in vitro part of the investigation, the H4 (a gift to the 
laboratory from Dr Zhongcong Xie, MGH, Harvard Medical School, USA),114 and N2aSwe (a gift 
to the laboratory from Dr Magdalena Sastre, Imperial College London).   
H4, a long established human neuroglioma cell line with epithelial morphology,221,222 was used as 
both naïve cells and as cells following stable transfection with full-length WT human APP gene, 
causing their over-expression of WT human APP protein.  Transfected cells were selected by 
G418 antibiotic supplemented to the media.  In the remainder of this thesis H4 refers to non-
transfected H4 cells, and H4-APP refers to cells stably transfected with WT human APP.  N2aSwe 
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are a mouse neuroblastoma cell line of neuronal and amoeboid stem cell morphology, stably 
transfected to express human APP Swedish mutation.  Only transfected cells were used.   
All procedures were performed at RT unless otherwise specified.  Immortal cells used in 
experiments were passaged ca. 8 times starting from a young passage (P2 – P5)223 and cultured 
using the following protocols:   
Reagents 
H4 working media  
H4-APP working media 
N2aSwe working media 
H4 and H4-APP cryoprotectant media  
PBS 1x for in vitro work 
Protocols describing the constituents of all media are detailed in Table 2-6..   
Aseptic technique 
All cell culture procedures were performed aseptically.  Disposable materials used in cell culture 
work were either purchased sterile (including flasks, large pipettes and Falcon tubes) or sterilized 
locally e.g. glass Pasteur pipettes, pipette tips and glass media storage bottles, by autoclaving at 
121 oC for 20 min.  All work was performed in a laminar flow hood sterilized ON by ultraviolet (UV) 
light and 70 % ethanol, using a dedicated set of measuring pipettes.  Culture flasks were sprayed 
with 70 % ethanol before transfer to and from the incubator.   
Cryostorage 
Cells were stored long term in the vapour phase of liquid N2 within labelled 1.5 ml cryoprotective 
ampules containing cryoprotectant media with density ca. 4 x 106 cells / ml.   
Thawing and plating frozen cells 
Appropriate cell media was warmed whilst frozen cells were removed from liquid N2 storage and 
rapidly thawed in a 37 oC water bath for 2 – 3 min (ensuring the cryovial cap was not in contact 
with the water).  The thawed cells in cryoprotectant media were transferred to a 15 ml centrifuge 
tube to which 5 ml warm media was added, mixed by inversion and centrifuged at 189 g for 5 min 
to remove residual cryoprotectant media.  The cell pellet was re-suspended in 5 ml warm media 
and gently agitated prior to transfer by pipette to a 25 cm3 flask containing approximately 50 ml 
 
60 
warm media.  The filter cap was applied and the flask placed in a humidified incubator at 37 oC 
with 5 % CO2.   
Cell culture maintenance 
Flasks were checked daily for any changes in media colour (red to pink / orange, indicating 
reduced pH of the media caused by the products of cell metabolism) and to assess the confluence 
of the monolayer under the inverted microscope.  Media was changed every 2 to 3 d with 75 % 
of spent media being removed and replaced with warmed fresh media appropriate to cell line.  
Both cell lines are adherent and were passaged when the monolayer was at ca. 80 % confluence.   
Sub-culturing cells (Passage) 
At 80 % confluence cells were sub-cultured to larger flasks or underwent preparation for use in 
experiments.  Early passage cells were also cryopreserved and returned to liquid N2 storage.   
To passage cells, an aliquot of the protease trypsin-EDTA 1x (0.5 %) was thawed in a 37 oC water 
bath.  Culture media was removed from the flask by pipette and the cell monolayer washed with 
10 ml PBS at RT by swirling the flask gently.  The PBS was removed and replaced with 1 – 2 ml 
trypsin-EDTA 1x, the flask rotated to ensure the monolayer was covered and transferred to the 
incubator for 5 min at 37 oC.  The flask was removed from the incubator, gently tapped to aid 
detachment of the cells and inspected under the inverted microscope to ensure all cells were re-
suspended.  When detached, trypsin was inactivated by the addition of 5 ml fresh working media 
at RT and the cell suspension transferred to a centrifuge tube and centrifuged at 189 g for 10 min 
at 4 oC.  The cell pellet was re-suspended in 1 ml fresh working media and mixed by vortexing, 
pending a cell count using tryptan blue prior to re-seeding.   
Total and viable cell count:  Tryptan blue method 
Tryptan blue is a diazo dye that is excluded by intact cell membrane.  Excluded by live cells, 
tryptan blue freely passes through the disrupted membrane of dead cells, giving their cytoplasm 
a detectable blue coloration.  This is used to distinguish live from dead cells in a dye exclusion 
method of cell quantification.   
The cell suspension was vortexed and 10 μl transferred to a 1.5 ml centrifuge tube containing 100 
μl tryptan blue 0.4 % w/v and 890 μl working media (original dilution factor of cell suspension = 
100), mixed again by vortexing briefly and allowed to incubate for 5 min at RT.   
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The coverslip was moistened with exhaled breath and slid over a clean haemocytometer until it 
was adherent.  An aliquot of the cell suspension was transferred to the haemocytometer chamber 
using a 10 μl pipette by slowly pipetting whilst touching the edge of the cover-slip with the pipette 
tip and allowing the chamber to fill by capillary action.   
Under the inverted microscope at x20 magnification, viable (unstained) and dead (blue) cells were 
counted in the 4 1 mm x 1 mm corner squares of the haemocytometer using a clicker, and the 
sum documented.   
This figure was used to calculate the number of viable cells in the 1 ml cell suspension by 
extrapolation  
Establishing seeding density:  Concentration response  
A concentration response experiment was performed to determine the optimal seeding density of 
H4 at 12 –18 h post seeding, the time point at which anaesthetic exposure would begin.  The 
desired confluence of the cell monolayer at this time point was 70 %.   
Using a 6 well plate each well 1 – 6 was seeded with a number of cells as detailed in Table 2-7, 
and allowed to incubate ON.   
Plates were then examined under the inverted microscope and photographed, the confluence of 
the cell layer at this time-point being determined using the computer software ImageJ.   
In all in vitro experiments performed, cells were seeded at 7 x 105 cells per well into a culture area 
of 962 mm2 (one well of a 6 well plate).   
Cryopreservation 
Cells of young passage were returned to liquid N2 cryostorage when available, suspended in 
cryoprotectant media following passive cryopreservation in cryovials.  Flasks were first inspected 
to ensure their contents were healthy, free of contaminants and approaching 90 % confluence (in 
a pre-confluent, log phase of growth).  Brought into suspension, cells were count, as described, 
and following centrifugation the supernatant was removed and the pellet re-suspended in cell line 
specific cryoprotectant media at a volume required to provide approximately 4 x 106 cells / ml.  1 
ml of the suspension was added to each vial, labelled with the cell line, date, passage number 
and concentration.  Closed vials were initially stored at – 20 oC for 2 h, then – 80 oC ON, followed 
by long-term storage in the vapour phase of the liquid N2 storage vessel.   
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2.7 WB for detection of protein 
Cell free assay, mouse brain tissue and cells grown in culture each underwent WB during this 
investigation.  WB identifies and quantifies proteins in a sample using a gel electrophoresis and 
two-stage antibody binding process.  This section describes the preparation of samples from cell 
culture and mouse brain specimens.  Cell free assay samples underwent WB using the non-A 
protocol due to the abundant amount of A present, whereas other samples analysed for A 
required specific protocol adaptations due to its low level expression.  All work was performed at 
RT unless otherwise stated.   
Reagents 
HEPES buffer  
Cell lysis buffer 
Tissue lysis buffer 
NuPAGE MES SDS running buffer for WB x1 
TBST for WB 
TBS for WB  
Electrotransfer buffer for A WB 
2.7.1 Sample preparation – cell lysis and tissue homogenisation 
Cultured cells 
Cell culture plates were removed from the incubator and placed on ice.  Media was aspirated 
using a pipette, transferred to a labelled centrifuge tube and snap frozen in a dewar containing 
liquid N2.  The cell layer was washed in ice-cold HEPES buffer before physical disruption in 200 
µl cell lysis buffer by scraping the base of the well plate using a cell scraper.  This was performed 
for 10 min on ice.  The cell lysate was collected by aspiration in a pipette and transferred to a 1.5 
ml centrifuge tube before centrifugation at 10,000 g for 30 min at 4 oC.  The supernatant fraction 
was collected and held on ice until storage at – 80 oC.  The pellet was discarded.   
Brain tissue 
Any dissection of brain samples was performed at the time of animal perfusion.  Tissue samples 
held in labelled centrifuge tubes were transferred from the – 80 oC freezer into a dewar containing 
liquid N2 and was kept frozen at all times prior to homogenization in tissue lysis buffer.  At the 
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time of homogenisation a sample was quickly weighed in its centrifuge tube using an analytical 
balance, before returning the sample to liquid N2.  Sample mass was calculated and the volume 
of tissue lysis buffer required was calculated (1 ml of tissue lysis buffer / 100 mg of sample).   
Samples underwent homogenization in labelled bijou tubes held on ice.  A calculated volume of 
ice-cold tissue lysis buffer and the frozen tissue sample were placed in contact with a clean 
homogenizer tip and homogenised in short sharp pulses to prevent sample overheating, until the 
sample was completely liquefied.  Care was taken to ensure that no ice from the beaker entered 
the bijou tube.  The homogenised brain tissue sample was then aspirated into a pipette and 
transferred to a centrifuge tube, followed by incubation on ice for 10 min and centrifugation at 
10,000 g for 30 min at 4 oC.  The supernatant fraction was recovered, transferred to a clean 
centrifuge tube and snap frozen in liquid N2 until storage at – 80 oC.  The pellet was discarded.   
A second centrifuge step was performed on homogenised brain samples used for A 
quantification.  Supernatant samples were further centrifuged at 4 oC and 14,000 g for 20 min.  
The supernatant was recovered and snap frozen in liquid N2 in centrifuge tubes prior to – 80 oC 
storage.   
2.7.2 Protein quantification:  Colorimetric Bradford assay 
The protein content of samples was quantified prior to WB analysis in order to ensure equitable 
amounts of protein were analysed from each sample.  Protein quantification was performed using 
the calorimetric protein assay using Bradford dye (Coomasie Brilliant Blue dye) that undergoes a 
brown to blue colour change when bound to protein.  The amount of colour change is dependent 
on the quantity of protein present and can be measured.  Working concentration Bradford dye 
was prepared by mixing Bradford dye x5 with double distilled water (dd.H2O) at a ratio of 1:4, 
followed by filtering through a 0.2 µm syringe filter.   
Preparation of protein standards 
Serial dilution of a protein stock solution (2 mg / ml) of Bovine serum albumin (BSA) with dd.H2O 
was performed to create a range of standard solutions containing differing protein concentrations 
(1.25 – 1000 µg / ml), used as standards (S1 – 6) in protein quantification work.  These were used 
to create a standard curve and are detailed in Table 2-8.   
Preparation of samples 
Samples were removed from – 80 oC storage and thawed on ice.  To ensure the protein content 
of samples was within the range of the protein standards, they were diluted 25 times in dd.H2O, 
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to a final volume of 100 µl (4 µl sample in 96 µl dd.H2O), being briefly vortexed prior to dilution, 
mixed with dd.H2O by pipetting up and down, and held on ice.   
Preparation of the plate 
Protein quantification was performed in a 96 well plate held on ice.  To each well, 10 µl of solution 
to be quantified (protein standards, 25 times diluted sample, or blanks (dd.H2O)) were loaded in 
triplicate.  200 µl of the working concentration Bradford reagent was added to each well and mixed 
by aspirating up and down.  The plate was incubated on ice for 5 min prior to a final mixing by 
rotation and immediate spectrophotometric analysis.   
Protein quantification 
Spectrophotometry was performed on the contents of each well to measure the absorbance of 
the solution at 595 nm wavelength, the protein concentration of unknown samples being 
calculated automatically by the apparatus from the standard curve generated.   
2.7.3 Western blotting 
Normalization of protein content 
To ensure the protein content of each sample undergoing electrophoresis was equal it was 
normalized to the lowest protein concentration measured in that group of samples.  This was 
achieved by dilution in cell lysis buffer, to protein concentration equal to that of the lowest 
measured.  Total volume of diluted sample was 30 µl, typically containing 45 – 60 µg protein.   
Two protocols were used for polyacrylamide gel electrophoresis (PAGE) of samples during WB.  
The non-A protocol is described first and was used for all proteins other than A, which is 
described later.   
2.7.4 WB for non-A proteins 
Denaturation 
Aliquots were held in labelled centrifuge tubes on ice.  To each aliquot 4x NuPAGE lithium dodecyl 
sulfate (LDS) sample buffer containing a blue tracking dye was added in a ratio of 3:1 (30 µl 
sample to 10 µl sample buffer) and mixed by aspirating up and down.  The mixture was heated 
to 90 oC for 5 min in a dry block heater before cooling on ice and centrifugation at 34 g for 20 sec 
to isolate the sample to the bottom of the centrifuge tube.   
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Electrophoresis 
Two precast polyacrylamide gels in cassettes (NuPage Bis-Tris Gel 4 – 12 % 10 or 12 well) were 
prepared by removal of their outer packaging, the comb from the wells and paper strip from the 
reverse, flushing the wells with running buffer and gentle realignment of the well walls with a 
needle.  Gels were loaded into an electrophoresis cell and locked in position.  The cell was half 
filled with 1X NuPAGE MES SDS running buffer for WB.  30 µl of denatured sample (45 – 60 µg 
protein) was pipetted into each well.  A pre-stained (visible) protein standard ladder (to enable 
direct visualization of the progress of protein movement during electrophoresis) and biotinylated 
ladder (to enable visualization during chemiluminescence) were also loaded into separate wells 
of the gel.  The cell was topped up with running buffer if required, closed and connected to the 
electrophoresis module.   
Non-A electrophoresis running conditions 
Electrophoresis occurred using a constant current with potential difference of 200 V for 45 min at 
RT.   
Electrotransfer 
Separated proteins were transferred from the electrophoresis gel to either a nitrocellulose or 
PVDF membrane using a dry transfer method.  The iblot® dry blotting system was used, where 
a pre-defined protocol performs electrotransfer using a potential difference of 20 V over 7 min at 
RT.  Electrotransfer was performed as per the manufacturer’s directions.  PVDF membrane had 
the advantage of being able to undergo stripping of the primary antibody and was chosen when 
this was anticipated.   
PVDF membranes were briefly washed in 100 % methanol prior to blocking.   
Immunodetection 
Following electrotransfer, membranes were blocked in a solution of 5 % non-fat dry milk in TBST 
for 3 h at RT to reduce non-specific binding of antibody.  All blocking, incubations and washing 
was performed on a rotating platform at 75 revolutions per minute (rpm) unless otherwise stated.  
All antibodies, their conditions of use and dilution in TBST are described in Table 2-9.   
Primary antibody incubation 
This occurred ON at 4 oC.  Primary antibody was diluted in 5 ml 5 % non-fat dry milk in TBST.  
The next day, primary antibody solution was removed and discarded.  Membranes were washed 
in TBST for 5 min at RT.  Washing was repeated with fresh TBST a total of 4 times.   
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Secondary antibody incubation  
Horseradish peroxidase (HRP) -linked secondary antibody was selected with specificity to the 
species in which the primary antibody was raised.  Incubation was at 4 oC for 2 h at concentration 
specified in Table 2-9.   
Antibody detection by chemiluminesence 
After secondary antibody incubation the membranes were washed in TBST for 5 min at RT.  
Washing was repeated with fresh TBST a total of 4 times.  This was followed by a single 5 min 
wash in TBS (to remove residual detergent which can interfere with chemiluminesence).   
Chemiluminesence reagent was prepared separately by mixing the two composite reagents as 
per manufacturer’s instructions.  For peptides expressed at lower concentrations the high 
sensitivity chemiluminescence agent ECL-Plus was used.224  Incubation in chemiluminesence 
agent was for 5 min at RT in the dark before visualization of protein bands using the Syngene G 
box.   
Internal control 
All membranes underwent internal control with either -actin or -tubulin quantification to 
normalize for protein content.   
2.7.5 WB for A protein 
Denaturation:   
The protocol was as for non-A protein except:   
The mixture was heated to 95 oC for 10 min in a dry block heater before cooling on ice and brief 
centrifugation.   
Electrophoresis 
Using NuPage Bis-Tris Gel 4 – 12 % 12 well, gels were installed in the cell which was filled to a 
working level with 1X NuPAGE MES SDS running buffer for WB and was not filled further.  This 
modification was needed due to the low molecular weight of the POI so as not to disrupt the 
sample after loading into the well.  30 µl of denatured sample was pipetted into each well, along 
with both ladders, as described.  500 µl of Nupage antioxidant was added to the running buffer in 
the central chamber just prior to closing the cell and starting electrophoresis.   
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A electrophoresis conditions 
Electrophoresis occurred using a constant current with potential difference of 100 V for 90 min.   
Electrotransfer 
Form A WB, proteins were transferred from the gel to nitrocellulose membrane (Whatman 
Protran Nitrocellulose transfer membrane, BA79, 0.1 µm pore size) using a semi-wet transfer 
method.  The buffer used was electrotransfer buffer for A WB and the cell was the Life 
Technologies XCell II™ Blot Module.  The nitrocellulose membrane, filter papers and sponges 
were soaked to saturation in electrotransfer buffer for A WB for several min prior to use and the 
gel was transferred immediately after electrophoresis was complete.   
The gel cassette was opened, a soaked filter paper placed over the exposed gel and air bubbles 
excluded using a roller.  The gel was trimmed, remaining cassette side removed and a pre-cut 
piece of soaked nitrocellulose membrane carefully positioned on the exposed gel surface.  This 
was covered by a further soaked filter paper and all air bubbles removed.   
The electrotransfer module was prepared by placing two soaked blotting sponges along the floor 
of the cathode (negative) core of the module.  The filter paper-gel-membrane-filter paper 
assembly was placed on the soaked pads so that the gel was nearest the cathode wall.  Using 
soaked sponges to fill the module, a second gel-membrane-filter paper assembly was inserted 
between these if there was one, always ensuring the correct anode-cathode orientation.  The 
module was then slid into an electrotansfer cell and locked in position.  Both module and 
electrotransfer cell were filled with buffer for A WB until the gel-membrane-filter paper assembly 
was covered and up to 2 cm beneath the top of the cell.   
A electrotransfer conditions 
Electrotransfer occurred using a constant current of 400 mA for 45 min, the cell placed in a bucket 
of ice.  Typical voltage achieved was 120 V.   
On completion of electrotransfer, membranes were boiled face down in PBS for 5 min.  This was 
performed in a large beaker placed on a heat plate, and the membrane was face down to prevent 
curling.   
Immunodetection 
Membranes were blocked as previously described.  Primary antibody incubation occurred ON at 
4 oC.  6E10 antibody was used for the detection of A, diluted in 1% BSA.  The next day primary 
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antibody solution was removed and stored at 4 oC.  Membranes were washed as previously 
described.   
Secondary antibody incubation 
Anti-mouse secondary antibody was used, diluted in 5 ml 5 % non-fat dry milk in TBST blocking 
solution.   
Antibody detection by chemiluminesence 
After washing, ECL-Plus was used for all A exposures, incubated for 5 min.   
Internal control 
All membranes underwent internal control with either -actin or -tubulin quantification.   
Membrane cleaning and storage 
All membranes were rinsed in PBS at the end of the chemiluminesence reaction and allowed to 
air dry ON, prior to wrapping in cling film and long-term storage at 4 oC.   
2.8 Immunoprecipitation for the detection of A by WB 
2.8.1 Measuring  Carboxyl-terminal fragments (-CTF) in in vitro cell membrane 
fraction preparations 
The purpose of this experiment was to determine if anaesthetic agents affect BACE-
this model of anaesthetic exposure in vitro.  To this end, N2aSwe, an N2A mouse neuroblastoma 
cell line stably transfected with the human APP 695 carrying Swe mutation was used.  These 
were only used in this proof of principle work and were the kind gift of Dr Magdalena Sastre.  
Gopal Thinakaran at the University of Chicago originally created N2aSwe.225     
The effect of anaesthetic agents on BACE-1 activity was determined by quantifying the amount 
of -CTFs in cell membrane fraction preparations of N2aSwe following 6 h exposure to the 
anaesthetic agents.  -CTFs are the cleavage product of APP by BACE-1 and were quantified by 
WB of membrane fraction (post nuclear supernatant) preparations.   
Reagents 
Phosphate buffered saline 1x for in vitro work 
Hypotonic lysis buffer 
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Cells were prepared and exposed to anaesthetic agents for 6 h (4 n per Condition), as described 
in 2.5.3.  To optimise the experiment for the detection of small amounts of POI the following 
adjustments were made to the protocol:  N2aSwe cells were used at the same seeding density 
as for H4 work.  Warm media containing serum were added to each well of a 6 well plate at a 
volume of 500 μl per well.  (This volume achieved good coverage of the cells throughout the 
duration of the anaesthetic exposure and was sufficient to maintain cell viability with the media 
remaining pink in colour at the end of the exposure whilst minimising media volume).   
At the end of the exposure samples were prepared as follows:   
Media 
Media was aspirated from each well, transferred to a 1.5 ml centrifuge tube, and centrifuged at 
16434 g for 10 min at 4 oC.  Media was carefully aspirated to avoid disturbing the small pellet of 
cell debris, transferred to a fresh centrifuge tube and snap frozen in liquid N2.  Samples underwent 
immunoprecipitation of A prior to WB, as described in 2.8.2.   
Cell lysate   
Cells were washed in 1 ml 1x PBS then immersed in hypotonic cell lysis buffer.  After scraping, 
the plate was incubated for 10 min on ice to allow the cells to balloon.  Using a 23 G needle and 
1 ml syringe, the lysate was aspirated 15 times to ensure mechanical breakdown of cells.  Lysate 
was transferred to a 1.5 ml centrifuge tube and centrifuged at 2096 g for 5 min at 4 oC, before 
holding on ice.  The supernatant was collected (membrane and cytosol fraction) and pellet 
(nuclear fraction) discarded.   
Supernatant was further centrifuged at 16434 g for 45 min at 4 oC.  The pellet was retained 
(membrane fraction) and the supernatant discarded.   
The membrane pellet was re-suspended in 10 μl 4X NuPAGE LDS sample buffer containing a 
blue tracking dye before boiling and directly loading onto the electrophoresis gel for WB following 
the A specific protocol detailed in 2.7.5.   
Following incubation with 6E10 antibody, membranes were examined for MPI of bands at 12 kDa.  
These bands are of -CTFs and their expression is considered a direct indication of BACE-1 
activity.224   
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2.8.2 Immunoprecipitation of A from cell-conditioned media 
The purpose of this experiment was to confirm that A from in vitro derived samples was 
detectable by WB.  Immunoprecipitation of A from the cell-conditioned media was necessary in 
order to capture all the A present within the volume of sample that underwent WB.   
Immunoprecipitation was performed as follows:   
To each sample of media held in 1.5 ml centrifuge tubes, 2 μl of antibody 4G8 was added (4G8 
recognises amino acids 17 – 24 of A and therefore binds all isoforms).   
Protein A Sepharose beads were agitated and 20 μl of the suspension was added to each sample.  
The mixture was rotated ON at 10 rpm, 4 oC, followed by centrifugation at 3018 g for 2 min at 4 
oC.   
Supernatant was discarded and the beads washed in 250 μl buffer B 1x, followed by centrifugation 
at 3018 g for 2 min at 4 oC.  Washing was repeated a total of 3 times.   
Beads were then suspended in 15 μl 1X NuPAGE LDS sample buffer with 10 % 2 
mercaptoethanol, before boiling and directly loading onto the electrophoresis gel for WB following 
the A specific protocol detailed in 2.7.5.  (Boiling dissociates the immunoglobulin and the A 
from the beads, freeing the protein to undergo electrophoresis through the gel).   
2.9 ELISA for the quantification of A 
ELISA was used to quantify A 1-42 in H4 and H4-APP lysate and cell-conditioned media that 
had been exposed to anaesthetic agents, as described in 2.5.3.  All work was performed at RT 
unless otherwise stated.   
This work was performed with the assistance of Yan Zhao.   
Reagents 
dd.H2O 
Standard reconstitution buffer  
Diluent and wash buffers, as provided in the kit by the manufacturer, reconstituted in dd.H2O as 
per the manufacturer’s instructions. 
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All antibodies, solutions and chromogens used in this ELISA were provided in kit that was stored 
at 4 oC and allowed to acclimatize to RT before use.  A consistent order of pipetting reagents from 
well-to-well to ensure equal incubation times for all wells.  All samples were analysed after first 
freeze-thaw cycle.   
Cell exposure to anaesthetic agent was performed in an identical fashion to that described in the 
protocol, apart from the following modifications that optimised the technique for the performance 
of ELISA:   
- Incubation with anaesthetic agent occurred in media containing 20 % newborn calf serum (H4 
or H4-APP working media, as appropriate).  Equal volumes of media were placed in each well at 
the start of the experiment.   
- The duration of incubation was for 24 h.   
At the end of the incubation, media was collected from the well and held on ice prior to 
centrifugation at 1341 g for 10 min at 4 oC followed by snap freezing in liquid N2.   
Cells lysates were prepared as described in the protocol in 2.7.1.   
Protein quantification was performed as per the protocol, on both media and cell lysate samples, 
to which ELISA results were normalised.   
Performance of the ELISA 
Samples were removed from – 80 oC storage and allowed to thaw on ice.   
Standards, wash buffer and Anti-rabbit IgG HRP linked secondary antibody were prepared to an 
appropriate working concentration in buffer, as per the manufacturer’s instructions.  Samples of 
media and cell lysate were diluted 1:5 in standard diluent buffer provided in the kit.  A peptide 
standards or dilute sample (50 μl) were added to each well except for the blanks.  All blanks, 
standards and diluted samples were tested in duplicate with standard diluted in the same diluent 
as the samples.  A 1-42 detection antibody (50 μl) was added to each well except for the blanks 
and the plate was allowed to incubate for 5 h on a rotating platform at 75 rpm.  To wash, inversion 
and gentle tapping on a hard surface covered in paper towel emptied the wells.  Each well was 
then filled with wash buffer using a wash bottle and the plate gently tapped.  Washing was 
repeated a total of 4 times.  Anti-rabbit IgG HRP linked secondary antibody (100 μl) was added 
to each well except for the blanks and allowed to incubate for 30 min, followed by a repeat 
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washings a total of 5 times.  Stabilised chromogen (100 μl) was then added to each well and 
incubated in the dark for 30 min.  The intensity of the blue colour change was assessed every few 
min after 30 min and the reaction stopped by the addition of 100 μl stop solution to each well, 
followed by gentle tapping to mix.  Absorbance of each well was read immediately using a 
microplate reader at 450 nm, reading against the blank wells containing only 100 μl each of 
stabilized chromogen and stop solution.  Curve fitting software was used to generate a standard 
curve and the concentration of A in the unknown samples read from the curve, correcting for the 
initial 1:5 dilution factor of the samples.   
2.10 Immunochemistry staining  
Immunochemistry was performed on formalin fixed H4-APP and mouse brain tissue following 
frozen section into 30 μm thick slices using a cryotome.  Both techniques are described here.   
Immunochemistry staining was used to detect POI in cultured cells and mouse brain tissue.  The 
POI were:   
Synaptic:   Synaptophysin, a marker of synaptic function.   
Glial:    Both microglia (IBA-1) and astrocyte (GFAP) 
APP:    In H4-APP 
A:    Using both immunofluorescence (6E10) and plaque staining (Thioflavin-S) 
Indirect immunochemistry involves permeabilisation of the cell layer / tissue section followed by 
immersion in a solution containing primary antibody that is specifically reactive to POI targets 
within.  This primary antibody, bound covalently to the POI, is detected using a specific secondary 
antibody that is conjugated to either a fluorescent (indirect immunofluorescence) or biotinylated 
(3,3'-Diaminobenzidine, DAB) tag.  This allows visualisation of the distribution of the POI and its 
quantification using fluorescent or light microscope.   
Reagents 
Cryoprotectant 
Gelatinised subbing solution and slide preparation 
Hydrogen peroxide 3 % in methanol 10% in PBS for immunochemistry 
Pepsin solution (working 0.15 mg / ml) for antigen retrieval 
PFA 4 % solution in PB 
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Sucrose 30 % solution 
Sudan black 0.1 % in 70 % ethanol solution 
Thioflavin-S 1 % w / v in dd.H2O 
TBS 1x for immunochemistry 
TBS_T for immunochemistry 
Triton® 1 % in TBS 
Triton® 0.3 % in TBS 
For both protocols sample preparation was carried out over two consecutive d.  All incubations, 
blocks and rinses were on a rotating platform at 75 rpm RT unless otherwise specified.  Antibodies 
were individually sourced from the supplier, summarised along with the working concentrations 
and incubation conditions in Table 2-9.   
2.10.1 Preparation of specimens for immunochemistry 
Cell specimens:  Fixation  
Cell specimens were fixed in Paraformaldehyde 4% (PFA) prior to immunochemistry.  Culture 
plates were briefly rinsed in ice-cold PBS and the cells covered in ice-cold PFA on ice for 10 min.  
Immunochemistry was then performed immediately.   
Brain tissue specimens:  Fixation and dehydration 
Brain tissue was fixed following ice-cold PBS perfusion, by either:   
- Perfusion-fixation with ice-cold PFA for 10 min prior to post-fixation in PFA 4% for a minimum of 
72 h at 4 oC.   
- Post-fixation by immersion in PFA at 4 oC for a minimum of 72 h.   
Following fixation, brain tissue specimens were dehydrated in 30 % sucrose solution.   
Fixed whole brain storage 
Fixed mouse brains (whole and hemi) were stored intact at 4 °C in 30 % sucrose solution 
containing 2 % sodium azide.   
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Brain tissue specimen sectioning and storage 
Brain tissue was sectioned into 30 µm slices using a cryotome.  Following removal from the 30 % 
sucrose solution brains were sectioned caudally approximately 3 and 10 mm posterior to the front 
of the cerebral cortex.  The mid-section was sectioned into 30 µm thick slices which were stored 
suspended in cryoprotectant in 24 well plates at – 20 °C.   
Brain tissue specimen selection and rehydration 
Prior to immunochemistry, brain sections were rehydrated in ice-cold PBS in a large petri dish.  
From here sections representative of the anterior, middle and posterior hippocampus were 
selected and transferred to PBS, held in a sterile 24 well plate, used for the immunochemistry 
work.   
2.10.2 Immunochemistry:  Thioflavin / IBA free-floating protocol  
A step-by-step guide to the protocol is provided in the appendix.   
Day 1.  Permeabilisation, Thioflavin-S staining and primary antibody incubation 
Immunohistochemistry work was carried out in a 24 well plate.  Representative brain slices (5 – 
10 slices per mouse in total) from anterior, middle and posterior hippocampus were washed in 
dd.H2O for 5 min.  Washing was repeated a total of 3 times followed by a PBS holding step.  Wells 
being actively stained were aspirated to dryness and 300 µl Thioflavin-S solution added for 7 min.  
The tissue was rinsed in 70 % ethanol rinse for 3 min a total of 3 times, prior to PBS for 5 min 
followed by a PBS holding step while other slices were being stained.  All slices were then blocked 
in 0.01 % PBS-T with 10 % normal Donkey serum for 1 h before immersion in block solution 
containing IBA-1 primary antibody, 250 µl per well.  Plate lids were sealed with adhesive tape to 
minimise evaporation during incubation.   
Day 2:  Rinse, secondary antibody incubation, Hoechst staining, mount, Sudan black block 
and coverslip 
The primary antibody solution was removed and each well was filled with PBS and rinsed for 5 
min.  Rinsing was repeated with fresh PBS a total of 3 times.  Secondary antibody incubation 
(rhodamine conjugated) was added at 300 µl per well for 2 h before rinsing in PBS for 5 min in 
low light.  Rinsing was repeated a total of 3 times.  Hoechst solution was used at 1:5000 in PBS, 
200 µl per well, incubated for 5 min in low light.   
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Free-floating sections were mounted on gelatine coated glass microscope slides and allowed to 
air dry for 1 h in low light.   
Sudan black was used to minimise auto fluorescence of brain sections.  Air dried slides were 
immersed in 0.1 % solution in 70 % ethanol for 5 min without agitation, in low light.  Slides were 
washed in dd.H2O, for 5 min without agitation in low light a total of 3 times before 1 h air dry.  
Coverslips were placed using glycerol mounting medium containing ascorbic acid to prevent 
fading.  The coverslip was sealed 24 h later and the slides stored at 4 °C.   
2.10.3 Immunochemistry:  Synaptophysin free-floating DAB protocol  
Differences between this protocol and the IBA Thioflavin-S protocol are described here.  A step-
by-step protocol is included in the appendix.   
Day 1.  Antigen retrieval, permeabilisation and quenching, block and primary antibody 
incubation 
Rinsing in PBS was performed 3 times followed by antigen retrieval using 0.15 mg / ml pepsin in 
0.2N HCL solution, 300 µl / well at 37 °C without agitation for 8 min.  Specimens were then rinsed 
in PBS for 5 min, repeated a total of 3 times.  Slices were permabilised using TBS-T rinse for 5 
min, repeated 3 times.  Tissue peroxidase was inactivated and the tissue quenched using 3 % 
H2O2 in 10 % methanol in PBS, 400 µl per well for 10 min followed by 3 rinses in TBS-T, each 
rinse for 2 min.   
Slices were blocked in 0.3 % Triton in TBS with 10 % normal Donkey serum for 30 min followed 
by a total of 3 rinses in TBS-T for 2 min.   
Slices were further blocked in Fab fragment Mouse IgG 0.12 mg / ml in PBS for 1 h.  This second 
block step was performed to minimise non-specific binding to the mouse tissue as the primary 
antibody was of mouse origin.  This was followed by TBS-T rinse for 2 min a total of 3 times.   
Synaptophysin primary antibody was used in 0.3 % Triton in TBS with 5 % normal donkey serum, 
250 µl per well, incubated ON at 4 °C.   
Day 2:  Rinse, secondary antibody incubation, Hoechst staining, mount, Sudan Black block 
and coverslip 
Tissue was rinsed in TBS-T for 5 min a total of 3 times.  Secondary antibody (Biotin conjugated 
donkey anti-mouse) was used at 1:500 in PBS, 300 µl per well.  Incubation occurred for 20 min.   
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The secondary antibody solution was aspirated to dryness followed by TBS-T rinse for 2 min in 
low light, repeated with fresh TBS-T a total of 3 times.   
At least 30 min before use, 10 ml ABC complex solution was prepared as per the manufacturer’s 
instructions.  Incubation was performed by adding 5 drops of ABC complex solution to each well 
and incubating for 40 min.   
DAB solution was prepared at least 30 min before use, as per the manufacturer’s instructions.  
Tissue was DAB stained one well at a time by adding 400 µl of DAB solution and incubating for 
55 sec.  The reaction was stopped by flooding the well with dd.H2O whilst gently agitating the 
plate.  The slices were immediately transferred to a labelled 5 ml bijou tube filled with dd.H2O 
using a paintbrush.  Specimens were rinsed for 5 min without agitation a total of 3 times.   
Free-floating stained sections were mounted on gelatine coated glass microscope slides and 
allowed to air dry ON, prior to the application of a coverslip using DPX mounting medium.  After 
drying, slides were stored in cardboard slide holders at RT.   
2.10.4 Immunochemistry:  APP, GFAP and 6E10 protocols 
Sample step-by-step protocols are included in the appendix.   
2.10.5 Microscopy 
Images of specimens were all recorded as Tagged Image File Format (TIFF) files. 
2.11 Results 
2.11.1 Results:  cell free assay 
Spontaneous oligomerisation behaviour 
Results of WB for A monomer and ADDL solutions exposed for 24 h to anaesthetic agents at 37 
oC are illustrated in Figure 2-3, Figure 2-4 and Figure 2-5.   
Monomer is defined as a band appearing at 4.5 kDa, LMW as bands between 5 – 20 kDa and 
HMW as bands at 50 – 140 kDa.  Results are described for each as % of the total protein content 
of the sample, determined during protein quantification.  The amount of protein in each sample 
was the same at the start of the experiment (11.28 µg per sample of A monomer solution).   
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Molecular profiling of the starting solutions 
A monomer solution (Figure 2-3) contained 69.44 % ± 2.286 % (SD) of total protein to be 
monomeric, with 20.84 % ± 1.545 % as LMW oligomers and 9.726 % ± 0.8555 % as HMW 
oligomers.   
ADDL solution (Figure 2-3) contained 64.76 % ± 4.362 % total protein as monomer, 24.39 % ± 
2.986 % and LMW oligomer and 10.85 % ± 1.390 % as HMW oligomers.   
No Fibrillar material removed by centrifugation was detected in either solution at the start of 
incubation.  However after 24 h incubation at 37 oC both solutions contained large amounts of 
Fibrillar material removed by centrifugation (Figure 2-3 C + D), showing that oligomerisation of 
the A had taken place in these conditions.   
Effect of anaesthetic agents on A monomer solution 
The percentage of total protein present as monomer was anaesthetic agent dependent, with 
highest % seen in Xenon 50 % (6.930 % ± 1.178 %) compared to Control values of 1.615 % ± 
0.05164 %).  Differences to Control were also found in Isoflurane (4.859 % ± 0.1386 %) and 
Nitrous Oxide 75 % (3.638 % ± 0.3347 %.  ANOVA p < 0.0001).   
Differences of the same magnitude were also observed in LMW and HMW oligomers (ANOVA p 
= 0.0004 and < 0.0001 respectively).  Large amounts of Fibrillar material removed by 
centrifugation were seen in all conditions.   
Data are illustrated in Figure 2-4.   
Effect of anaesthetic agents on ADDL solution 
The amount of Fibrillar material removed by centrifugation, as a percentage of total protein 
content, was less when starting with ADDL solution.  This suggests that more protein remains in 
its monomeric, LMW and HMW oligomeric forms.   
The percentage of total protein present as monomer was anaesthetic agent dependent, with 
highest percentage seen in Nitrous Oxide 75 % (43.71 % ± 7.332 %) compared to Control at 
9.510 % ± 2.283 %, Isoflurane 2% at 19.59 % ± 2.910 % and Xenon 50 % at 21.99 % ± 4.740 %.   
For each of monomer, LMW and HMW oligomers ANOVA p was < 0.0001 for the experiment.   
Data are illustrated in Figure 2-5.   
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2.11.2 Results:  in vitro 
The effect of anaesthetic agents on primary neuronal culture  
Concentration-response of A on cell viability 
Cell viability of primary neuronal cells decreased with increasing concentration of A 
supplementation in media above 0.078 μM.  Cell viability was seen to plateau at 0.6 of Control at 
A concentration above 1.25 μM.   
The sigmoidal shape of the dose response curve reveals a non-linear concentration-response 
relationship between A and cell viability, as assessed using MTT assay.  The curve (illustrated 
in Figure 2-6 A) reveals threshold-concentration of 0.078 μM, EC50 = 0.4 μM and maximal-dose 
of 1.25 μM.   
On microscopy (x20), Control neurones had normal, healthy phenotype with large cell bodies and 
dense dendritic networks.  Neurones in A supplemented media showed shrunken cell bodies 
with reduced dendritic networks at concentrations above 0.078 μM.   
Data are illustrated in Figure 2-6 A.   
Dose response of anaesthetic agents on primary neurone viability in A supplemented 
media 
This data (illustrated in Figure 2-6 B – D) revealed the concentration dependent effects of 
anaesthetic agents on cell viability in A supplemented media.   
The effect of Isoflurane 
In cells cultured in A 0.8 μM supplemented media, isoflurane at concentrations above 0.5 % had 
a concentration dependent effect on cell viability.  In Isoflurane 0.5 %, viability was no different to 
that seen with A alone (0.58 and 0.53 fold relative to A-free Control).  In Isoflurane 1.5 %, 
viability was increased compared to A alone (0.65 and 0.53 fold relative to Control, p = < 0.01), 
but remained significantly reduced compared to A-free Control.  Isoflurane 2 % showed viability 
decreased compared to A alone (0.19 and 0.53 fold of Control, p = < 0.0001).   
Cell viability was improved by isoflurane at 1 %, but reduced at 1.5 %, revealing a dose dependent 
effect of isoflurane cell viability in the presence of 0.8 μM A.   
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Data are illustrated in Figure 2-6 B.   
The effect of nitrous oxide 
Nitrous oxide reduced the impact of A on viability at all concentrations investigated, when 
compared to A alone (p = < 0.0001), but was unable to restore viability Control level.   
Data are illustrated in Figure 2-6 C.   
The effect of xenon 
Similarly, xenon reduced the impact of A on cell viability at all concentrations investigated, (p = 
< 0.0001), but was unable to restore viability to A-free Control level.   
Data are illustrated in Figure 2-6 D.   
Both nitrous oxide and xenon were protective of cell viability in 0.8 μM A supplemented media, 
in a concentration dependent manner, at all concentrations tested.   
Concentration response of H4 
Examination of the wells showed that cells at all seeding density had become adherent to the well 
floor during the 18 h incubation and all had normal morphology at all seeding densities.  Cells had 
circular morphology at 1 x 105 but there was no evidence of recent cell division (they were all 
isolated and none were closely abutting).  More evidence of extracellular matrix was seen on the 
well floor with seeding densities above 3 x 105.  Cell growth after 5 x 105 seeding appeared stunted 
but intact cells were present with lots of matrix and no evidence of contamination.   
Analysis using ImageJ (data not shown) showed the no clear trend in confluence achieved at this 
time point regardless of seeding density.  The 7 x 105 density displayed the most favourable 
characteristics of those examined (large, circular cells with evidence of recent cell division and 
deposition of matrix) with highest degree of measured confluence and this seeding density was 
selected for the in vitro work described in this investigation.   
The confluence of a typical cell monolayer used during exposure experiments is illustrated in 
Figure 2-1.   
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WB for detection of protein 
WB for protein was performed on lysates of H4 and H4-APP that had been exposed to different 
anaesthetic agents.   
The effect of anaesthetic agents on immortal cell culture 
APP-Full length 
The expression of APP-Full length was examined (using WB of lysate) in H4 and H4-APP under 
Control conditions (37 oC and 5 % CO2), and in H4-APP after 6 h exposure to Isoflurane 2 %, 
Nitrous Oxide 75 % and Xenon 75 %.  The data are illustrated in Figure 2-7 as fold change 
compared to H4 Control with n = 6 per condition.   
No difference was found in the expression of WT APP-Full length between H4 and H4-APP.   
Different anaesthetic agents had no effect on the expression on WT APP-Full length in H4-APP 
(ANOVA p = 0.3877).   
BACE-1 
BACE-1 expression 
BACE-1 expression was quantified by WB.  The data showed that BACE-1 expression was the 
same in H4 and H4-APP, and showed a trend towards reduction in Isoflurane, but this reduction 
did not reach statistical significance.   
Data are illustrated in Figure 2-8, n = 4 per condition.   
BACE-1 activity 
The activity of BACE-1 was examined by quantifying -CTF’s (10 kDa) using WB of membrane 
preparations of N2aSwe under Control and anaesthetic exposure conditions.  This immortal cell 
line was chosen as it is known to produce large amounts of A that is quantifiable by WB.  The 
antibody used was 6E10.  Quantification of -CTF are considered a direct marker of BASE-1 
activity224 and -CTF’s have previously been shown to be reduced by Isoflurane 2 %.114  The WB 
was normalised against APP-Full length (100 – 105 kDa) that is also detected by 6E10.   
The data are illustrated in Figure 2-9, n = 3 per condition.   
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Xenon was found not to affect -CTF level.   
Both Isoflurane 2 % and Nitrous Oxide 75 % reduced CTF in membrane preparations of 
N2aSwe.  This directly reflects reduced BACE-1 activity, (ANOVA p = 0.0002).  A WB from cell-
conditioned media that underwent immunoprecipitation of A also showed reduced A after 
isoflurane exposure (data not shown).   
-secretase expression 
Several experiments were performed to determine if -secretase activity was affected in a similar 
way using WB for nicastrin subunit of the -secretase complex.  The data are illustrated in Figure 
2-10, n = 15 – 17 per condition.   
There was no difference in -secretase expression between H4 and H4-APP and the different 
anaesthetic exposure conditions did not influence -secretase expression in H4-APP (ANOVA p 
= 0.5246).   
Human A 1-42 synthesis 
A 1-42 expression was determined in the same experimental model using ELISA for human A 
1-42.  This was performed on both cell-conditioned media and cell lysate.  The data are illustrated 
in Figure 2-11, n = 3 – 4 per condition.   
Analysis of cell-conditioned media (Figure 2-11 A) showed that human A 1-42 expression was 
higher in H4-APP than in H4 (p < 0.05).  This is in keeping with their stable transfection with 
human Swedish APP gene.   
Isoflurane 2 % increased the amount of human A 1-42 expressed by H4-APP.  This increase 
was statistically significant when compared to H4 Control (p < 0.001), but did not reach statistical 
significance when compared to H4-APP Control.   
Nitrous oxide and xenon did not appear to affect human A 1-42 expression in the same way, 
levels being different to H4 Control (p < 0.05 for both conditions) but not different to H4-APP 
Control.   
Analysis of cell lysate samples (Figure 2-11 B) showed human A 1-42 levels to be higher in 
lysate than in cell-conditioned media.  There was no difference between H4 and H4-APP and 
anaesthetic exposure had no effect on levels in lysate (ANOVA p = 0.5576).   
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The effect of anaesthetic agents on cell death and apoptosis in H4-APP 
Cytochrome c 
Cytochrome c was used as a marker of cell injury, levels being determined by WB.  The data are 
illustrated in Figure 2-12, n = 4 per condition.   
There was no difference in cytochrome c expression between H4 and H4-APP.  The spread of 
the data meant no difference between groups was detectable in this experiment (ANOVA p = 
0.72).  Although the figure suggests that cytochrome c was increased in H4-APP by isoflurane 
and reduced by xenon, the broad 95 % CI show that this did not achieve statistical significance.   
BCL-2 
Similarly, expression of the anti-apoptotic oncogene BCL-2 was quantified by WB.   
BCL-2 expression was significantly less in H4-APP Control than H4 Control (p < 0.01).  However, 
H4-APP exposed to Xenon 75 % expressed BCL-2 at levels that were not different to H4 Control.   
Xenon appears to promote the expression of the anti-apoptotic oncogene BCL-2 in H4-APP.   
Data are illustrated in Figure 2-13, n = 4 per group.   
Cleaved caspase-3 
Dose response of cleaved caspase-3 
The dose response of cleaved caspase-3 was examined in H4-APP in difference concentrations 
of isoflurane, nitrous oxide and xenon.  The data are illustrated in Figure 2-14, n = 3 per condition.   
Isoflurane and cleaved caspase-3 
Isoflurane increased cleaved caspase-3 in H4-APP at all concentrations investigated (ANOVA p 
= < 0.0001) in a concentration dependent manner up to 1.5 % (Isoflurane 1 % to Control p = < 
0.01, Isoflurane 1.5 % to Control p = < 0.0001 and Isoflurane 2 % p = < 0.0001).   
Nitrous oxide and cleaved caspase-3 
Nitrous oxide had a concentration dependent effect on cleaved caspase-3.   
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In Nitrous Oxide 25 % and 50 %, cleaved caspase-3 was reduced compared to Control (p = < 
0.0001).  A difference was found between Nitrous Oxide 25 % and 50 % (p = < 0.0001).   
In Nitrous Oxide 75 % cleaved caspase-3 was increased compared to Control (p = < 0.0001).   
Xenon and cleaved caspase-3 
Xenon had a concentration dependent effect on cleaved caspase-3.   
At Xenon 25 %, cleaved caspase-3 was increased compared to Control (p = < 0.0001).  At Xenon 
50 and 75 %, cleaved caspase-3 was reduced compared to Control (p = < 0.0001).  There was 
no difference between Xenon 50 % and 75 %.   
The experiments were further repeated with n = 7 – 10, using Isoflurane 2 %, Nitrous Oxide 75 % 
and Xenon 75 %.  These experiments showed that cleaved caspase-3 expression was not 
different in H4 and H4-APP.   
Data confirmed the preliminary dose response work, showing cleaved caspase-3 reduced by 
Xenon 75 % (p < 0.05) but increased by Isoflurane 2 % (p < 0.05).  A statistically significant 
difference was found between xenon and both isoflurane and nitrous oxide conditions (p < 
0.0001).   
Data are illustrated in Figure 2-15.   
2.12 Summary 
Cell free assay and in vitro results are summarized in Table 2-10 
Both A and anaesthetic agents exert independent effects on several cellular process that 
culminate in altered protein expression and cell viability.  These effects are seen both in immortal 
cell lines and in primary neuronal culture.   
A effect on primary neuronal viability shows dose dependence, the shape of the data suggesting 
a receptor mediated mechanism.   
H4-APP did not appear to produce more WT human APP, suggesting a defect in transfected gene 
expression in H4-APP.  H4-APP did appear to produce more A than H4.   
Isoflurane was confirmed to modulate BACE-1 activity in this laboratory.   
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Isoflurane affected A synthesis in H4-APP, as determined by ELISA.   
Cleaved caspase-3 expression was the same in H4 and H4-APP.  All the agents investigated 
affected cleaved caspase-3 expression and may therefore modulate apoptosis.   
BCL-2, an anti-apoptotic oncogene, had reduced expression in H4-APP than H4 under Control 
conditions.  Xenon exposure made its expression the same.   
Cell viability was reduced by A in a dose dependent manner.  Isoflurane 2 % increased the 
neurotoxicity of A in vitro but both nitrous oxide and xenon appeared to show neuroprotective 
properties. 
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Figure 2-1:  H4 cell confluence at the start of anaesthetic exposure 
 
Photograph of a healthy H4 cell layer adherent to a culture flask. The layer is at 50 – 70 % 
confluence, cells are actively dividing.  Confluence approaching 70 % was used for all anaesthetic 
exposure experiments.  Magnification x20.   
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Figure 2-2:   The anaesthetic exposure chamber 
 
With 1.5 l internal volume, main features of this airtight chamber are highlighted.   
This image was originally created by Olar Adeyi and modified by Dafydd Lloyd.   
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Figure 2-3: Spontaneous oligomerisation of A 
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This figure illustrates A quantification in solution using WB with 6E10 antibody to observe the change in molecular composition of a standard 
A monomer solution over 24 h at different temperatures.  The x-axes represent the molecular species and the y-axes represent the amount of 
species as a % of total protein.   
 A:   This scatter plot illustrates analysis of the starting monomer solution, confirming that most protein is present in its monomeric form (4.5 
kDa) with smaller amounts of LMW (5 – 20 kDa) and HMW (50 – 140 kDa) oligomers but no fibrillar material that was removed by 
centrifugation.   
B:   This scatter plot illustrates analysis of the solution after 24 h incubation at 37 oC.  The solution contains mainly fibrillar structures that were 
removed by centrifugation.   
C:   This scatter plot illustrates analysis of the solution after 24 h at 4 oC.  The % protein detected as A monomers is reduced as compared to 
the starting solution, with an increase in predominantly the low molecular weight oligomers.  This solution was used as a source of ADDL 
in subsequent experiments.   
D:   Incubation of the ADDL at 37 oC showed most molecules had spontaneously oligomerised into fibrillar material that was removed by 
centrifugation.   
All data are presented as mean (95 % CI), n numbers per group are illustrated in the figure.   
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Figure 2-4: Oligomerisation of A monomer solution 
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This figure illustrates A quantification in solution using WB with 6E10 antibody to observe the change in molecular composition of monomer 
starting solution after 24 h exposure to different anaesthetic agents at 37 oC.  The x-axes represent the Condition and the y-axes the % oligomer 
of total protein.  The protein content of both starting solutions is the same.   
A:   Monomers (4.5 kDa) in solution 
B:   LMW oligomers (5 – 20 kDa) in solution 
C:  HMW oligomers (50 – 140 kDa) in solution 
D:   Fibrillar material removed by centrifugation 
Comparing products from monomer and ADDL (Figure 2-5) starting solutions, these scatter plots illustrate that the % of total protein present as 
monomers, LMW oligomers and HMW oligomers after the incubation was dependent on both the starting solution and the anaesthetic agent.   
A higher % total protein was present in monomer, LMW and HMW forms at this time point when starting with ADDL solution, as compared to A 
monomer solution.  Plots D illustrate that more A has oligomerised into fibrillar material removed by centrifugation when starting with monomer 
solution than with ADDL solution.  This suggests the protein content of analysates from monomer starting solution is higher than analysates from 
ADDL solution, as more A monomers, LMW oligomers and HMW oligomers remain in solution.   
All data are presented as mean (95 % CI).  A:  F3 8= 39, p = < 0.0001; B:  F3 8= 20, p = < 0.0004; C:  F3 8= 53, p = <0.0001.  p value derived from 
one-way ANOVA, *, **, *** and **** mean p = < 0.05.  n numbers per group are illustrated in the figure.   
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Figure 2-5 Oligomerisation of A ADDL solution 
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This figure illustrates A quantification in solution using WB with 6E10 antibody to observe the change in molecular composition of ADDL starting 
solution after 24 h exposure to different anaesthetic agents at 37 oC.  The x-axes represent the Condition and the y-axes the % oligomer of total 
protein.  The protein content of both starting solutions is the same.   
A:   Monomers (4.5 kDa) in solution 
B:   LMW oligomers (5 – 20 kDa) in solution 
C:   HMW oligomers (50 – 140 kDa) in solution 
D:   Fibrillar material removed by centrifugation 
Comparing products from monomer (Figure 2-4) and ADDL starting solutions, these scatter plots illustrate that the % of total protein present as 
monomers, LMW oligomers and HMW oligomers after the incubation was dependent on both the starting solution and the anaesthetic agent.   
A higher % total protein was present in monomer, LMW and HMW forms at this time point when starting with ADDL solution as compared to A 
monomer solution.  Plots D illustrate that more A has oligomerised into fibrillar material removed by centrifugation when starting with monomer 
solution than with ADDL solution.  This suggests the protein content of analysates from monomer starting solution are higher than analysates 
from ADDL starting solution, as more A monomers, LMW oligomers and HMW oligomers remain in solution.   
All data are presented as mean (95 % CI).  A:  F3 16= 46, p = < 0.0001; B:  F3 16= 63, p = < 0.0001; C:  F3 16= 23, p = < 0.0001.  p value derived 
from one-way ANOVA, *, **, *** and **** mean p = < 0.05.  n numbers per group are illustrated in the figure.   
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Figure 2-6: Primary neuronal cell viability after anaesthetic exposure in A supplemented media 
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This plate of 4 figures illustrates the effect of A and the effect of A with anaesthetic agents, on primary neuronal culture cell viability using MTT 
assay.   
A:  This line graph illustrates a concentration-response curve.  The x-axis represents the concentration of A in media (μM) and the y-axis the 
fold change compared to A free Control.   
B:  This scatter plot illustrates the effect of isoflurane at 0.5, 1.5 and 2 % on cell viability after 24 h exposure in media containing 0.8 μM A.  The 
x-axis represents the Condition and the y-axis the fold change compared to A free Control.   
C:  This scatter plot illustrates the effect of Nitrous Oxide 25 %, 50 % and 75 %.   
D:  This scatter plot illustrates the effect of Xenon 25 %, 50 % and 75 %.   
A:  A reduces cell viability of primary neuronal culture at concentration above 0.078 μM.   
B:  Isoflurane effect on cell viability is concentration dependent, with no effect at 0.5 %, increased cell viability at 1.5 % and reduced cell viability at 2 
%.   
C:  Nitrous Oxide reduced the impact of A on cell viability in a concentration dependent manner, at all Nitrous Oxide concentrations investigated.   
D:  Xenon reduced the impact of A on cell viability in a concentration dependent manner, at all Xenon concentrations investigated.   
All data are presented as mean (95 % CI).  B:  F4 55= 108, p = <0.0001; A to A + Isoflurane 0.5 % t = 1.6, p > 0.05, A to A + Isoflurane 1.5 
%:  t = 1.5, p < 0.01; A to A + Isoflurane 2 %:  t = 9, p < 0.0001.  C:  F4 50= 83, p = <0.0001;  A to N20 25 %:  t = 6.9, p = <0.0001;  D:  F4 52= 
66, p = <0.0001; A to Xenon 25%:  t = 7, p = <0.0001.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple Comparison 
Test, *, **, *** and **** mean p = < 0.05.  n numbers per group are illustrated in the figure.   
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Figure 2-7: The effect of anaesthetic exposure on APP-Full length 
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This figure illustrates normalised WB for protein from cell lysates of H4 and H4-APP cells exposed to isoflurane, nitrous oxide and xenon using 
APP antibody.  The x-axis represents the condition (cell type and anaesthetic agent) and the y-axis represents fold change in MPI compared to 
H4 Control.   
The scatter dot plot illustrates that the expression of APP-Full length (mature and immature isoforms) is the same in H4 and H4-APP and in H4-
APP is not affected by exposure to the anaesthetic agents.  
All data are presented as mean (95 % CI).  F4 23=1.1, p = 0.39.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple 
Comparison Test.  n numbers per group are illustrated in the figure.   
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Figure 2-8: The effect of anaesthetic exposure on BACE-1 
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This figure illustrates normalised WB for protein from cell lysates of H4 and H4-APP cells exposed to isoflurane, nitrous oxide and xenon using 
BACE-1 antibody.  The x-axis represents the condition (cell type and anaesthetic agent) and the y-axis represents fold change in MPI compared 
to H4 Control.   
The scatter dot plot illustrates that the expression of BACE-1 is the same in H4 and H4-APP and in H4-APP is not affected by exposure to the 
anaesthetic agents.   
All data are presented as mean (95 % CI).  F4 15=2.8, p = 0.06.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple 
Comparison Test.  n numbers per group are illustrated in the figure.   
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Figure 2-9: The effect of anaesthetic exposure of -CTF’s 
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This figure illustrates normalised WB for protein from membrane fraction (post nuclear supernatant) preparations of N2aSwe cells exposed to 
isoflurane, nitrous oxide and xenon, using 6E10 antibody for A.  The x-axis represents the Condition and the y-axis represents % -CTF 
compared to Control.   
The figure illustrates that -CTF is significantly reduced in N2aSwe cells in Isoflurane and Nitrous Oxide compared to Control.   
All data are presented as mean (95 % CI).  F3 8= 26, p = 0.0002.  Control to Isoflurane:  t = 8.8 df = 8, p < 0.001; Control to Nitrous Oxide:  t = 
3.8, df = 8, p < 0.05.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple Comparison Test.  * means p < 0.05, *** means p 
< 0.001.  n numbers per group are illustrated in the figure.   
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Figure 2-10: The effect of anaesthetic exposure on -secretase, nicastrin subunit 
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This figure illustrates normalised WB for protein from cell lysates of H4 and H4-APP cells exposed to isoflurane, nitrous oxide and xenon using 
secretase, nicastrin subunit antibody.  The x-axis represents the Condition and the y-axis represents fold change in MPI compared to H4 
Control.   
The scatter dot plot illustrates that the expression of -secretase nicastrin subunit is the same in H4 and H4-APP and in H4-APP is not affected 
by exposure to the anaesthetic agents.   
All data are presented as mean (95 % CI).  F4 74=0.81, p = 0.52.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple 
Comparison Test.  n numbers per group are illustrated in the figure.   
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Figure 2-11: A quantification by ELISA 
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This figure illustrates normalised ELISA data for protein from cell-conditioned media and cell 
lysates of H4 and H4-APP exposed to isoflurane, nitrous oxide and xenon using ELISA specific 
to human A 1-42.  The x-axis represents the Condition (cell type and the anaesthetic agent) and 
the y-axis represents [A 1-42] in either A:  media or B:  cell lysate, in pg / ml.   
A:   The scatter dot plot illustrates that the level of A 1-42 is higher in H4-APP Control as 
compared to H4 Control.  The difference between H4-APP Control and H4-APP Isoflurane 
did not reach statistical significance.  (Data illustrated is normalised to protein in respective 
media.  The result is the same if normalised to protein in respective cell lysate also).   
B:   This scatter dot plot illustrated that the level of A 1-42 in H4 and H4-APP is the same and 
is unaffected by exposure to the anaesthetic agents.   
All data are presented as mean (95 % CI).  A:  F4 14=9.2, p = 0.0007, H4 Control to H4-APP 
Control t = 3.4, p = < 0.05; B:  F4 15=0.78, p = 0.56.  p value derived by one-way ANOVA with post 
hoc Bonferroni's Multiple Comparison Test.  * means p < 0.05, n numbers per group are illustrated 
in the figure.   
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Figure 2-12: The effect of anaesthetic exposure on Cytochrome c 
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This figure illustrates normalised WB for protein from cell lysates of H4 and H4-APP exposed to isoflurane, nitrous oxide and xenon using 
cytochrome c (136F3) antibody.  The x-axis represents the Condition (cell type and the anaesthetic agent) and the y-axis represents fold change 
in MPI compared to H4 Control.   
The scatter dot plot illustrates that the level of total cytochrome c expressed is the same in H4 Control and H4-APP Control and in H4-APP is 
not altered by exposure to the anaesthetic agents.   
All data are presented as mean (95 % CI).  F4 15= 0.53, p = 0.71.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple 
Comparison Test.  n numbers per group are illustrated in the figure.   
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Figure 2-13: The effect of anaesthetic exposure on BCL-2 
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This figure illustrates normalised WB for protein from cell lysates of H4 and H4-APP exposed to isoflurane, nitrous oxide and xenon using BCL-
2 antibody.  The x-axis represents the Condition (cell type and the anaesthetic agent) and the y-axis represents fold change in MPI compared 
to H4 Control.   
The scatter dot plot illustrates that the total expression of BCL-2 is lower in H4-APP Control, H4-APP Isoflurane and H4-APP Nitrous Oxide 
compared to H4 Control, which is also seen in.  No difference is seen between H4 and H4-APP Xenon.  H4-APP Xenon is different to H4-APP 
Isoflurane.   
All data are presented as mean (95 % CI).  F4 15=9, p = 0.0006.  H4 to H4-APP t = 4.2, p = < 0.01; H4 to H4-APP Xenon t = 1.2, p > 0.05; H4-
APP Isoflurane to H4-APP Xenon t = 3.8, p < 0.05.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple Comparison Test.  
** means p < 0.01, * means p < 0.05.  n numbers per group are illustrated in the figure.   
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Figure 2-14: Concentration response of cleaved caspase-3 
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This figure illustrates normalised WB for protein from cell lysates of H4-APP exposed to isoflurane, nitrous oxide and xenon, using cleaved 
caspase-3 (Asp 175) antibody.  The x-axis represents the [anaesthetic agent] in 21 % O2 and 5 % CO2 and the y-axis represents fold change in 
MPI compared to H4-APP Control.   
A:   The scatter dot plot illustrates that the amount of cleaved caspase-3 (large fragment) increases with increasing [isoflurane] up to 1 % and 
then remains the same.   
B:   The scatter dot plot illustrates that nitrous oxide has a concentration dependent effect with cleaved caspase-3, which is significantly reduced 
compared to Control at both 25 % (p < 0.0001) and 50 % (p < 0.001), but significantly increased at a 75 %.   
C:   The scatter dot plot illustrates that xenon has a concentration dependent effect on cleaved caspase-3 with levels increased at 25 % but 
reduced at 50 % and 75 %.   
All data are presented as mean (95 % CI).  A:  F3 8=281, p = < 0.0001, H4-APP to H4-APP Isoflurane 2 % t = 23, p < 0.0001.  B:  F3 8= 2728, p 
= < 0.0001.  H4-APP to H4-APP Nitrous Oxide 25 % t = 35, p < 0.0001; H4-APP to H4-APP Nitrous Oxide 50 % t = 6.9, p < 0.001, H4-APP to 
H4-APP Nitrous Oxide 75 % t = 53, p < 0.0001.  C:  F3 8=365, p = < 0.0001, H4-APP to H4-APP Xenon 25 %, t = 10, p = <0.0001, H4-APP to 
H4-APP Xenon 50 % t = 16, p = <0.0001, H4-APP to H4-APP Xenon 75 % t = 18, p = <0.0001.  p value derived by one-way ANOVA with post 
hoc Bonferroni's Multiple Comparison Test.  *** and **** mean p < 0.01, n numbers per group are illustrated in the figure.   
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Figure 2-15: Cleaved caspase-3 in H4 and H4-APP 
 
  
1
1
3
 
This figure illustrates normalised WB for protein from cell lysates of H4 and H4-APP cells exposed to isoflurane, nitrous oxide and xenon using 
cleaved caspase-3 (Asp 175) antibody.  The x-axis represents the Condition (cell type and the anaesthetic agent) and the y-axis represents fold 
change in MPI compared to H4 Control.   
The scatter dot plot illustrates that the level of cleaved caspase-3 is the same in both H4 and H4-APP Control.  In H4-APP Xenon the level of 
cleaved caspase-3 was reduced compared to Control.  In Isoflurane the level of cleaved caspase-3 was increased.  There was a difference 
between the levels in Xenon and Isoflurane.   
All data are presented as mean (95 % CI).  F4 38=14, p = < 0.0001, H4-APP to H4-APP Xenon t = 3.4, p < 0.05; H4-APP to H4-APP Isoflurane t 
= 3.4, p < 0.05; H4-APP Isoflurane to H4-APP Xenon t = 6.7, p < 0.0001.  p value derived by one-way ANOVA with post hoc Bonferroni's Multiple 
Comparison Test.  * and **** means p = < 0.05, n numbers per group are illustrated in the figure.  Data illustrated are amalgamated from 
independent experiments of DL and MM.   
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Table 2-1:  Conditions during spontaneous oligomerisation of A monomer 
Condition Exposure chamber contents 
Control Room air 
Isoflurane Isoflurane 2 % in air 
Nitrous Oxide 75% N2O % 21 % O2 
Xenon Xenon 50 % + 21 % O2  
Chamber contents for each Condition during A and ADDL solution exposure to anaesthetic 
agents.  Each condition was in 21 % O2 balanced with CO2 and N2.  Steady state was achieved 
within the chamber using the gas flows for the durations specified in  Table 2-5.   
 
Table 2-2:  Concentration response of primary neuronal cell viability to A 
Condition Media [A] supplementation  
0  
 
 
 
Neurobasal 
0 
0.039 μM A 0.039 
0.078 μM A 0.078 
0.156 μM A 0.156 
0.313 μM A 0.313 
0.625 μM A 0.625 
1.25 μM A 1.25 
2.5 μM A 2.5 
5 μM A 5 
10 μM A 10 
Concentration A in each condition used for exposure of primary neurones before cell viability 
assay using MTT.  Concentration in μM.   
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Table 2-3:  Primary neuronal cell viability in anaesthetic agents with A supplemented media 
Condition Media + [A] Chamber contents 
Control Neurobasal + 0 Room air 
A Neurobasal + 0.8 Room air 
Isoflurane Neurobasal + 0.8 0.5 % isoflurane  
1.5 % isoflurane  
2 % isoflurane  
Nitrous Oxide Neurobasal + 0.8 25 % N2O  
50 % N2O 
75 % N2O 
Xenon Neurobasal + 0.8 25 % xenon  
50 % xenon  
70 % xenon  
Conditions for primary neuronal cell exposure to anaesthetic agents in A supplemented media.  
Each Condition was in 21 % O2 with 5 % CO2.  [A] in μM.  
 
Table 2-4:  In vitro anaesthetic agent exposure conditions 
Condition Cell type Chamber contents 
H4 Control H4 Air 
H4-APP Control  
 
 
H4-APP 
Air 
Isoflurane 2 % isoflurane in air with 5 % 
CO2 
Nitrous Oxide 75 % N2O in 21 % O2 and 5 % 
CO2 
Xenon 75 % xenon in 21 % O2 and 5 % 
CO2 
Detail of group titles in the in vitro investigation, the immortal cell type exposed and the contents 
of the exposure chamber during the anaesthetic exposure.   
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 Table 2-5: Gas flows during chamber filling 
Condition Source Analyser Measured gas 
flows to achieve 
steady state 
Time to steady 
state 
Isoflurane  Anaesthetic 
machine common 
gas outlet 
Medical 
anaesthetic gas 
analyser 
2 l / min air + 
isoflurane 2 %.   
75 ml CO2 
injected at steady 
state.   
5  
Nitrous Oxide Anaesthetic 
machine common 
gas outlet 
Medical 
anaesthetic gas 
analyser 
2 l / min N2O + 0.4 
l / min l O2.  75 ml 
CO2 injected at 
steady state.   
5  
Xenon  Xenon flow meter 
+ anaesthetic 
machine common 
gas outlet 
Xenon analyser  1.5 l / min xenon + 
0.4 l / min O2.  75 
ml N2 +  
75 ml CO2 
injected at steady 
state.   
 5  
Chamber contents for each Condition during H4 and H4-APP anaesthetic exposure.  Each 
Condition was in 21 % O2 with 5 % CO2.  Steady state was achieved using the gas flows for the 
durations specified.  At steady state chamber contents was analysed, balancing gases added and 
chamber sealed for 6 h.  Time to steady state in min.   
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Table 2-6:  Cell culture media 
H4 working media 
Constituent Concentration Volume per 500 ml working 
media 
Dulbecco’s modified Eagle’s 
Medium (DMEM) 
1x 390 
(78 % v/v) 
L-Glutamine 200 5 
Penicillin / Streptomycin 10000 U / 10 mg 5 
Newborn calf serum 1x 100 
(20 % v/v) 
H4 media serum free 
Constituent Concentration  Volume per 500 ml media 
serum free 
Dulbecco’s modified Eagle’s 
Medium (DMEM) 
1x 490  
(98 % v/v) 
L-Glutamine 200 5  
Penicillin / Streptomycin 10000 U / 10 mg 5  
H4-APP working media 
Constituent Concentration  Volume per 500 ml working 
media 
Dulbecco’s modified Eagle’s 
Medium (DMEM) 
1x 387.8  
(77.56 % v/v) 
L-Glutamine 200 5  
Penicillin / Streptomycin 10000 U / 10 mg 5  
Newborn calf serum 1x 100  
(20 % v/v) 
G418 disulphate 50 mg / ml 2.2  
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H4-APP media serum free 
Constituent Concentration Volume per 500 ml media 
serum free 
Dulbecco’s modified Eagle’s 
Medium (DMEM) 
1x 487.8 
97.56 % v/v 
L-Glutamine 200 5 
Penicillin / Streptomycin 10000 U / 10 mg 5 
G418 disulphate 50 mg / ml 2.2 
H4 and H4-APP Cryoprotectant media 
Constituent Amount per 10 ml Cryoprotectant media 
Working media 8.5 
(85% v/v)  
DMSO 1  
(10 % v/v) 
Newborn calf serum 0.5  
(5 % v/v) 
N2aSwe working media 
Constituent Concentration  Volume per 510 ml working 
media 
Dulbecco’s modified Eagle’s 
Medium (DMEM) 
High glucose 
1x 225 
(44 % v/v) 
Opti-MEM 1x 250 
(49 % v/v) 
L-Glutamine 200 5  
Penicillin / Streptomycin 10000 U / 10 mg 5  
Newborn calf serum 1x 25 
(5 % v/v) 
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Dissecting media 
Constituent Concentration  Amount per 500 ml  
dissecting media 
Dulbecco’s modified Eagle’s 
Medium (DMEM) 
1x 490 ml 
(98 % v/v) 
L-Glutamine 200 5 ml 
Penicillin / Streptomycin 10000 U / 10 mg 5 ml 
Anhydrous sucrose 0.2 M 34.23 g 
Anhydrous D-glucose  0.3 M 18.01 g 
Neurobasal media 
Constituent Concentration / ml Volume or amount per 100ml 
neurobasal media 
Neurobasal ® medium 1x 97 ml 
(97 % v/v) 
Glutamax  100x 250 μl (0.5 mM) 
B27 Supplement  50x 2 ml 
(2 % v/v) 
Penicillin / Streptomycin 10000 U / 10 mg 1 ml 
Murine Fibroblast Growth 
Factor-basic 
 2 μg 
Detailed composition of cell culture media used for in vitro work during this investigation.  
Separate media were required for H4, H4-APP, N2aSwe and primary neuronal cells.  Working 
media was used for day-to-day incubation of cells.  Serum free media was used during 
anaesthetic exposure.  Cryoprotectant media was used during the cryostorage of cells.  
Dissecting media was used during the dissection of fresh tissue for the preparation of primary 
neuronal culture.  Neurobasal media was used for the day-to-day culture of primary neurons.  
Concentrations detailed are of starting solutions.  Volume in ml, concentration in mM, unless 
otherwise specified.   
Table 2-7:  Dose response H4 cell seeding 
Well designation Number cells seeded Relative volume cell 
suspension seeded 
Total volume working 
media  
A1 1 x 105 1 2012.5 
A2 3 x 105 3 2037.5 
A3 5 x 105 5 2062.5 
B1 7 x 105 7 2087.5 
B2 9 x 105 9 2112.5 
B3 1.1 x 106 11 2137.5 
Detail of cell numbers seeded and volume working media per well for the dose response 
experiment.  Volume in μl.   
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Table 2-8:  Protein standards 
Protein Standard Protein concentration Volume of protein 
solution 
Volume of dH2O 
 
S1 1000 50 (of stock) 50 
S2 500 50 (of S1) 50 
S3 250 50 (of S2) 50 
S4 125 50 (of S3) 50 
S5 12.5 10 (of S4) 90 
S6 1.25 10 (of S5) 90 
Protein concentration and diluent volumes used in serial dilution of a 2 mg / ml stock solution used 
during protein quantification for WB and ELISA.  Concentration in μg / ml, volumes in μl.   
Table 2-9:  Antibodies used in this investigation 
Primary 
POI Application Atomic mass 
POI 
Working 
concentration 
and 
incubation 
conditions 
Species Manufacturer 
and Cat. No 
-Tubulin 
 
WB 50 1:1000, 2 h RT Mouse Sigma-Aldrich 
T6074 
APP Full 
Length 
WB  
 
 
Immunochemi
stry 
110 – 140 1:1000 
 
 
1:200 
Rabbit Cell Signalling 
#2452 
 
Amyloid  
6E10 
 
4G8 
 
WB 
 
 
Immunoprecipi
tation 
5 
 
 
5 
1:1000 in 1% 
BSA 
 
1:500 
Mouse 
 
 
Mouse 
Covance 
SIG39300 
 
Covance 
SIG39220 
BCL-2 
 
WB 24 1:1000 Rabbit Cell Signalling 
#2876 
BACE-1 WB 70 1:1000 Rabbit Cell Signalling 
#5606 
-actin 
 
WB 45 1:1000 Rabbit Cell Signalling 
#3967 
Cleaved 
caspase-3 
WB  
 
18 – 20 1:1000 Rabbit Cell Signalling 
#9664L 
 
Cytochrome c WB 14 1:1000 Rabbit Cell Signalling 
#4280S 
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POI Application Atomic mass 
POI 
Working 
concentration 
and 
incubation 
conditions 
Species Manufacturer 
and Cat. No 
GFAP Immunochemi
stry 
N/A 1:750 Rabbit Dako, 
Denmark,  
#Z0334 
IBA-1 Immunochemi
stry 
N/A 1:200 Rabbit Wako, Japan, 
#019-19741 
secretase - 
Nicastrin 
subunit 
WB 110 – 120 1:1000 Rabbit Cell Signalling 
#3632 
Synaptophysin 
(7H12) 
Immunochemi
stry 
N/A 1:200 Mouse Cell Signalling 
#9020 
Secondary 
Specificity Conjugate Application Working 
concentration 
and incubation 
conditions 
Manufacturer 
and Cat. No 
Anti-biotin HRP WB 1:2000, 2 h RT Cell Signalling 
#7075 
Anti-mouse HRP WB 1:1000, 2 h RT Cell Signalling 
#7074 
Anti-rabbit HRP WB 1:1000, 2 h RT Cell Signalling 
#7076 
Donkey anti-goat 
IgG (H+L) 
 
Fluorescein 
(FITC) 
Immunochemistry 1:200, PBS, 2 h 
RT in the dark.   
Jackson 
Immunoresearch 
705-095-003 
Donkey anti-rabbit 
IgG (H+L)  
 
Rhodamine 
(TRITC) 
Immunochemistry 1:200, PBS, 2 h 
RT in the dark.   
Jackson 
Immunoresearch 
711-025-152 
Donkey anti- 
mouse IgG (H+L)  
 
Biotin Immunochemistry 1:500, 20 min RT Jackson 
Immunoresearch 
715-065-150 
Blocking 
Specificity Application Working 
concentration and 
incubation conditions 
Manufacturer and Cat. 
No. 
Mouse on mouse Fab 
fragment goat anti-
mouse IgG (H+L) 
Immunochemistry 120 μg / ml, 1 h RT Jackson 
Immunoresearch 
115-007-003 
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Specificity and application data for primary, secondary and blocking antibodies used in this 
investigation.  For WB, diluent is 5 % skimmed milk solution and incubation is 4 oC ON, unless 
otherwise specified.  For immunochemistry, diluent is 5 % Normal Donkey serum blocking solution 
and incubation is 4 oC ON, unless otherwise specified.  Atomic mass in kDa.   
 
Table 2-10: In vitro results summary table 
POI Analytic 
application 
H4 vs. H4-
APP 
Isoflurane   Nitrous oxide  Xenon 
APP Full 
Length 
WB H4 = H4-APP − − − 
BACE-1 
expression 
WB H4 = H4-APP −  
(p = 0.06) 
− − 
BACE-1 
activity 
-CTF’s 
WB  N/A  
 
 
 
 
− 
 
A 
 
6E10 in 
N2A.Swe 
 
H4-APP 
 
 
Membrane 
preparations 
 
ELISA of 
media 
 
Elisa of lysate 
 
More A in 
media than 
lysate 
N/A 
 
H4-APP > H4 
H4-APP = H4 
 
 
 
 
− 
 
− 
 
 
 
 
− 
 
− 
 
 
 
− 
 
− 
 
− 
 
BCL-2 
 
WB H4-APP<H4 − 
 
− 
 
 
Cleaved 
caspase-3 
WB H4 = H4-APP  
[ ] dependent 
up to 1.5 % 
  
at lower [ ] 
 
 
at higher [ ] 
 
at lower [ ] 
 
 
at higher [ ] 
Cytochrome c WB H4 = H4-APP − 
 
− 
 
− 
 
This table summarises the results of the H4, H4-APP and N2aSwe In vitro data.   
 means increased,  means reduced, − means the same.   
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Chapter 3 Trace Fear Conditioning study 
3.1 Introduction 
The TFC study was performed on a colony of APP23 and WT littermate mice bred at Imperial 
College London.  Mice were genotyped in house, and used in experiments between the ages of 
3 – 6 month, prior to the reported age of appearance of A plaque in APP23 brain.  The rationale 
for this was to mimic a preclinical stage of AD.  Mice from this colony were also characterised 
behaviourally and biochemically.  The conduct of the breeding, characterisation and TFC study 
are described here.   
3.2 Aims of the TFC study 
1:   To further characterise the phenotype of APP23 mice, to detect and describe distinction with 
WT littermates.   
2:   Learning:  Is the ability of APP23 and WT to learn TFC the same?   
3:   Memory:  Does the modifiable risk factor have an impact on hippocampal dependent and 
independent memory in APP23 and WT that have undergone learning in TFC, and does 
perioperative atorvastatin have an effect on this.   
4:   To detect and examine any associated neuropathology.   
3.3 Materials and methods 
3.3.1 Mouse colony management 
Mouse housing and maintenance, breeding, transfer and disposal 
All regulated procedures were performed under and within premises approved by the Animals 
(Scientific Procedures) Act 1986, PIL 70/23136 (Procedure Personal Licence) and PPL 6966 
(Project Licence) at Imperial College London.   
The colony of mice was bred from 3 original APP23 (one male and two females) and 2 WT 
littermates (one male and one female) of 2 months age generously given as a gift by Dr 
Magdalena Sastre of Imperial College London.   
A materials transfer agreement with Novartis, patent holders for APP23 mice, was agreed before 
breeding commenced (a copy is included in the appendix).   
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Responsible individuals in colony management 
The author was responsible for the mouse breeding programme, weaning, management of cage 
numbers, ear notching, proprietary handling, arranging timely transfer between sites, all 
experimental work involving the mice, their killing and the immediate perfusion, preparation and 
the storage of samples.   
Imperial College CBS staff were involved in the day-to-day maintenance of cages housing the 
mice at two holding facilities, and their transfer between facilities.  CBS and UK Home Office 
veterinarians were closely involved in the day-to-day conduct of the animal work.   
Housing and maintenance of live mice 
Animals were housed in Individually Ventilated Cages (IVCs) at two facilities:  (Central Biological 
Service (CBS), South Kensington and at Chelsea and Westminster Hospital (C+W)).  Cage base 
dimensions were as follows:   
CBS:  391 x 199 x 150 mm (W x D x H) 
C+W:  350 x 140 x 130 mm (W x D x H) 
Bedding (coarse sawdust and shredded paper), feed and environmental enrichment materials 
(hollow tubes) were provided by CBS, as is standard.  Up to 5 littermates of the same sex but 
mixed genotype were housed in one individual IVC cage.  Mice were housed in a temperature 
(22 oC ± 2 oC) and humidity (55 % ± 5 %) regulated environment with 12 h light / dark cycles 
(lights on at 8am).  They had free access to unlimited standard rodent feed and water at all times.  
Environmental controls, length of light / dark cycle and feed were identical at both holding facilities.   
Mouse breeding 
All mouse breeding occurred at CBS, South Kensington.  Both male and female heterozygous 
APP23 mice and WT littermates were bred within the facility by crossing either an APP23 male 
with an inbred C57BL/6 WT female, or by crossing an inbred C57BL/6 WT male with a WT female.  
Breeding mice were sourced from within the colony and every 5 generations a new WT C57B/6N 
female was introduced to the colony to prevent genetic drift.   
Breeding cages were initially populated with one male and two females, all over 8 weeks of age.  
APP23 mice were sensitive breeders with average litter size of 6 – 12 pups and there was a 
higher rate of infanticide than with WT C57BL/6 mice.  Mice were minimally interfered with in the 
perinatal period but were regularly inspected through the IVC cage walls, ensuring the presence 
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of adequate feed.  At the end of their natural reproductive life, breeding mice were retired, for use 
both in old age animal behaviour experiments and for positive control tissue in analytic work.   
Mouse pups were weaned at post-natal d 21, prior to birth of a subsequent litter.  At weaning they 
were sex identified (by assessing the ano-genital distance) and separated into storage IVC cages 
isolated by sex.   
Transfer of live animals between animal holding facilities 
Mice were transferred to C+W animal holding facility by CBS staff using an SOP for the transfer 
of animals between facilities within Imperial College London then operational.  They were aged 
no less than 6 weeks (young adult) on transfer and were acclimatised at the C+W site for at least 
1 week prior to any experimental work.   
Movement of animals within the department at C+W 
Live animals were transferred from holding to procedure rooms only in closed IVC cages on the 
transfer trolleys provided.  Cages were covered with a disposable polythene sheet when in non-
licensed areas.  Mice were returned, when necessary, for IVC housing in the holding room, for 
example after surgery or behaviour work.   
Routine health screening 
Routine health screening detected mouse parvovirus in the CBS breeding room mid-study.  This 
is estimated a 3.64 % prevalence in European laboratory animal houses.226   
Mouse ear notching 
Reagents 
Ethanol 70 %, diluted in tap water 
DNA used for genotyping was isolated from ear notch samples.  Ear notching was performed in 
a manner that enabled the notching to act as an animal identifier within that cage, as outlined in 
Table 3-1.  Ear notching was performed on mice over 21 d old and always several weeks before 
use in any experimental work (as earlier ear notching of litters within the breeding cage resulted 
in infanticide).  The ear notching procedure was performed in a cage changing station; equipment 
was decontaminated between animals by wiping with 70% ethanol and allowing to air dry.  Ear 
notch tissue samples were held in clearly labelled centrifuge tubes before storage at – 20 oC 
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pending DNA isolation and genotyping.  After ear notching, all animals were returned to their 
home cage.   
3.3.2 Genomic DNA Isolation and purification 
DNA was isolated from ear notch tissue samples for the purpose of genotyping.  Two protocols 
were used for genomic DNA isolation:  the kit based DNeasy blood and tissue kit by Qiagen and 
a NaOH-Tris-HCl based protocol.  All steps were performed at RT unless otherwise specified.   
Reagents 
Pre-prepared DNeasy reagents made by Qiagen 
Ethanol 100% 
NaOH for genomic DNA isolation 
Tris-HCL buffer for genomic DNA isolation 
DNeasy protocol 
DNeasy is a kit based tool for total DNA isolation through proteinase K cell lysis, followed by 
adsorption of total DNA into spin column membranes prior to purification, washing and liberation 
by buffers.   
All kits were used and maintained as per the manufacturer’s instructions.   
Briefly, 1 – 4 mouse ear notches were digested in proteinase K before addition and mixing in pre-
prepared buffers and 99% ethanol.   
The mixture was pipetted into a DNeasy mini spin column and a protocol of centrifugation and 
buffer addition followed closely until final elution of the purified DNA solution.   
NaOH-Tris-HCl protocol 
This alkali based DNA extraction protocol was adopted mid study for cost and efficiency reasons 
and was equally effective in DNA isolation for Polymerase Chain Reaction (PCR) as the kit based 
method.  Simultaneous PCR for actin gene was performed as internal control throughout the 
protocol transition.   
Briefly, 1 – 4 ear notch tissue samples, held in labelled 1.5 ml centrifuge tubes, were submerged 
in 75 µl NaOH for genomic DNA isolation, vortexed and heated to 95 oC in a thermomixer rotating 
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at 300 rpm for 10 min before further vortexing.  After cooling on ice to 4 oC, 75 µl Tris-HCL buffer 
for genomic DNA isolation was added before vortexing and centrifugation at 268 g for 30 sec.   
The DNA solution prepared using either protocol was used directly in PCR at 1 µl per reaction 
volume and stored long-term at – 20 oC.   
3.3.3 Genotyping by PCR 
Reagents 
Autoclaved dd.H2O 
Taq DNA 5 units / μl recombinant enzyme ready made by Quiagen 
PCR Buffer 10x ready made by Quiagen 
Q-Solution 5x ready made by Quiagen 
MgCl2 25 mM ready made by Quiagen 
Deoxynucleotide mix –10 mM of each of dATP, dCTP, dGTP, and dTTP ready made by Prime 
Primers 
Forward and reverse primers for APP gene and actin gene were purchased and diluted to 200 
μM stock solutions in dd.H2O, as specified by their manufacturer.  Primer sequence is described 
in Table 3-2.   
PCR was performed in an area of the laboratory dedicated to DNA work using PCR grade 
materials and two preprogramed automatic cyclers.  All reagents used for PCR were aliquoted on 
opening to prevent cross contamination and repeated freeze-thaw cycling.   
Two separate PCR protocols were used, one for APP gene (present only in APP23 transgene 
carriers), and another for actin gene internal control (present in all mice as a constitutively 
expressed gene, positive PCR confirming the presence of adequate DNA within the sample to 
support a PCR reaction).  PCR mastermix contains all the components required for PCR bar the 
DNA template.  APP and actin PCR were performed simultaneously but separately using different 
mastermix.  Positive and negative control and blank were performed for each PCR experiment.  
Control DNA was sourced from the parent colony of APP23 and dd.H2O was used instead of DNA 
solution in the blank.   
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Recipes for the PCR mastermix for both APP gene and actin gene are detailed in Table 3-3 and 
the PCR cycle for both APP gene and actin gene are detailed in Table 3-4.   
Both PCR reactions followed the same basic protocol.   
APP gene PCR protocol 
Surfaces were sprayed with ethanol 70% before starting.  Genomic DNA samples, positive and 
negative control DNA samples, Taq DNA polymerase, 10X buffer, MgCl2, deoxynucleotide mix 
and forward and reverse primers were removed from – 20 oC storage and allowed to thaw on ice.  
All were vortexed briefly prior to use.  The number of PCR reactions anticipated was counted and 
the volumes required of each constituent in the mastermix calculated.   
The mastermix was prepared in a 1.5 ml centrifuge tube by the addition of all constituents.  Stock 
solutions of both Forward and Reverse primers were diluted to 20 μM working concentration in 
dd.H2O and Taq DNA polymerase was always added to the mastermix last, prior to vortexing.   
The PCR reaction took place in clear, thin walled, flat-topped 200 μl PCR tubes.  These were 
placed in a cooling block at 4 oC and mastermix aliquoted into each.  For APP gene, the mastermix 
volume was 24 μl and genomic DNA sample volume 1 μl (Total reaction volume = 25 μl).   
Tubes were centrifuged at 268 g for 10 sec to ensure the contents were at the bottom of the PCR 
tube before transfer to an automated PCR cycling machine.  The PCR protocol, programmed in 
the automated cycler, is described in Table 3-4.   
At the end of the reaction, tubes were again briefly centrifuged at 268 g before gel electrophoresis.   
Actin gene PCR protocol 
Actin gene PCR was identical to that of APP except for the following:   
Q Solution was required for this reaction.  Q solution is an additive that affects the melting of DNA 
and improves PCR performance.  The mastermix volume was 19 μl per tube for actin gene and 
genomic DNA sample volume was 1 μl (Total reaction volume = 20 μl).   
No truly negative control was available for actin as the gene is constitutively present and active.  
The negative control was anticipated to be positive for this reaction.  The same negative control 
sample was used for APP gene and actin gene PCR.  A different automated cycling machine was 
used for actin PCR reactions so that they could be performed simultaneously.   
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Gel electrophoresis of PCR products 
PCR products were separated by electrophoresis in order to identify products by DNA length, 
when compared to a known base length ladder.   
Reagents 
TAE buffer 10x, diluted to 1x in dd.H2O 
A 2 % w/v agarose gel was prepared as follows, 30 min before it was required.  1.2 g agarose 
was weighed on an analytical balance and placed in a conical flask, mixed with 60 ml x1TAE 
buffer.  The mixture was heated in a microwave oven at maximum energy for 1 min or until all the 
agarose had fully dissolved.  5 μl etidium bromide liquid was added to the molten agarose and 
mixed by gentle swirling (working concentration 1:12,000).  The mixture was transferred to a 
levelled mould, air bubbles removed with a pipette tip and the gel allowed to solidify (ca. 30 min).  
The gel and gel holder were then positioned in an electrophoresis cell and immersed in TAE buffer 
1x.   
DNA ladder was used for each electrophoresis, at 5 μl volume in one well.  PCR products, held 
at 4 oC, were mixed with an appropriate volume of loading dye 4x by pipetting.  15 μl volume of 
sample-dye mixture was loaded into each well, taking care not to cross contaminate.   
After loading, the cell was closed and electrophoresis performed using a potential difference of 
100 V and current 100 A for 15 min.  Running time was extended if necessary to ensure clear 
separation of the PCR products.   
Bands were visualised under UV transilumination in a Syngene G box, exposure time being 5 
msec.   
Exposure of the gels revealed PCR products at the following base pair (bp) lengths along the 100 
bp DNA ladder:   
APP23 gene PCR:  bright band at 400 – 500 bp 
Actin gene PCR:  bright band at 900 – 1000 bp 
Typical gels are illustrated in Figure 3-1.   
Total numbers of genotyped animals 
816 mice were genotyped according to the methods detailed in this protocol.   
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3.4 Mouse behaviour work 
Mice were habituated to their new environment for 1 h before starting any behaviour work.  The 
assessment of learning and the assessment of memory always occurred during the same time of 
day in a quiet environment and apparatus was thoroughly cleaned between mice.  After testing, 
animal were held in clean IVC cage bases containing clean bedding, to minimize the transmission 
of odour cues.  Littermates were not reunited until all had been tested.   
3.4.1 Characterising the APP23 mouse model:  Behaviour 
Phenotypic and behavioural data were collected on APP23 and WT littermates to determine 
baseline characteristics of each genotype.  Several distinct behavioural characteristics of APP23 
are described,126 although hotplate literature is lacking.  Assessments were performed at least 7 
d after transfer to the C+W holding facility, after several episodes of manual handling by the 
investigator and prior to starting daily intervention (daily statin or placebo by oral gavage).  
Characterisation work was completed prior to any behavioural test for the assessment of learning 
and memory, with the order being from least to most stressful.227   
Reagents 
Trigene 1 % solution in tap water 
General, routine observation 
General observations of mouse behaviours and activity within the cage, aggression and violence 
toward littermates, cannibalism, infanticide and general indicators of mouse anxiety, were made 
throughout the investigation.   
Weighing 
Weight was documented routinely for all mice at several time-points:   
- before starting behaviour characterisation work 
- before starting intervention, and daily thereafter 
- at the time of killing (cull) 
The same method and balance were used for all weight data collection.  Males were weighed 
before females and always in the same order.  When changing from male to female cages, gloves 
were changed.   
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Rota-rod 
The Rota-rod228 evaluates motor coordination and fatigue resistance of mice, measuring latency 
to fall from a revolving roller lane during a single trial.  This was necessary to determine a baseline 
motor function as open field, MWM and Y maze behavioural tests require motor activity.   
The semi-automatic Rota-rod apparatus consists of 4 adjacent roller lanes rotating at 60 rpm after 
constant acceleration, and separated by opaque acrylic separators.  The rollers surface was 
moulded as shallow parallel grooves without any seams onto which the mouse can grasp and 
drop height from roller to grid was 37 cm.  Start-point was when the roller started rotating, end-
point was the mouse touching the grid below and by protocol, start-point to end-point was of 
maximum duration of 250 sec.  Latency to fall was used as an index of motor function.   
Equipment was cleaned with Trigene 1 % in water at the start of the session and between each 
mouse, rollers fully air-dried before starting the test.  4 mice were tested simultaneously, being 
transferred sequentially to a roller lane, acclimatized for 3 sec before start-point when roller and 
a stopwatch were activated simultaneously.  End-point automatically triggered recording of 
latency to fall by the apparatus.  One cage was tested at a time and gloves were changed between 
cages.   
Rota-rod data was collected for 316 mice using this protocol.   
Hot plate test 
The hot plate test229,230 evaluates thermal pain reflexes due to footpad contact with a heated 
surface during a single trial.  This was necessary to determine if mice in this colony possessed 
intact nociceptive reflexes and to assess any nociceptive difference caused by genetic 
manipulation.  Intact nociception is necessary for TFC.   
Hot plate analgesia meter apparatus consists of a clear acrylic cylinder resting vertically on a 10 
mm thick metal plate heated to a consistent temperature of 47.5 oC.  Incorporated into the device 
is an electronic timer used to measure latency.  Start-point was when 4 mouse paws touched the 
hot plate surface, facing away from the operator, end-point was hind paw lick or jump from the 
hot plate surface.  By protocol, start-point to end-point was of maximum duration 35 sec, to 
prevent tissue damage.  Latency to lick or jump was used as an index of nociception.   
With the hot plate at working temperature the clear acrylic cylinder was applied.  The mouse was 
removed from its home cage, gently dropped onto the hot plate and timer started simultaneously.  
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The mouse was carefully observed throughout for end-point, when the timer was stopped, the 
mouse recovered and latency to lick or jump recorded.   
The hot plate was cleaned and allowed to return to working temperature before proceeding, 
gloves being changed between each mouse.   
Hot plate data was collected for 307 mice using this protocol.   
Open field 
The open field test, originally developed in rats231 but widely used in mice, involves the 
observation of spontaneous ambulation of the animal within a clean, featureless arena during a 
single trial.  It enables evaluation and quantification of motor activity and the response to novelty.  
Motor function is required for TFC, MWM and Y maze.   
The open field apparatus consists a featureless white plastic tray (45 x 30 x 10 cm) surrounded 
by a white, featureless environment in reduced light conditions.  A hidden video camera located 
overhead records movements within the arena, data being analysed to establish total distance 
moved during a single 10 min trial.  Total distance moved during a 10 min exploration was used 
as an index of motor function.   
Software controlled recording occurred from start-point (entry of the mouse into arena) to end-
point (10 min later).  At start-point the mouse was placed in the centre of the arena facing away 
from the investigator.  Movement was observed on screen and a manual count of significant 
events, including corner and centre visits, was documented in real time.  At end-point the mouse 
was removed from the arena.  The record sheet for open field is provided in the appendix.   
Open field test data was collected for 89 mice using this protocol.   
Feed consumption 
APP23 mice are reported to have higher feed consumption than WT littermates.232  Feed 
consumption was measured daily in 12 cages containing sex and genotype segregated mice, as 
detailed in Table 3-5.   
Cages investigated were normal IVC cages with paper bedding and environmental enrichment 
but no sawdust.   
Daily for 14 – 21 d the following measures were recorded:   
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- body weight of each mouse in the cage 
- weight of feed in the cage feeding rack 
Data were used to determine, for each individual cage on each day, g feed consumed / day / g 
mouse body weight.   
Feed consumption data was collected for 25 mice using this protocol, the characteristics of the 
study population are detailed in Table 3-6 and Table 3-7.   
3.4.2 Characterising the mouse model APP23:  Biochemistry 
Rationale:  Mimicking preclinical AD in APP23 mice 
Heterozygous APP23 mice show 7-fold over-expression of APP and first develop Aβ deposits at 
6 months of age.233  However, the age at which they begin to over-express A was unclear.  This 
characterization looked to achieve several aims regarding the nature of A over-expression in 
this colony of APP23 mice.  The time-points were chosen as, from 4 weeks of age, the animals 
were potentially suitable to undergo the unilateral nephrectomy protocol.   
Aims 
1:   To prove that A is over-expressed in adult APP23 in this colony 
2:   To determine the age at which APP23 express A at levels detectable by WB 
3:   To determine if A expression increases with age in young APP23 
4:   To determine if both young male and female APP23 express A at similar levels 
Materials and methods 
WB of whole brain lysate from genotyped mice bred within the colony was performed on age 
appropriate tissue prepared as described in 3.3 and 2.7.5.   
WB were analysed by measuring MPI of chemiluminescent bands found at the appropriate 
molecular weight for the POI using ImageJ and normalized using -tubulin.   
1:   Proving that A is over-expressed in adult APP23 in this colony 
WB of whole brain (right hemi-cortex) lysate from 5 male mice at 14 weeks (100 d) of age was 
performed.  2 mice were genotyped as APP23 and 3 as WT.   
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Whole brain samples were dissected and cerebral cortices snap frozen in liquid N2.  Tissues were 
homogenized in tissue lysis buffer and protein quantification performed prior to WB using 6E10 
antibody.  Samples from older adult male APP23 mice were tested simultaneously to act as 
positive control.   
The data are illustrated in Figure 3-10 A.   
2:   Determining the age APP23 express A at levels detectable by WB 
WB of whole brain lysate from infant and young adult male and female mice using 6E10 antibody 
determined this.  Mice were genotyped at weaning (21 d) and killed at 4 or 8 weeks of age.  All 
mice were known to be APP23 by genotyping.   
The data are illustrated in Figure 3-10 B.   
3:   Determining if A expression increases with age in young APP23 
These data were examined to compare A expression in male APP23 at 4, 8 and 14 weeks of 
age.   
The data are shown in Figure 3-11 A.   
4:   Determining if both young male and female APP23 express A at similar levels 
This information was needed to decide if only one sex should be used in the study, with 4 and 8 
week-old APP23 being characterised in this experiment.   
The data are shown in Figure 3-11 B.   
3.5 The assessment of learning and memory using mouse behaviour 
Location and apparatus 
All behaviour work for the assessment of learning and memory was performed in a dedicated 
room at C+W.   
Mouse allocation to group 
Mice handled and acclimatised at C+W underwent genotyping and behavioural characterisation 
before being randomly allocated to a group.  Care was taken to distribute evenly the allocation of 
mice so that each group was populated with subjects simultaneously throughout the investigation, 
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and randomisation was performed either blindly by the author, or using a web-based algorhythm 
at www.randomization.com.   
General nomenclature for groups 
The term ‘modifiable risk factor’ refers to either anaesthesia alone or anaesthesia with surgery.  
Intervention refers to either statin (atorvastatin 10 mg / kg by oral gavage) or placebo (tap water 
0.01ml / g by oral gavage).  ‘Before’ and “After’ refer to time relative to introduction of the 
modifiable risk.  Capitalised words e.g. Young, Statin, Tone and Control, are names referring to 
specific cohorts of animals, specific groups in the experiment or specific aspects of the protocol.   
The study protocol timeline 
To assess the effect of the modifiable risk on learning and memory, three behavioural methods 
were used within a larger study protocol, the schematic for which is illustrated in Figure 3-3.   
The schedule of data collection time-points for each behaviour technique is detailed in Table 3-8.   
3.6 The assessment of learning and memory using TFC  
3.6.1 Introduction 
This protocol was developed from one that showed memory deficits in C57B/6 WT mice after 
surgery in this laboratory that were ameliorated by acute atorvastatin.150  A standard operating 
procedure for TFC is included in the appendix.   
3.6.2 Aims of the TFC study 
TFC was used to answer the following questions:   
1:   The assessment of learning:  Is the ability of APP23 and WT to learn by classical 
conditioning in TFC, and to display that learning through freezing behaviour, the same?   
2:   The assessment of memory:  Does the modifiable risk have an impact on hippocampal 
and non-hippocampal dependent memory in APP23 and WT that have undergone classical 
conditioning by TFC, and does perioperative atorvastatin have an effect on this?   
3.6.3 The TFC study protocol time line 
Key time-points of the TCF study are:   
-  Mice were administered daily statin or placebo from d -5 
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-  The assessment of learning by TFC was performed on d -1 
-  The modifiable risk was introduced on d 0  
-  The assessment of memory by TFC was performed on d 3 or 14 
A schematic of the time line is shown in Figure 3-8 and the groups described in detail in Table 3-
9.   
3.6.4 The population studied 
Both young (Young) and old (Old) APP23 and WT mice underwent behavioural study using TFC.  
The age and weight characteristics at the time of starting training for the Young mice is described 
in Table 3-10 and data are further characterised by genotype and group in Table 3-11, Table 3-
12 and Table 3-13.   
Data for Old mice is described in Table 3-14 and Table 3-15.  
Logistically, the TFC study was performed on 24 mixed cohorts of young APP23 and WT 
littermates (Young), and separately in 3 cohorts of old APP23 and WT littermates (Old), over a 7 
month time period.   
3.7 Materials and methods 
3.7.1 The data collected in the TFC study 
The data collected by the TFC apparatus measures and quantifies freezing behavior in animals.  
Freezing is defined as immobility except for movements caused by ventilation, and is a natural 
response to fear in mice and other rodents.  TFC is used to assess learning and memory by 
quantifying the amount of time an animal spends displaying freezing behaviour, as a % of total 
time.  This occurs in response to learning an association between a benign Conditioned Stimulus 
(CS, Tone) and one that generates fear, an Unconditioned Stimulus (US, Shock).   
3.7.2 The TFC apparatus 
A computerized TFC system was used for both the assessment of learning and memory.  Two 
separate sets were available and could be used simultaneously.  The apparatus comprised a 
large sound proofed cupboard within which a clear fronted metal box on a sliding tray was housed.   
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The cupboard wall housed a fan that produced a constant background sound of 60 dB, on the 
roof were lamps (visible and Infrared (IR) light) and on the door a digital video camera that 
captured both visible and IR lit images at 30 frames / sec.   
The clear fronted metal box held a removable metal floor (of metal rods of 3 mm diameter and 3 
mm apart) and the wall a microphone through which the tone was played.  For any animal, the 
assessment of both learning and memory took place within the same box.   
The apparatus is illustrated in Figure 3-4 
3.7.3 The assessment of learning during TFC 
The assessment of learning took place the day before introducing the modifiable risk (d -1).  Mice 
were individually trained in a single training session of 720 sec duration with 6 repetitions of Tone 
– Shock (CS – US) pairs, separated by an inter-training interval (ITI) of pseudo-random duration.  
The tone (Tone, CS) played during training was at 80 dB for 40 sec and foot shock (Shock, US) 
was 0.7 mA constant current for 2 sec.  The box was lit by only IR light.  The protocol and 
nomenclature of each component is detailed in the Table 3-16 and is schematically illustrated in 
Figure 3-5.   
3.7.4 The assessment of memory after TFC 
All assessments of memory occurred d 3 or d 14 after introduction of the modifiable risk factor.  
Different cohorts of mice were used for each time point.  The assessment of memory protocol for 
hippocampal dependent memory (Contextual response) is illustrated in Figure 3-6 and described 
in further detail in Table 3-17.  Similarly for non-hippocampal dependent memory (Conditioned 
response), in Figure 3-7 and Table 3-18.   
Hippocampal dependent Contextual response was always assessed first, followed after an 
interval of at least 2 hours, by non-hippocampal dependent Conditioned response.   
Contextual response 
Mice were placed in the same box with the identical environment as for learning and their 
behaviour was recorded for 120 sec.  Contextual response to environment was used as a marker 
of hippocampal dependent memory.   
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Conditioned response 
Mice were placed in the same box but in a novel context.  The floor was covered with an acrylic 
sheet and the roof substituted by an acrylic A-frame.  The box was lit with visible and IR light and 
a different scent applied.  The only constant feature with the learning environment was the audible 
tone (Tone), which was introduced at 80 dB for 30 sec.  The conditioned response to Tone in a 
novel environment was used as surrogate marker of hippocampal independent memory.   
Different variables present or absent in the box during the assessment of learning and the 
assessment of memory are detailed in Table 3-19.   
Fear conditioning housekeeping 
Calibration of both the intensity of Tone (dB) and Shock (mA) was performed at the start of each 
session.  Motion index calibration was performed automatically for each individual mouse.  A 
mouse was always trained and assessed in the same box and a batch of mice would undergo 
assessments in the same sequential order.  The box was thoroughly cleaned at the start of the 
training or assessment session and in between each and every mouse, with the scent re-applied.  
The box was scented using peppermint or vanilla food flavouring; one scent was used for the 
assessment of learning and for the contextual response and a different scent for the conditioned 
response.  The acrylic door to the inner box was always locked closed when a mouse was within 
as it could be opened inadvertently by jumping during delivery of Shock.  The mouse was 
continually monitored throughout its time within the box via a video link to the computer screen.  
Gloves were changed between each mouse.   
Analysis of data in the TFC study 
Digital video recordings of the training or assessment were analysed for movement by motion 
detection software (Video Freeze) to generate a motion index, illustrated in green in Figure 3-5.  
The outcome data used in analysis was the percentage time spent displaying freezing behaviour 
during each component of the protocolled assessment of learning or memory.   
All TFC data was analysed using the following parameters within the software:   
Motion threshold 18 
Sample rate to 7.5 fps 
Method linear 
Min freeze duration 1 frame 
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3.8 Unilateral nephrectomy surgery in mice 
General anaesthesia with unilateral nephrectomy surgery was used as a model of major sterile 
single cavity surgery.  The standard operating procedure is presented in the appendix.   
Reagents  
Sodium chloride 0.9 % w/v, in sterile 10 ml aliquots 
Chlorhexidine 4 % (Hibiscrub) for hand decontamination 
Ethanol gel for hand decontamination 
Providone-iodine 10 % surgical skin preparation 
70 % ethanol in water for surface decontamination 
Trigene 1 % in warm water for surface cleaning and decontamination 
The operating room 
Surgery was performed in a dedicated operating room approved for the performance of licenced 
procedures under the Animals Scientific Procedures Act 1986.   
The room was quiet, had good lighting, ventilation, running water and hard surfaces that could be 
scrubbed and disinfected.  Surgery was performed under a dedicated surgical microscope.   
Preparations for surgery  
All hard surfaces and the inside of the warm air holding box were disinfected prior to the start of 
surgery using Trigene 1 % in water followed by 70 % ethanol spray.  All surgical equipment was 
freshly autoclaved (121 oC for 20 min) prior to surgery.  Multiple sets of equipment were available, 
the essential surgical equipment for sterilization being listed in Table 3-20 
The maintenance of sterility 
The surgeon wore standard surgical PPE (cap, facemask, single use long sleeve sterile surgical 
gown with elasticated cuffs and sterile gloves).  Hands were cleaned in chlorhexidine gluconate 
4 % w/v and alcohol based skin rub between each surgery.  A sterile surgical field was created 
using disposable paper sterile drapes and single-use disposable syringes and needles were used.   
  
141 
Anaesthesia equipment 
The anaesthesia equipment used was an anaesthetic machine connected to a piped oxygen 
supply.  An isoflurane vaporizer provided a controlled source of isoflurane to the common gas 
outlet connected to either an induction chamber or coaxial breathing circuit.  Active (negative 
pressure) scavenging was used.   
Temperature control 
The ambient room temperature was raised to 25 – 29 oC by active warming to minimise the risk 
of inadvertent perioperative hypothermia.  Active warming of the operating room and table was 
commenced at least 2 h before starting surgery using warm air and radiant heaters.  A heat mat 
operating at 25 oC was placed under the sterile drapes and a warm air heated holding box for 
immediate postoperative recovery was set to run at 34 oC.   
Temperature at the operating table was measured using a mercury thermometer and documented 
at the start of each surgical procedure.  Surgery was not performed if the operating table was 
cold.  The mean temperature measured at the operating table at the time of starting each surgery 
was 27.45 oC.   
3.8.1 Perioperative procedures 
Identification and documentation 
Mice were identified by tail markings and all were weighed immediately before surgery.  The 
perioperative checklist used is provided in the appendix.   
Anaesthesia and analgesia 
Anaesthesia was induced using a small induction chamber using isoflurane 2 – 2.5 % in 100 % 
oxygen.  Anaesthetic machine settings were:  fresh gas flow oxygen 2 l / min, isoflurane 
vapouriser set to 2 % – 2.5 %, titrated to effect.  Surgical anaesthesia was confirmed prior to the 
onset of surgery using a paw pinch test with flat-ended forceps.  Depth of anaesthesia was 
monitored during surgery by observing respiratory rate and movement in response to stimulus.  
In general, 2 % isoflurane with 2 l fresh gas flow was adequate to maintain surgical anaesthesia 
in both APP23 and WT.   
Multimodal analgesia was used.  The incision line was infiltrated with bupivacaine 0.05 % before 
cutting the skin and by topical application to the wound after closure.  IP buprenorphine was 
instilled at closure at a dose of 0.1 µg / g and the closed wound secured with tissue glue.   
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General intraoperative care 
The eyes were protected intraoperatively by a piece of sterile gauze and the rest of the body was 
wrapped in dry sterile gauze to prevent wetting of the fur, a cause of profound hypothermia.   
3.8.2 Unilateral nephrectomy surgery technique 
The mouse was positioned in dorsal recumbency and the depth of anaesthesia confirmed.  The 
fur was cleaned with 10 % providone-iodine and 0.3 – 0.5 ml 0.05 % bupivacaine infiltrated into 
the skin along the abdominal midline.  The skin and muscle layers of the abdominal wall were 
carefully incised creating a midline 2 cm incision.  Viscera were lifted leftward form the peritoneal 
cavity and wrapped in a clean, wet sheet of plastic film.  The right-sided kidney and its vasculature 
came into clear view when the animal was in a true supine position once the viscera were moved 
aside.  Tightly closed curved forceps were passed behind the renal vessels, through the 
retroperitoneal wall from superior to inferior and were used to grasp a length of suture that was 
passed so as to lasso them.  A single knot was tied in the lasso to permanently occlude the 
vessels, pulling tight in a superior and inferior direction only, the suture being trimmed to 
approximately 0.5 cm.   
The kidney became immediately cyanosed with adequate vascular occlusion and was completely 
excised using vannas spring scissors.  The renal bed was inspected for bleeding and haemostasis 
ensured before returning the viscera to the peritoneal cavity.  Buprenorphine analgesia and 
warmed sodium chloride 0.9 % was then instilled to fill the cavity.  The muscle and skin were 
closed with 3.0 or 4.0 silk suture on a curved needle in 2 layers.  10 % providone-iodine was 
applied to both the muscle layer and skin to disinfect the wound and a small amount of tissue glue 
was then applied over the closed wound.   
A more detailed description of the surgical procedure is included in the SOP, provided in the 
appendix and the setup illustrated in Figure 3-2.   
Unilateral nephrectomy surgery was performed on ca. 283 mice during the conduct of this 
investigation, using this protocol. 
Duration of anaesthesia and surgery 
The mean duration of anaesthesia and surgery, from induction of anaesthesia to time off the 
operating table, was 36 min 45 sec.   
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Recovery and postoperative care 
The animal was recovered in a 34 oC warm air box for a period of 2 h with frequent inspection.   
Mice were singly caged after surgery in clean IVC cages with a small amount of bedding from the 
home cage and minimal sawdust.  Feed slurry and dilute ‘complan’ nutritional supplement solution 
was placed in a petri dish on the floor of the cage.   
Postoperative animals were checked every 12 – 24 h and their weight and condition recorded as 
a postoperative wellbeing assessment scale score.  This was calculated during each observation 
and a copy of the assessment scale is included in appendix.  Further analgesia (buprenorphine 
0.1 µg / g IP) and resuscitation fluid (warm sodium chloride 0.9 % w/v, 0.02 ml / g) was 
administered if score = 5 – 6.   
Unwell mice that did not show improved assessment score after fluid resuscitation, warming and 
analgesia were immediately killed.   
3.8.3 Mouse euthanasia and perfusion  
Mice were euthanized and immediately perfused with ice-cold heparinised PBS and PFA before 
collection of tissue samples for further processing.   
Reagents:   
PBS 1x for in vitro work  
PFA 4 % solution in PB  
Mouse euthanasia:   
The mouse was weighed before administration of a lethal dose of pentabarbitone (200 mg / ml) 
injected IP at > 100 µg / g to achieve terminal anaesthesia.   
Mouse perfusion 
Reagents were prepared as near the time of perfusion as possible and stored on ice during the 
perfusion process.   
The unconscious mouse was placed in dorsal recumbercy on a polystyrene board.  Terminal 
anaesthesia was confirmed by the absence of respiratory movement and the lack of response to 
firm paw pinch using a flat-ended forceps.  When confirmed, a midline thoracotomy was 
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performed, taking care to avoid cutting the large blood vessels in the axillae.  The tip of a 25G 
needle was passed into the right ventricle; blood aspirated using a 1 ml syringe was held on ice 
for later centrifugation and storage at – 80 oC.   
Gravity pre-wash perfusion 
The left ventricle was cannulated with a perfusion needle through a small incision through the 
ventricular wall created by vannas scissors, and the needle clamped in place.  The SVC or right 
atrium was cut and pre wash perfusion performed for 10 min using PBS 1X (ca. 20 ml volume), 
initially at a rate ca. 120 drops / min until the lungs, snout, paws or tail showed signs of anaemia, 
when the rate was reduced to ca. 60 drops / min.  The equipment required for the perfusion of 
mice is listed in Table 3-21.   
Post pre-wash, the tissues were either perfuse fixed with ice-cold PFA for 10 min or immediately 
dissected on ice, as described in 2.10.1.   
Dissection of unfixed tissues after PBS pre-wash 
Dissection was performed in ice cold PBS held on ice and under a dissecting stereoscope.  The 
tools required are listed in Table 3-22.   
The brain was halved along the sagittal plane with a scalpel blade and a random side hemi-brain 
allocated to post fixation in PFA at 4 oC.  The opposite hemi-brain was dissected to isolate the 
olfactory bulbs, cerebellum, cerebral cortex, hippocampus and mid and hindbrain, as illustrated 
in Figure 3-9.  These were stored in separate 1.5 ml centrifuge tubes and immediately snap frozen 
in liquid N2.   
3.9 Molecular analysis of brain tissue by immunochemistry 
3.9.1 The brain tissues analysed 
The staining described below was performed on 30 µm frozen section brain tissue slices from 
female mice that had undergone the assessment of learning and memory using TFC.   
Brains from three groups were analysed at both d 3 and d 14:   
-  Control APP23 and WT 
-  Surgery + Placebo APP23 and WT 
-  Surgery + Statin APP23 and WT 
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All mice used for immunochemistry analysis were between 130 – 160 d of age.  The POI, n per 
group, brain region examined and the number of brain slices analysed from each mouse are as 
follows:   
3.9.2 Synaptophysin 
Immunochemistry and DAB staining was performed (as described in 2.10.3) with 5 mice per 
group, 4 brain slices per mouse.   
Three areas of the hippocampus were manually outlined on the TIFF image using the ImageJ 
selection tool and quantified for MPI:   
1:   Cornu ammonis-1 (CA-1) region 
2:   Granular layer of the DG 
3:   Hilus of the DG 
3.9.3 IBA-1 and Thioflavin-S 
Thioflavin-S staining followed by immunochemistry with IBA-1 antibody was performed on brain 
tissues of the same mice as for synaptophysin analysis.  Methods are described in 2.10.2).   
Three mice were used per group with 4 brain slices per mouse, which were representative of 
anterior, mid and posterior hippocampus.  The same three hippocampal areas were examined.   
3.10 Results 
3.10.1 Characterising the APP23 mouse model:  Behaviour 
General observation 
All were overtly curious and playful and slept in a single nest within the cage.  APP23 appeared 
slightly smaller and leaner than WT littermates, most notably the females.  Some APP23 were 
very lean, and others less so, whereas the phenotype of the WT was more uniform.  The fur of 
APP23 always appeared well groomed whereas WT littermates could possess fur coarser in 
texture.  It was not possible to distinguish APP23 and WT genotype from physical appearance 
alone and there were no incidence of gross physical malformation observed within the colony.   
As a general descriptive term, the APP23 appeared more hyperactive than their WT littermates.  
APP23 displayed a stereotyped jumping behaviour (from a rearing stance in the cage corner the 
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mouse would repeatedly jump toward the cage roof corner at a frequency of approximately 90 
jumps / min for several min.  After spontaneous termination of the behaviour it was sometimes 
resumed a few min later).  This myoclonic jumping was not observed in WT littermates but is well 
described in APP23.128  Paw clasping on suspension by the tail was seen rarely in APP23.   
Male and female APP23 spontaneously exhibited tonic-clonic seizures.  This was triggered by 
anxiety and spontaneous bursts of activity within the cage.  Seizures would last 20 – 30 sec and 
the mouse would resume normal activity and not appear post-ictal.  However seizures were 
sometimes fatal.   
Both male and female APP23 were more aggressive than WT littermates, with higher incidence 
of tail biting of littermates by APP23.   
The incidence of infanticide in breeding cages was higher in APP23 breeding cages than in WT, 
notably if a young harem had been disturbed.   
Phenotypic differences were also evident during surgery where the quantity of intra-abdominal 
adipose was less in APP23, notably within the omentum that was often string like, perforated and 
adipose free.   
Weight 
There was a genotype dependent difference in weight (p < 0.0001) when comparing both male 
(mean APP23 28.25 g, WT 32.39 g), and female (APP23 21.86 g, WT 25.14 g), as has been 
described previously.126   
The data are illustrated in Figure 3-12.   
Motor function 
Rota-rod 
The mean latency to fall from the Rota-rod for APP23 males was 35.39 sec and for WT males 
17.98 sec (p < 0.0001).   
No difference was seen when comparing female APP23 and WT.   
The data are illustrated in Figure 3-13.   
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Open Field 
There was no genotype dependent difference in mean total path length travelled in 10 min in the 
open field in either male (APP23 2554 cm, WT 2315 cm), or female (APP23 = 3252 cm, WT = 
2870cm) mice.   
No difference was observed in their mean velocity.   
The data are illustrated in Figure 3-14.   
Feed consumption 
Male APP23 consumed more feed than WT male (Male APP23 mean 0.14 g feed / day / g body 
weight, WT 0.11 g feed / day / g body weigh).   
Female APP23 consumed more feed than WT females (Female APP23 mean 0.20 g feed / day / 
g body weight, WT 0. 0.14 g feed / day / g body weigh).   
Both APP23 and WT females consume more g feed / day / g body weight than males of the same 
genotype (p < 0.0001).   
The data are illustrated in Figure 3-15 and Figure 3-16.   
Nociception:  Hot plate test 
Hot plate latency to lick was longer in female APP23 compared to female WT (APP23 26.19 sec, 
WT = 21.85 sec, p < 0.001).   
No difference was seen in males (APP23 22.14 sec, WT 21.10 sec).   
Female APP23 had longer latency to lick than male APP (p < 0.0005).  This was not seen in WT.   
The data are illustrated in Figure 3-17 and Figure 3-18.   
3.10.2 Summary of characterising behaviour results 
APP23 showed behaviours and external phenotype that were not seen in WT littermates but it 
was not possible to distinguish genotype by physical examination and observation alone.  
Phenotypic differences extended to include the internal viscera.  APP23 weighed less than WT 
littermates although they consumed more feed per g body weight.  Males showed genotype 
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dependent differences in motor function on the Rota-rod.  APP23 female mice showed differences 
in nociception when compared to WT female, using the hot plate test.   
3.10.3 Characterising the mouse model APP23:  Biochemistry 
1:   Proving that A is over-expressed in adult APP23 in this colony 
Analysis of the normalized WB showed a ca. 10 fold over expression of A 1-16 in 3 month old 
APP23 male mice, compared to WT littermates.  This confirmed that both APP23 and WT in this 
colony express A at anticipated levels.  Data are illustrated in Figure 3-10.   
2:   Determining the age APP23 express A at levels detectable by WB 
A was detectable at both 4 and 8 weeks of age in both male and female mice, as shown in Figure 
3-10 
3:   Determining if A expression increases with age in young APP23 
The data, shown in Figure 3-11, suggests that A expression increased between 4 and 14 weeks 
of age in APP23.  Any difference between 4 and 8-week mice appeared to be smaller.  (p values 
were not calculated due to small numbers per group).   
4:   Determining if both young male and female APP23 mice express A at similar levels 
No difference in A expression was detectable between young male and female mice.  The data 
are shown in Figure 3-11.   
3.10.4 Summary of characterising biochemistry 
APP23 over express soluble A, even in infancy.  The amount of A expressed increases with 
age.   
3.11 Results:  The assessment of learning and memory using TFC 
3.11.1 The assessment of learning 
The percentage freezing behaviour displayed was analysed for evidence of learning during 3 
components of the single training session:   
1:   Tone 1 – 6:  The interval during the audible Tone 
2:   Trace 1 – 6:  The interval between end of Tone and start of Shock 
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3:   ITI 1 – 6:  The interval between end of Shock and start of Tone 
Statistical interaction of the data:   
Interaction analysis showed significant interaction within the data of genotype and % freezing 
displayed during Tone (p = 0.049).   
This represents a genotype dependent difference in learning in TFC.  Consequently, all data 
described in this investigation was analysed stratified by genotype.   
No statistical interaction with genotype was found for Trace (p = 0.2) and ITI (p = 0.38).  Similarly, 
no statistical interaction was found when stratifying for sex and genoptype for Tone (p = 0.08), 
Trace (p = 0.4) or ITI (p = 0.46).   
The assessment of learning 
APP23 and WT learned during the single training session.  This was observed in data from each 
interval of the training session.   
Young mice 
Genotype dependent difference in maximal performance 
Maximal performance describes the mean % freezing behaviour displayed for each group within 
a particular interval of training.  A genotype dependent difference in maximal performance was 
seen during Tone when comparing APP23 and WT (illustrated in Figure 3-19).  WT showed higher 
maximal performance than APP23.   
A genotype dependent difference was also seen during ITI (ITI 3, see Figure 3-27).   
No genotype dependent difference in maximal performance was seen during Trace (see Figure 
3-23).   
When stratifying by genotype and sex, females showed a trend toward higher maximal 
performance than males.  This difference approached statistical significance in Young APP23 
during Trace (see Figure 3-24).   
Old Mice 
In common with Young mice, Old mice showed increased freezing behaviour with repeated 
exposure to the Tone – Shock pairs.  A genotype dependent difference in maximal performance 
  
150 
was again seen during Tone when comparing Old APP23 and Old WT (illustrated in Figure 3-22).  
This was not seen during any other training interval (Figure 3-26 and Figure 3-30).   
All assessment of learning data are illustrated in Figure 3-19 to Figure 3-30.   
3.11.2 The assessment of memory 
The assessment of memory was performed on d 3 and 14 after the introduction of the modifiable 
risk (Anaesthesia ± Surgery) with or without intervention (Statin or Placebo).   
No consistently reproducible effect was caused by introduction of the modifiable risk (Anaesthesia 
± Surgery) or intervention (Statin or Placebo), either when comparing groups within time-points 
or longitudinally between d 3 and d 14.  The analysis did not reveal a difference between groups 
within any one-time point.   
3.11.3 Young APP23 
Data are illustrated in Figure 3-31, Figure 3-34 and Figure 3-37.   
Effect of the intervention (Statin or Placebo) 
Longitudinally, there was no difference in Contextual or Conditioned response caused by 
intervention with Statin or Placebo alone.   
Effect of Anaesthesia with intervention (Statin or Placebo) 
Introducing Anaesthesia to both Statin and Placebo treated mice had no effect on Contextual 
memory.   
Longitudinally, Anaesthesia + Placebo group showed worse performance on d 14 (p = 0.039) in 
Conditioned response during Tone.  This deterioration was not seen in the Anaesthesia + Statin 
intervention group in the same analysis, data being illustrated in Figure 3-34.   
Effect of the modifiable risk 
Introducing Surgery to both Statin and Placebo treated mice had no effect on Contextual memory.   
Longitudinally, the Surgery + Placebo group showed improved performance in Conditioned 
response after Tone on d 14 compared to d 3 (p = 0.006), but this was not seen in APP23; (p = 
0.89), illustrated in Figure 3-37.   
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3.11.4 Young WT 
Data are illustrated in Figure 3-32, Figure 3-35 and Figure 3-38.   
Effect of the intervention (Statin or Placebo) 
Longitudinally, there was no difference in Contextual response due to intervention with Statin or 
Placebo alone.  Improved Conditioned response after Tone was seen in Young WT receiving both 
Placebo (p = 0.001) and Statin (p = 0.034).  This was not seen for Conditioned response during 
Tone (p = 0.8 for both interventions).  Improved performance on d 14 was also observed after 
Anaesthesia + Stain (p = 0.019) and is illustrated in Figure 3-38.   
Effect of Anaesthesia with intervention (Statin or Placebo) 
Longitudinally, Anaesthesia + Statin showed improved performance on d 14 in both Conditioned 
response during Tone (p = 0.02, Figure 3-35) and Conditioned response after Tone (p = 0.019, 
Figure 3-38).  This was not seen in Anaesthesia + Placebo in either analysis.   
Effect of the modifiable risk 
Longitudinally, both Surgery + Placebo and Surgery + Statin groups showed improved 
performance in Conditioned response during Tone on d 14 (p = 0.019 and (p = 0.07) respectively), 
but this difference was not seen in conditioned response after Tone (p = 0.27 and p = 0.62 
respectively).   
3.11.5 Old mice 
Data are illustrated in Figure 3-33, Figure 3-36 and Figure 3-39.   
Old APP23 and WT that received handling only displayed similar % freezing behaviour to Young 
APP23 and WT.   
Old APP23 showed improved Conditioned response during Tone (p = 0.01) on d 14 compared to 
d 3.   
There was no difference between the genotypes in Old mice in any other analyses.   
3.11.6 Summary of the TFC behavioural findings 
Both APP23 and WT showed evidence of associative learning using TFC.   
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There was a detectable genotype dependent difference in maximal performance during learning 
in both young and old mice.   
There was no difference between the groups within any one-time point for both APP23 and WT 
in any analysis.   
When comparing longitudinally between d 3 and d 14 time-points:   
Hippocampal dependent memory was not affected by any intervention or by the modifiable risk in 
either genotype.   
Non-hippocampal memory was affected by the intervention with statin or placebo and by 
introduction of the modifiable risk, but its detection was not consistent throughout all measures 
used.   
There was no strong effect of statin.   
All results are summarised in Table 3-23.   
3.12 Results:  Molecular analysis of brain tissue by immunochemistry 
3.12.1 Immunochemistry for synaptophysin 
Coefficient of variance of the MPI data obtained was calculated and showed small variance of the 
signal between all samples.   
Data are illustrated in Figure 3-40, with representative images of the staining presented in Figure 
3-44.   
No difference in the synaptophysin expression was detectable in CA-1, granular layer or hilus of 
the DG, when comparing Control, Statin or Placebo intervention groups at both d 3 and d 14 after 
introduction of the modifiable risk.  This was the finding for both APP23 and WT mice.   
3.12.2 IBA-1 and Thioflavin-S 
Data are illustrated in Figure 3-41, Figure 3-42 and Figure 3-43, with representative images of the 
staining presented in Figure 3-45.   
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Results are expressed as fold change compared to Control (to enable the microscopy to be 
performed in smaller batches with separate controls for each batch).   
No difference in the IBA-1 expression was detectable in subiculum, CA-1 or cortex, between 
Control, d 3 and d 14 after introduction of the modifiable risk with either Statin or Placebo 
intervention.  This was the finding for both APP23 and WT mice.   
Similarly, no difference was detected in the same tissue slices when examining Thioflavin-S 
staining for A plaque.   
3.13 Interim analysis of early data 
An interim analysis of samples was performed early in the investigation, examining brain of 3 – 6 
month old APP23 and WT.   
A number of preliminary observations were made that are described here and illustrated in the 
appendix.    
3.13.1 GFAP expression in the hippocampal fissure 
Immunofluorescence was performed using GFAP antibody, the region of interest was the 
hippocampal fissure, a highly vascular region of the hippocampus susceptible to incoming signals 
in blood.   
We saw strong up regulation of GFAP in perivascular astrocytes in the hippocampal fissure 24 h 
after introducing the modifiable risk in both APP23 and WT.   
Interestingly, at this early time point the GFAP activation was not present throughout the 
hippocampal parenchyma, but focussed on major vessels and their proximal branches supplying 
the entire hippocampus.   
This GFAP up-regulation had markedly subsided in WT by d 7.  By contrast, sustained activation 
was present in APP23.   
This suggests either enhanced pro-inflammatory signalling, or insufficient anti-inflammatory 
signalling in the APP23.   
Representative images are illustrated in the appendix.   
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3.13.2 Soluble A  
WB of whole brain lysate using 6E10 antibody:   
A reduction in 4 kDa fragments, representing soluble A, were detected in both Anaesthesia and 
Anaesthesia + Surgery in APP23 24 h after introduction of the modifiable risks.   
This reduction may represent an increase in fibrillar species of A.   
The data are illustrated in the appendix.   
3.13.3 Soluble and fibrillar A quantified using 6E10 and Thioflavin-S 
Early in the study, quantification of A using 6E10 in WB showed Anaesthesia and Anaesthesia 
+ Surgery had the same impact on A, independent of genotype, with both APP23 and WT 
showing reduction in expression after introduction of the modifiable risks.  We feared this may 
have been secondary to inadvertent perioperative hypothermia and therefore introduced 
adaptations to the protocol that would prevent this.   
When quantifying A using Thioflavin-S staining of hippocampus, 3 – 6 month old APP23 Control 
showed no evidence of A aggregation in the subiculum, a site of early A deposition in AD.  At 
d 7 and 14 after introduction of the modifiable risk Anaesthesia + Surgery, significant 
accumulation of A fibrillar species were detected in subiculum.   
Remarkably, in statin treated APP23, the amount of fibrillar A did not differ from Control.   
This data influenced our approach toward developing the model and are illustrated in the 
appendix.   
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Chapter 3 Figures 
Figure 3-1: Representative PCR gels 
 
Two representative images of agarose gels following PCR.  Gel A:  PCR for APP gene.  Gel B:  
PCR for actin gene.    
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Figure 3-2: The modifiable risk factor:  Sterile unilateral nephrectomy surgery under general 
anaesthesia 
 
Photograph of the operating table and surgeon during the modifiable risk, general anaesthesia 
with unilateral nephrectomy surgery on mice.  Main features of the operating table and 
environment are identified.   
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Figure 3-3: Timeline of the study protocol 
 
Schematic illustrating the timeline used during this investigation.  Ear notching for genotyping 
always occurred several weeks before any behaviour characterization work.  Dosing by oral 
gavage from d -5 occurred concurrent with behaviour work for the assessment of learning.  The 
modifiable risk was introduced on d 0.  The assessment of memory was always performed on d 
3, 7 and 14.  The assessment of new learning was performed later, prior to killing.   
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Figure 3-4: TFC apparatus 
 
Photograph of the TFC apparatus, with main features highlighted.    
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Figure 3-5: The assessment of learning during TFC 
 
Schematic illustrating learning during TFC.  Reduction in the motion index (green) illustrates how 
freezing behaviour increases with repeated exposure to six Tone (blue) – Shock (red) pairs.  This 
reflects the learning of the Tone – Shock association during the course of a single training session 
of 772 sec duration.  Context of the learning is shown in the insert at the top right.     
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Figure 3-6: The assessment of memory after TFC:  Contextual response 
 
Schematic illustrating the assessment of Contextual response after TFC.  Motion within the box 
during the 120 sec assessment is quantified and used as an index of the hippocampal dependent 
memory of the Tone – Shock association that was learnt in the identical context (shown top right).    
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Figure 3-7: The assessment of learning after TFC:  Conditioned response 
 
Schematic illustrating the assessment of Conditioned response after TFC.  This occurs in a novel 
environment (shown top right) where Tone (blue) is the only common feature with the context in 
which learning occurred.  Motion during and for 60 sec after Tone is quantified and used as an 
index of the non-hippocampal dependent memory of the Tone – Shock association.  Time in sec.    
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Figure 3-8: Timeline of the TFC study protocol 
 
Schematic illustrating the timeline of the TFC study.  The assessment of learning occurred on d -
1, whilst mice were receiving daily Statin or Placebo.  The assessment of memory was performed 
on separate cohorts of mice on d 3 and 14.   
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Figure 3-9: Hippocampal dissection  
 
Hemi-brains were dissected in ice-cold PBS to isolate the cortex, hippocampus, olfactory bulb, 
cerebellum and mid and hind brain, prior to snap freezing in liquid N2.   
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Figure 3-10: Characterising A expression in the colony 
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This figure illustrates WB for protein from cortex homogenate of 3 month APP23 and WT using 
6E10 antibody.   
A:   The x-axis represents the genotype and the y-axis represents MPI.   
B:   The x-axis represents the sex and the y-axis represents MPI.   
A:   This histogram illustrates the over expression of A in male APP23, as compared to male 
WT littermates.   
B:   This histogram illustrates the expression of A in infant APP23 mice at 8 and 4 weeks of 
age.  A is measurable in APP23 using WB at both 4 and 8 weeks of age.   
All data are presented as the value.  n = 1 per column.   
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Figure 3-11: Characterising A expression in APP23 infants and young adults 
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This figure illustrates WB for protein from cortex homogenate of male APP23 mice using 6E10 
antibody.   
A:   The x-axis represents the mouse age and the y-axis represents MPI.   
B:   The x-axis represents the sex and the y-axis represents MPI.   
A:   The scatter dot plot illustrates that in young male APP23 A expression increases from 4 to 
14 weeks of age.   
B:   This scatter dot plot illustrates that there was no measureable difference between A 
expression in male and female mice of 4 and 8 weeks of age.   
All data presented and mean or mean (95 % CI).  A:  Statistical analysis not performed due to 
small n numbers.  B:  t test:  t = 0.6909 df = 5, p = 0.5204.  n numbers per group are illustrated in 
the figure.   
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Figure 3-12: Characterising weight 
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This figure illustrates weight data at the start of the experiment of young APP23 and WT mice 
with free access to feed and water.  The x-axis represents the genotype and the y-axis represents 
the weight in g.   
A:   This histogram illustrates the weight of male mice.  APP23 had lower body weight when 
compared to WT littermates.   
B:   This histogram illustrates the weight of female mice.  APP23 had lower body weight than 
WT littermates.   
All data are presented as A:  mean (95 % CI), B:  median (IQR).  A:  t test:  t=9.211 df=185, p = 
< 0.0001; B:  Mann-Whitney test U = 1033, p = < 0.0001.  **** means p < 0.01, n numbers per 
group are stated in the figure.   
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Figure 3-13: Characterising motor function:  Rota-rod 
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This figure illustrates Rota-rod data for male and female APP23 and WT mice aged 3 – 6 months 
old.  The x-axis represents the genotype and the y-axis represents the latency to fall in sec.   
A:   This histogram illustrates that male WT showed reduced latency to fall when compared to 
male APP23 littermates (p < 0.0001).   
B:   This histogram illustrates that female showed no genotype dependent difference in latency 
to fall.   
All data are presented as Median (IQR).  A:  Mann-Whitney U = 2091, p = < 0.0001; B:  Mann-
Whitney U = 1418, p = 0.1684.  **** means p < 0.01, n numbers per group are stated in the figure.   
  
  
176 
Figure 3-14: Characterising motor function:  Open field 
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This figure illustrates Open field data for male and female APP23 and WT mice aged 3 – 6 months 
old.  A + B:  the x-axis represents the genotype and the y-axis represents the total path length in 
cm.  C:  the x-axis represents the genotype and the y-axis represents the mean velocity in cm / 
sec.  
A:   This histogram illustrates that there was no genotype dependent difference in the path length 
travelled by males.   
B:   This histogram illustrates that there was no genotype dependent difference in the path length 
travelled by females.   
C:   This scatter dot plot illustrates that there is no difference in mean velocity travelled in the 
open field by APP23 and WT.   
All data are presented as mean (95 % CI).  A:  t test:  t = 1.1 df = 27, p = 0.2936; B:  t test:  t = 
1.530 df = 37, p = 0.1345; C:  t test:  t = 1.655 df = 66, p = 0.1026.  n numbers per group are 
stated or illustrated in the figure.   
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Figure 3-15: Characterising feed consumption:  across genotype 
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This figure illustrates daily feed consumption for APP23 and WT mice 15 – 21 weeks of age with 
free access to feed and water.  The x-axis represents the genotype and sex and the y axis the 
amount of feed consumed / day / unit body weight (g feed consumed / day / g mouse body weight).   
A:   The scatter dot plot illustrates that APP23 male mice consume more feed per day per gram 
body weight than WT male mice.   
B:   The scatter dot plot illustrates that APP23 female mice consume more feed per day per 
gram body weight than WT female mice.   
All data presented and mean (95 % CI).  A:  t test:  t = 7.8 df = 163, p = < 0.0001; B:  t test:  t = 
7.0 df = 76, p = < 0.0001.  **** means p < 0.01.  n numbers per group are stated or illustrated in 
the figure.   
  
  
180 
Figure 3-16: Characterising feed consumption:  within genotype 
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This figure illustrates daily feed consumption for APP23 and WT mice 15 – 21 weeks of age with 
free access to feed and water.  The x-axis represents the genotype and sex and the y axis the 
amount of feed consumed / day / unit body weight (g feed consumed / day / g mouse body weight).   
A:   This histogram illustrates that APP23 female mice consume more feed per day per gram 
body weight than APP23 male mice.   
B:   This histogram illustrates that WT female mice consume more feed per day per gram body 
weight than WT male mice.   
All data presented and mean (95 % CI).  A:  t test:  t = 8.2 df = 120, p = < 0.0001.  B:  t test:  t = 
4.5 df = 119, p = < 0.0001.  **** means p < 0.01.  n numbers per group are stated or illustrated in 
the figure.   
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Figure 3-17: Characterising nociception:  Hot plate across genotypes 
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This figure illustrates hot plate data recorded in 3 – 6 month old mice, expressed as latency to 
hind paw lick or jump in sec.  The x-axis represents the genotype and the y-axis represents the 
latency to lick in sec.   
A:   This histogram illustrates that there was no difference in latency to lick seen in male mice of 
either genotype.   
B:   This histogram illustrates that APP23 female mice showed a longer latency to hind paw lick 
on the hot plate than female WT littermates.   
All data are presented as mean (95 % CI).  B:  t = 4.41 df = 131, p = < 0.0001; **** means p < 
0.01, n numbers per group are stated in the figure.   
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Figure 3-18: Characterising nociception:  Hot plate within genotype 
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This figure illustrates hot plate data recorded in 3 – 6 month old mice, expressed as latency to 
hind paw lick or jump in sec.  The x-axis represents the sex and the y-axis represents the latency 
to lick in sec.   
A:   This histogram illustrates that APP23 female mice showed a longer latency to hind paw lick 
on the hot plate than male APP23 mice.   
B:   This histogram illustrates that there was no difference in latency to lick seen in WT mice of 
either sex.   
All data are presented as mean (95 % CI).  A:  t test:  t=3.584 df=129, p = 0.0005.  B:  t test:  t = 
0.92 df = 174, p = 0.3574.  *** means p < 0.01, n numbers per group are stated in the figure.   
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Figure 3-19: Young mice learning during TFC:  % freezing observed during Tone 
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This figure illustrates learning that took place in Young APP23 and WT mice during the single training session using TFC.  The x-axis represents 
the number of the Tone interval, and the y-axis the change in % freezing observed compared to Tone number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both APP23 (p < 0.0001) and WT (p < 0.0001).  This represents learning of the Tone – Shock 
association with repeated exposure to the Tone – Shock pairs during the single training session.   
A difference in maximal performance is seen between genotypes (as shown by separation of the 95 % CI illustrated), with WT freezing more 
than APP23 at equivalent time-points. 
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23 = 122, WT = 144.   
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Figure 3-20: Young APP23 learning during TFC:  % freezing observed during Tone  
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This figure illustrates learning that took place in Young APP23 mice during the single training session using TFC.  The x-axis represents the 
number of the Tone interval, and the y-axis the change in % freezing observed compared to Tone number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both male (p < 0.0001) and female (p < 0.0001) APP23 with repeated exposure to the Tone – 
Shock pairs, but no sex specific difference was seen.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23-Male 78, APP23-Female = 44.   
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Figure 3-21: Young WT learning during TFC:  % freezing observed during Tone 
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This figure illustrates learning that took place in Young WT mice during the single training session using TFC.  The x-axis represents the number 
of the Tone interval, and the y-axis the change in % freezing observed compared to Tone number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both male (p < 0.0001) and female (p < 0.0001) WT with repeated exposure to the Tone – Shock 
pairs, but no sex specific difference was seen.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are WT-Male 74, WT-Female = 70.   
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Figure 3-22: Old mice learning during TFC:  % freezing observed during Tone 
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This figure illustrates learning that took place in Old APP23 and WT mice during the single training session using TFC.  The x-axis represents 
the number of the Tone interval, and the y-axis the change in % freezing observed compared to Tone number 1.   
An increase in freezing behaviour is shown by both Old APP23 (p < 0.0001) and Old WT (p < 0.0001) mice.  This represents learning of the 
Tone – Shock association.   
A difference in maximal performance is seen between genotypes (as shown by separation of the 95 % CI illustrated), with Old WT freezing more 
than Old APP23 at equivalent time-points.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23 = 9, WT = 17.   
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Figure 3-23: Young mice learning during TFC:  % freezing observed during Trace 
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This figure illustrates learning that took place in Young APP23 and WT mice during the single training session using TFC.  The x-axis represents 
the number of the Trace interval, and the y-axis the change in % freezing observed compared to Trace number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both APP23 (p < 0.0001) and WT (p < 0.0001).   
No difference in maximal performance is seen between genotypes during this interval.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23 = 122, WT = 144.   
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Figure 3-24: Young APP23 learning during TFC:  % freezing observed during Trace 
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This figure illustrates learning that took place in Young APP23 mice during the single training session using TFC.  The x-axis represents the 
number of the Trace interval, and the y-axis the change in % freezing observed compared to Trace number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both male (p < 0.0001) and female (p < 0.0001) APP23.  The small overlap of the 95% CI in 
interval 4 and 5 suggests the 2 groups are approaching statistically different maximal performance during these intervals.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23-Male 78, APP23-Female = 44.   
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Figure 3-25: Young WT learning during TFC:  % freezing observed during Trace 
  
  
1
9
9
 
This figure illustrates learning that took place in Young WT mice during the single training session using TFC.  The x-axis represents the number 
of the Trace interval, and the y-axis the change in % freezing observed compared to Trace number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both male (p < 0.0001) and female (p < 0.0001) WT, but no sex specific difference was seen.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are WT-Male 74, WT-Female = 70.   
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Figure 3-26: Old mice learning during TFC:  % freezing observed during Trace 
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This figure illustrates learning that took place in Young APP23 and WT during the single training session using TFC.  The x-axis represents the 
number of the Trace interval, and the y-axis the change in % freezing observed compared to Trace number 1.   
An increase in freezing behaviour is shown by both Old APP23 (p < 0.0001) and Old WT (p < 0.0001).   
No difference in maximal performance is seen between genotypes during this interval.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23 = 9, WT = 17.   
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Figure 3-27: Young mice learning during TFC:  % freezing observed during ITI 
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This figure illustrates learning that took place in Young APP23 and WT during the single training session using TFC.  The x-axis represents the 
ITI number, and the y-axis the change in % freezing observed compared to ITI number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both APP23 (p < 0.0001) and WT (p < 0.0001).   
A difference in maximal performance is seen between genotypes during ITI 3, as illustrate by separation of the 95 % CI illustrated.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23 = 122, WT = 144.   
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Figure 3-28: Young APP23 learning during TFC:  % freezing observed during ITI 
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This figure illustrates learning that took place in Young APP23 mice during the single training session using TFC.  The x-axis represents the ITI 
number, and the y-axis the change in % freezing observed compared to ITI number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown in both APP23-Male (p < 0.0001) and APP23-Female (p < 0.0001).  No sex specific difference was 
seen.   
All data are presented as mean (95% CI).  All data are presented as mean ± 95% CI.  p value derived by linear mixed model.  n numbers are 
APP23-Male =78, APP23-Female = 44.   
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Figure 3-29: Young WT learning during TFC:  % freezing observed during ITI 
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This figure illustrates learning that took place in Young WT mice during the single training session using TFC.  The x-axis represents the ITI 
number, and the y-axis the change in % freezing observed compared to ITI number 1.   
Mice were receiving either Statin or Placebo by oral gavage.   
An increase in freezing behaviour is shown by both male (p < 0.0001) and female (p < 0.0001) WT with repeated exposure to the Tone – Shock 
pairs, but no sex specific difference was seen.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are WT-Male 74, WT-Female = 70.   
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Figure 3-30: Old mice learning during TFC:  % freezing observed during ITI 
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This figure illustrates learning that took place in Old APP23 and WT mice during the single training session using TFC.  The x-axis represents 
the ITI number, and the y-axis the change in % freezing observed compared to ITI number 1.   
An increase in freezing behaviour is shown by both APP23 (p < 0.0001) and WT (p < 0.0001).   
No difference in maximal performance is seen between genotypes during this interval.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are APP23 = 9, WT = 17.   
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Figure 3-31: Young APP23 remembering after TFC:  Contextual response d 3 and 14 
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This line graph represents the assessment of hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable risk 
factor in Young APP23 mice.  The x-axis represents the day and the y-axis the change in % freezing observed during the 120 sec assessment.   
No difference between groups was detectable, either within any time point or when comparing performance on d 3 with d 14.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are Placebo = 14, Statin = 19, 
Anaesthesia + Placebo = 14, Anaesthesia + Statin = 22, Surgery + Placebo = 21, Surgery + Statin = 23.   
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Figure 3-32: Young WT remembering after TFC:  Contextual response d 3 and 14 
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This line graph represents the assessment of hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable risk 
factor in Young WT mice.  The x-axis represents the day and the y-axis the change in % freezing observed during the 120 sec assessment.   
No difference between groups was detectable, either within any time point or when comparing performance on d 3 with d 14.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are Placebo = 21, Statin = 27, 
Anaesthesia + Placebo = 20, Anaesthesia + Statin = 17, Surgery + Placebo = 22, Surgery + Statin = 24.   
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Figure 3-33: Old mice remembering after TFC:  Contextual response d 3 and 14 
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This line graph represents the assessment of hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable risk 
factor in Old APP23mice that were receiving handling only.  The x-axis represents the day and the y-axis the change in % freezing observed 
during the 120 sec assessment.   
No genotype dependent difference was detectable, either within any time point or when comparing performance on d 3 with d 14.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are APP23 Nil = 9, WT Nil = 13.   
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Figure 3-34: Young APP23 remembering after TFC:  Conditioned response during Tone, d 3 and 14 
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This line graph represents the assessment of non-hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable 
risk factor in Young APP23 mice.  The x-axis represents the day and the y-axis the change in % freezing observed during the 30 sec Tone.   
No difference between groups was detectable within any time point.  When comparing longitudinally between d 3 and 14 Anaesthesia + Placebo 
group showed reduced % freezing on d 14 (p = 0.039).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are Placebo = 14, Statin = 19, 
Anaesthesia + Placebo = 14, Anaesthesia + Statin = 22, Surgery + Placebo = 21, Surgery + Statin = 23.   
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Figure 3-35: Young WT remembering after TFC:  Conditioned response during Tone, d 3 and 14 
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This line graph represents the assessment of non-hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable 
risk factor in Young WT mice.  The x-axis represents the day and the y-axis the change in % freezing observed during the 30 sec Tone.   
No difference between groups was detectable within any time point.  Increased % freezing was observed on d 14 in Anaesthesia + Statin (p = 
0.027), Surgery + Placebo (p = 0.019) and Surgery + Statin (p = 0.073).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are Placebo = 21, Statin = 27, 
Anaesthesia + Placebo = 20, Anaesthesia + Statin = 17, Surgery + Placebo = 22, Surgery + Statin = 24.   
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Figure 3-36: Old mice remembering after TFC:  Conditioned response during Tone, d 3 and 14 
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This line graph represents the assessment of non-hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable 
risk factor in Old APP23 mice that were receiving handling only.  The x-axis represents the day and the y-axis the change in % freezing observed 
during the 30 sec Tone.   
No genotype dependent difference was detectable within any time point.  When comparing performance on d 3 with d 14, Old APP23 mice 
showed a statistically significant increase in freezing on d 14 (p = 0.01).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are APP23 Nil = 9, WT Nil = 13.   
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Figure 3-37: Young APP23 remembering after TFC:  Conditioned response after Tone, d 3 and 14 
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This line graph represents the assessment of non-hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable 
risk factor in Young APP23 mice.  The x-axis represents the day and the y-axis the change in % freezing observed during the 60 sec after the 
Tone.   
No difference between groups was detectable within any time point.  When comparing longitudinally between d 3 and 14 Surgery + Placebo 
group showed increased % freezing on d 14 (p = 0.006).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are Placebo = 14, Statin = 19, 
Anaesthesia + Placebo = 14, Anaesthesia + Statin = 22, Surgery + Placebo = 21, Surgery + Statin = 23.   
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Figure 3-38: Young WT remembering after TFC:  Conditioned response after Tone, d 3 and 14 
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This line graph represents the assessment of non-hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable 
risk factor in Young WT mice.  The x-axis represents the day and the y-axis the change in % freezing observed during the 60 sec after the Tone.   
No difference between groups was detectable within any time point.  When comparing longitudinally between time-points, increased % freezing 
was observed on d 14 in Placebo (p = 0.001), Statin (p = 0.034) and Anaesthesia + Statin (p = 0.019) groups.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are Placebo = 21, Statin = 27, 
Anaesthesia + Placebo = 20, Anaesthesia + Statin = 17, Surgery + Placebo = 22, Surgery + Statin = 24.   
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Figure 3-39: Old mice remembering after TFC:  Conditioned response after Tone, d 3 and 14 
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This line graph represents the assessment of non-hippocampal dependent memory using TFC on d 3 and 14 after introduction of the modifiable 
risk factor in Old APP23mice that were receiving handling only.  The x-axis represents the day and the y-axis the change in % freezing observed 
during the 60 sec after the Tone.   
No genotype dependent difference was detectable within any time point or between d 3 and 14.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  Sum n numbers per group are APP23 Nil = 9, WT Nil = 13.   
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Figure 3-40:   Synaptophysin in hippocampus, d 3 and 14 
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This plate of 6 figures A – F illustrates immunochemistry using DAB for synaptophysin in 
hippocampus of brain from female mice 130 – 160 d of age that had undergone the assessment 
of learning and memory using TFC.   
For each figure the x-axis represents the group and the y-axis represents the MPI.   
The left hand column (A, C, E) illustrates data from APP23 mice.  The right hand column (B, D, 
F) illustrates data from WT mice.   
A + B illustrate data from CA1 region of the hippocampus.   
C + D illustrate data from Granular layer of the DG of the hippocampus.   
E + F illustrate data from the hilus of the hippocampus.   
The groups illustrated in each figure from left to right are: Control, Surgery + Placebo d 3, Surgery 
+ Statin d 3, Surgery + Placebo d 14 and Surgery + Statin d 14.   
No difference was found in the MPI of synaptophysin in either APP23 or WT mice at d 3 or 14 
post introduction of the modifiable risk in any group analysed.   
Data are illustrated as Mean (95% CI).  A:  F4 17= 1, p = 0.41; B:  F4 20= 1.19, p = 0.34; C:  F4 19= 
0.6, p = 0.66; D:  F4 20= 1.6, p = 0.21; E:  F4 19= 0.6, p = 0.66; F:  F4 20= 1.69, p = 0.19.  p value 
derived from one-way ANOVA.  n = 5 mice per group, with 4 brain slices per mouse.   
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Figure 3-41: IBA-1 and A in subiculum, d 3 and 14 
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This plate of 4 figures A – D illustrates immunochemistry using IBA-1 antibody and Thioflavin-S staining of brain from female mice 130 – 160 d 
of age that had undergone the assessment of learning and memory using TFC.  The region of interest was the subiculum of the hippocampus.   
For each figure the x-axis represents the group and the y-axis represents the Fold change compared to Control.   
The left hand column (A and C) illustrates data from APP23.  The right hand column (B and D) illustrates data from WT.   
A + B illustrate data of IBA-1 immunochemistry.   
C + D illustrate data of Thioflavin-S staining.   
The groups illustrated in each figure from left to right are: Control, Surgery + Placebo d 3, Surgery + Statin d 3, Surgery + Placebo d 14 and 
Surgery + Statin d 14.   
No difference was found in the expression of IBA-1 or Thioflavin-S staining of A in the subiculum of either APP23 or WT at d 3 or 14 post 
introduction of the modifiable risk with either Statin of Placebo.   
Data are illustrated as mean (95% CI).  n = 3 per group, with 4 brain slices per mouse.  A:  F4 10= 1.6, p = 0.25; B:  F4 10= 0.77, p = 0.57; C:  F4 
10= 1.56, p = 0.26; D:  F4 10= 1, p = 0.44.  p value derived from one-way ANOVA.   
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Figure 3-42: IBA-1 and A in CA-1, d 3 and 14 
 
  
2
3
3
 
This plate of 4 figures A – D illustrates immunochemistry using IBA-1 antibody and Thioflavin-S staining of brain from the same mice as for 
subiculum.  The region of interest here was CA-1 region of the hippocampus.  The figure is set out the same as for subiculum.   
No difference was found in the expression of IBA-1 or Thioflavin-S staining of A in the CA-1 region of either APP23 or WT at d 3 or 14 post 
introduction of the modifiable risk with either Statin of Placebo.   
Data are illustrated as mean (95% CI).  A:  F4 10= 1.3, p = 0.33; B:  F4 10=0.49, p = 0.75; C:  F4 10= 1.5, p = 0.26; D:  F4 10=0.67, p = 0.63 p value 
derived from one-way ANOVA.  n = 3 per group, with 4 brain slices per mouse.   
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Figure 3-43: IBA-1 and A in cortex, d 3 and 14 
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This plate of 4 figures A – D illustrates immunochemistry using IBA-1 antibody and Thioflavin-S staining of brain from the same mice as for 
subiculum.  The region of interest here was the cortex.  The figure is set out the same as for subiculum.   
No difference was found in the expression of IBA-1 or Thioflavin-S staining of A in the cortex of either APP23 or WT at d 3 or 14 post introduction 
of the modifiable risk with either Statin of Placebo.   
Data are illustrated as mean (95% CI).  A:  F4 10= 1.2, p = 0.38; B:  F4 10= 0.4, p = 0.8; C:  F4 10=1.4, p = 0.29; D:  F4 10= 0.76, p = 0.57.  p value 
derived from one-way ANOVA.  n = 3 per group, with 4 brain slices per mouse.   
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Figure 3-44: Synaptophysin immunochemistry:  representative images of the staining 
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This plate of images illustrates representative immunochemistry staining on brain slices from 
APP23 and WT mice using synaptophysin antibody with DAB.  The mice had undergone the 
assessment of learning and the assessment of memory in either the TFC study or the maze study, 
and the layout of the figure is described in the table. 
The same microscope with constant settings was used to image all specimens within any one 
study.  However, different microscopes were used for each respective study.  This, as well as the 
older age of the maze study mice at cull, may contribute to differences in the quality of the tissue, 
the image and the staining, and is appreciable in this illustration.  
All images at x5 magnification. 
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Figure 3-45: IBA-1 and A immunochemistry of APP23 brain tissue:  representative images of 
the staining 
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This plate of images illustrates representative immunochemistry staining on brain slices from 
APP23 mice.  The left column shows IBA-1 staining of microglia (red channel), the centre column 
Thioflavin-S staining of A plaque (green channel) and the right column a composite image of 
IBA-1 and Thioflavin-S staining (merged).   
Rows A and B are positive control tissue from oldest old APP23 female mice.  A shows 
hippocampal tissue and B shows cortex.   
Rows C-E are APP23 mice that underwent the assessment of learning and memory in the TFC 
study.  C = APP23 Control, D = APP23 Surgery + Placebo d 3 and E = APP23 Surgery + Placebo 
d 14.   
A + B:  Large amyloid plaques (green) are present in both hippocampus (Row A) and cortex (Row 
B).  This is associated with increased expression of IBA-1 (red) in surrounding microglia, 
with change in their phenotype consistent with activation.  Grayscale insets contrast 
microglial processes, present in the IBA-1 images, but absent from the Thioflavin-S images. 
C-E:  IBA-1 expression is seen in both Control and post-Surgery APP23 brain, but A plaque is 
seen only in the post-Surgery mice. This is associated with an increase in IBA-1 expression 
and thickening of microglial processes, consistent with gliosis, observed on both d 3 and 14. 
Magnification:  A + B:  x40, C-E x20.   
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Table 3-1:  Schedule for mouse identification by ear notching 
Mouse ID within the cage Ear notch Abbreviation 
1st Left L 
2nd Right R 
3rd Left and Right LR 
4th Left and Left LL 
5th Right and Right RR 
The standard schedule used for the identification of littermate mice.  The ear notcher was cleaned 
with 70 % ethanol between mice.  Ear notch samples were used for DNA extraction and 
genotyping.   
 
Table 3-2:  Primers for PCR of APP and actin genes 
APP gene 
Primer name Molecular weight  Primer length Sequence 5’ to 3’ 
APP Forward 6454.2 21 GCT TGC ACC AGT 
TCT GGA TGG 
APP Reverse 6164.0 20 GAG GTA TTC AGT 
CAT GTG CT 
Actin gene 
Primer name Molecular weight  Primer length Sequence 5’ to 3’ 
Actin Forward 7715.0 25 GAT GAC GAT ATC 
GCT GCG CTG GTC G 
Actin Reverse 8335.4 27 GCC TGT GGT ACG 
ACC AGA GGC ATA 
CAG 
Detailed molecular weight, base length and nucleotide sequence 5’ to 3’ for primers used during 
PCR for both APP23 gene and actin gene.  Genotyping was performed with APP gene and actin 
gene as internal control for DNA quality.  Molecular weight in μg / μmole.   
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Table 3-3:  The PCR mastermix 
APP23 gene 
Constituent Volume per sample  Volume for n samples +15 %  
Buffer 2.5 2.5 * n * 1.15 
MgCl2 1 1 * n * 1.15 
dNTPs  0.2 0.2 * n *1.15 
Primer APP Forward  1.25 1.25 * n * 1.15 
Primer APP Reverse  1.25 1.25 * n * 1.15 
dd.H2O 17.675 17.675 * n * 1.15 
Taq DNA Polymerase 0.125 0.125 * n * 1.15 
Total mastermix volume 
aliquoted to PCR tube 
24  
 
Genomic DNA sample 1 1 * n * 1.15 
Total reaction volume 25 25 * n * 1.15 
Actin gene 
Constituent Volume per sample  Volume for n samples + 15 %  
Buffer 2 2 * n * 1.15 
MgCl2  0.8 1 * n * 1.15 
dNTPs  0.4 0.2 * n *1.15 
Primer actin Forward  1 1.25 * n * 1.15 
Primer actin Reverse  1 1.25 * n * 1.15 
Q solution 4 4 * n * 1.15 
dd.H2O 9.6 9.6 * n * 1.15 
Taq DNA Polymerase 0.2 0.2 * n * 1.15 
Total mastermix volume 
aliquoted to PCR tube 
19  
 
Genomic DNA sample 1 1 * n * 1.15 
Total reaction volume 20 20 * n * 1.15 
Mastermix composition for APP gene and actin gene used during genotyping of mice using PCR.  
The volume of mastermix prepared was dependent on the number of samples (n), and a 
correction factor of 15 % was introduced for pipetting error, as described in the right hand columns 
of the tables.  Concentrations are Buffer 10x, MgCl2 15 mM, dNTPs 10 mM and Primers 20 μM.  
Volume in μl.   
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Table 3-4:  PCR cycle protocol  
APP gene PCR cycle 
Cycle stage Temperature oC Duration Number of cycles 
Initial denaturation 94 5 min 1 
Denature 94 30 sec 20 
Annealing 53 30 sec 
Extension 72 60 sec 
Final extension 72 3 min 1 
Finish 4 Hold  
Actin gene PCR cycle 
Cycle stage Temperature oC Duration Number of cycles 
Initial denaturation 94 3 min 1 
Denature 94 30 sec 30 
Annealing 60 45 sec 
Extension 72 45 sec 
Final extension 72 10 min 1 
Finish 4 Hold  
Conditions for PCR for APP gene and actin gene, used during genotyping using an automated 
PCR cycler.  Temperature in oC, duration of the cycle stage and the number of cycle repetitions 
are as specified in the table.   
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Table 3-5:  Characteristics of mice investigated for feed consumption 
Sex and genotype Total number mice investigated 
APP23_M 7 
WT_M 9 
APP23_F 4 
WT_F 5 
Mouse genotype, sex and number used to investigate feed consumption in APP23 mice and WT 
littermates.  _M = male, _F = female.   
 
Table 3-6:  Feed consumption in male mice 
Genotype and sex No. mice in cage Age  Average weight per 
mouse 
APP23_M 
 
3 131 31.0 
 
1 112 26.4 
 
1 107 27.5 
 
2 131 31.6 
 
Total number of mice = 
7 
 
Average per cage 1.75 120 29.1 
 
Genotype and sex No. mice in cage Age Average weight per 
mouse 
WT_M 
 
2 131 34.2 
 
3 112 35.0 
 
4 107 34.6 
 
Total number of mice = 
9 
 
Average per cage 3 116 34.6 
Population statistics and numbers per cage of mice used to investigate feed consumption in 
APP23 and WT littermates.  All mice in a cage were from the same litter.  Average weight per 
mouse is the mean of all weight measurements recorded for each mouse in that cage throughout 
the course of the experiment.  _M = male, _F = female.  Age in d, weight in g.   
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Table 3-7:  Feed consumption in female mice 
Genotype and sex No. mice in cage Age Average weight per 
mouse  
APP23_F 
 
1 112 20.3 
 
2 112 21.1 
 
1 107 19.5 
 
Total number of mice = 
4 
 
Average per cage 1.3 110 20.3  
 
Genotype and sex No. mice in cage Age Average weight per 
mouse  
WT_F 
 
2 147 32.3 
 
3 107 23.1 
 
Total number of mice = 
5 
 
Average per cage 2.5 127 27.7 
Population statistics and numbers per cage of mice used to investigate feed consumption in 
APP23 and WT littermates.  All mice in a cage were from the same litter.  Average weight per 
mouse is the mean of all weight measurements recorded for each mouse in that cage throughout 
the course of the experiment.  _M = male, _F = female.  Age in d, weight in g.   
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Table 3-8: Time points of data collection in behaviour work 
Purpose of the test Method Day of the protocol at which trials occurred 
Pre modifiable risk Post modifiable risk 
Characterisation of the 
model 
Weight Before -8  
 Rotor-rod Before -8 
Open field Before -8 
Hot plate Before -8  
Feed consumption Before -8  
Assessment of learning  TFC -1  
MWM -5 to -1 for Young 
-7 to -2 for Old 
 
Assessment of memory TFC  3, 14 
MWM  3, 7, 14 
 
Y Maze Before -8 3, 14 
Assessment of new 
learning 
MWM  From 15 
Assessment of new 
memory 
MWM  From 17 
Details of methods used in this study to assess learning, memory, new learning and new memory 
and the time point of assessment within the protocols.  Time-point in day.   
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Table 3-9: Groups in the TFC study 
Group Drug intervention and risk factor 
Placebo 5 d Placebo or Statin, 30 min 100 % O2 d 0, + 
daily handling 
Statin 
Anaesthesia + Placebo 5 d Placebo or Statin, 30 min 2 % isoflurane in O2 
d 0, + daily handling 
Anaesthesia + Statin 
Surgery + Placebo 5 d Placebo or Statin, 2 % isoflurane in O2 + 
unilateral nephrectomy surgery d 0, + daily 
handling Surgery + Statin 
Groups in the TFC study.  Littermates were randomly allocated to groups throughout the study.  
Once daily oral gavage of Placebo or Statin starting d -5, TFC assessment of learning d -1, 
introduction of modifiable risk d 0 and assessment of memory d 3 and d 14.   
 
Table 3-10: Characteristics of the TFC study population:  Young mice 
n = 266 
 
 n (%) 
Genotype APP23 
WT 
122 (45.9) 
144 (54.1) 
Sex _M 
_F  
152 (57.1) 
114 (42.9) 
Genotype & Gender 
 
APP23_M 
APP23_F 
WT_M 
WT_F 
78 (29.3) 
44 (16.5) 
74 (27.8) 
70 (26.3) 
Intervention group 
 
Placebo 
 
Statin 
 
137 (50.5) 
 
132 (49.5) 
Population statistics of Young mice that underwent the assessment of learning during TFC, 
described by genotype and sex.  n numbers are quoted with (% of total study population).  _M = 
male, _F = female.   
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Table 3-11: Characteristics of the TFC study population:  Young APP23 
  Placebo Statin p = 
n = 122   
58 
 
64 
 
 
Sex 
 
Male 
Female 
36 
22 
42 
22 
 
Age  
 
Male  
Female 
145 (141 – 149) 
146 (142 – 149) 
144 (141 – 146) 
147 (143 – 151) 
0.56   df = 76 
0.61   df = 42 
Weight (start of 
training)  
Male  
Female 
28.15 (27 – 29)  
20.91 (20.1 – 23)  
28.6 (27.6 – 29.5) 
22 (21 – 23) 
0.52   df = 76 
0.06   df = 41 
Population statistics of Young APP23 and WT mice that underwent the assessment of learning 
during TFC.  Age in d, weight in g, quoted as mean (95 % CI).  p value and df calculated by two-
tailed t-test.   
 
Table 3-12: Characteristics of the TFC study population:  Young WT 
  Placebo Statin p = 
n = 144  79 65  
Sex 
 
Male 
Female 
37 
39 
37 
31 
 
 
Age  
 
Male  
Female 
145 (142 – 149) 
146 (142 – 150) 
143 (141 – 146) 
143 (139 – 146) 
0.43, df = 72 
0.27, df = 68 
Weight (start of 
training) 
Male  
Female 
32.4 (31.4 – 33.4) 
25.5 (24.4 – 26.7) 
32.5 (31.3 – 33.7) 
24.8 (23.6 – 26) 
0.96, df = 72 
0.35, df = 68 
Population statistics of Young APP23 and WT mice that underwent the assessment of learning 
during TFC.  Age in d, weight in g, quoted as mean (95 % CI).  p value and df calculated by two-
tailed t-test.   
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Table 3-13: Characteristics of the TFC study population:  Young animals by group 
 Placebo Statin Anaesthe
sia + 
Placebo 
Anaesthe
sia + 
Statin  
Surgery + 
Placebo  
Surgery + 
Statin 
p = 
Total n = 
244 
 
n = 35 
 
n = 46 
 
n = 34 
 
n = 39 
 
n = 43 
 
n = 47 
 
 
Genotype 
APP23 
WT 
 
14 (40.0) 
21 (60.0) 
 
19 (41.3) 
27 (58.7) 
 
14 (41.2) 
20 (58.8) 
 
22 (56.4) 
17 (43.6) 
 
21 (48.8) 
22 (51.2) 
 
23 (48.9) 
24 (51.1) 
 
0.748 
Sex 
Female 
Male 
 
13 (37.1) 
22 (62.9) 
 
22 (47.8) 
24 (52.2) 
 
19 (55.9) 
15 (44.1) 
 
13 (33.3) 
26 (66.7) 
 
19 (44.2) 
24 (55.8) 
 
18 (38.3) 
29 (61.7) 
 
0.516 
Genotype 
& sex 
APP23_F 
APP23_M 
APP23_F 
APP23_M 
 
 
4 (11.4) 
10 (28.6) 
9 (25.7) 
12 (34.3) 
 
 
8 (17.4) 
11 (23.9) 
14 (30.4) 
13 (28.3) 
 
 
6 (17.7) 
8 (23.5) 
13 (38.2) 
7 (20.6) 
 
 
5 (12.8) 
17 (43.6) 
8 (20.5) 
9 (23.1) 
 
 
8 (18.6) 
13 (30.2) 
11 (25.6) 
11 (25.6) 
 
 
9 (19.2) 
14 (29.8) 
9 (19.2) 
15 (31.9) 
 
 
0.906 
Population statistics of mice that underwent the assessment of memory after TFC, described by 
group, genotype and sex.  n numbers are quoted with (% of total study population).  _M = male, 
_F = female.  p value and df calculated by two-tailed t-test.   
 
Table 3-14: Characteristics of the TFC study population:  Old mice 
n = 22  n (%) 
Genotype APP23 
WT 
9 (40.9) 
13 (59.1) 
Sex Male 
Female 
10 (45.5) 
12 (54.5) 
Intervention group Nil 22 (100) 
Population statistics of Old mice that underwent the assessment of learning during TFC, 
described by genotype and sex.  Nil means handling only.  n numbers are quoted with (% of total 
study population).  _M = male, _F = female.   
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Table 3-15: Characteristics of the TFC study population:  Old mice by genotype 
n = 22  Nil 
  APP23 WT 
  9 13 
Sex 
 
Male 
Female 
6 
3 
4 
9 
Age  
 
Male  
Female 
454 (324 – 583) 
436 (363 – 509) 
263 (189 – 337) 
397 (340 – 455) 
Weight (start of 
training) 
Male  
Female 
34.6 (27.8 – 41.3) 
34.6 (14 – 55) 
39 (25 – 42.8) 
35.5 (30.4 – 40.6) 
Population statistics of Old APP23 and WT mice that underwent the assessment of learning and 
memory in TFC.  Age in d, weight in g, quoted as mean (95 % CI).   
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Table 3-16: The assessment of learning in TFC:  Components of the training session 
Component name Start time  End time  Duration 
Acclimatization 0 120 120 
Tone 1 120 160 40 
Trace 1 160 180 20 
Shock 1 180 182 2 
 ITI 1 182 222 40 
Tone 2 222 262 40 
Trace 2 262 282 20 
Shock 2 282 284 2 
ITI 2 284 315 31 
Tone 3 315 355 40 
Trace 3 355 375 20 
Shock 3 375 377 2 
ITI 3 377 410 33 
Tone 4 410 450 40 
Trace 4 450 470 20 
Shock 4 470 472 2 
ITI 4 472 510 38 
Tone 5 510 550 40 
Trace 5 550 570 20 
Shock 5 570 572 2 
ITI 5 572 630 58 
Tone 6 630 670 40 
Trace 6 670 690 20 
Shock 6 690 692 2 
ITI 6 692 772 80 
 
Total duration 772 
Component name, start time, end time and duration for each component of the training session 
used for the assessment of learning during TFC.  ITI means ITI.  Start time and end time of each 
component are sec from start of session.  Duration in sec.   
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Table 3-17: The assessment of memory after TFC:  Contextual response 
Component name Start time  End time  Duration  
Acclimatization 0 120 120 
 
Total duration 120 
Component name, start time, end time and duration for each component of the training session 
used for the assessment of memory after TFC.  Contextual response is hippocampal dependent 
memory; Conditioned response is non-hippocampal dependent memory.  Contextual response 
was always assessed at least 2 hours before Conditioned response.  Start time and end time of 
each component are sec from start of session.  Duration in sec.   
 
Table 3-18: The assessment of memory after TFC:  Conditioned response 
Component name Start time  End time  Duration  
Acclimatization 0 120 120 
Tone  120 150 30 
Conditioned response 150 210 60 
 
Total duration 210 
Component name, start time, end time and duration for each component of the training session 
used for the assessment of memory after TFC.  Contextual response is hippocampal dependent 
memory; Conditioned response is non-hippocampal dependent memory.  Contextual response 
was always assessed at least 2 hours before Conditioned response.  Start time and end time of 
each component are sec from start of session.  Duration in sec.   
 
Table 3-19: TFC:  Variables within the box 
In-box variable The assessment of 
learning (training) 
Assessment of memory 
Contextual Conditioned 
Background noise Yes Yes No 
Tone Yes No Yes 
Light:  IR Yes Yes No 
Light:  visible No No Yes 
Scent Scent 1 Scent 1 Scent 2 
A-frame and acrylic floor No No Yes 
Details of the variables within the TFC clear fronted box during the assessment of learning and 
the assessment of memory by Contextual and Conditioned response.  Contextual response is 
assessed in a context identical to which learning took place.  Conditioned response is assessed 
in a novel context where Tone is the only consistent feature.   
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Table 3-20: Surgical equipment for sterile unilateral nephrectomy surgery 
Instrument Number per kit 
Fine-toothed tissue forceps 2 
Curved ending tissue forceps 2 
Flat-ended tissue forceps 1 
Scissors:  iris, straight 2 
Scissors:  surgical, straight 1 
Scissors:  vannas spring, curved 2 
Needle holder 1 
4.0 silk suture on a reel  1 
3.0 – 4.0 silk suture on a curved needle  2 
Surgical equipment required in each kit for the performance of unilateral nephrectomy surgery on 
mice.   
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Table 3-21: Equipment for mouse perfusion 
Equipment Number required 
Adhesive tape 1 
Drawing blunt up needle 3 
Forceps, fine toothed 1 
Forceps, flat ended 1 
Hypodermic needle 25 G 4 
Hypodermic syringe, 1 ml 1 
Hypodermic syringe 20 ml 3 
Ice bucket, with ice 2 
Intravenous fluid bags, 100 ml, plastic, labelled 2 
Intravenous giving sets with, vented with rate 
control thumb wheel, labelled 
2 
Scientific timer 1 
Scissors blunt ended  2 
Scissors, vannas, curved tip 1 
Needle holder, medium sized 1 
Kidney dish 1 
Needle holder, small sized 1 
Perfusion needle, 3 cm 30 G, bulb ended 1 
Plastic bag approved for the holding of mouse 
carcasses 
1 
Polystyrene board, washable, approximately      
30 cm x 30 cm x 3 cm 
1 
Trolley 1 
Toothbrush 1 
3 way tap with extension 1 
3 way taps 2 
Paper towels Many 
Equipment required for the performance of perfusion fixation of mice.   
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Table 3-22: Equipment for dissection of brain 
Equipment Number required 
Centrifuge tubes, 1.5 ml Many 
Centrifuge tube 50 ml Many 
Centrifuge tube holder 100 unit 1 
Curved scalpel blade, stainless steel 2 
Dewar with lid containing liquid N2 1 
Forceps, fine toothed 1 
Ice bucket, with ice 1 
Indelible ink pen 1 
Scissors, blunt ended  1 
Scissors, Iris tissue 1 
Scissors, vannas, curved tip 1 
Petri dish, clear acrylic, 15 cm diameter 1 
Equipment required for the micro-dissection of mouse brain to isolate cortex, hippocampus, 
cerebellum, olfactory bulb, and mid and hindbrain, prior to snap freezing in liquid N2.   
Table 3-23: TFC results summary table 
Assessment Young APP23 
 
Young WT Old APP23 + WT 
Learning  all groups   all groups  all groups 
 Genotype difference in learning during Tone and 
ITI 
WT > APP23 
Young and Old  
Contextual response − − − 
 No difference detected in any analysis 
 
Conditioned 
Response during Tone 
  
Anaesthesia + Placebo 
(p = 0.039) 
 
Anaesthesia + Statin  
(p 0.027) 
Surgery + Placebo  
(p = 0.019) 
Surgery + Statin  
(p = 0.073) 
 
 
 
Old APP23 (p = 0.01) 
  
Conditioned 
Response after Tone 
 
Surgery + Placebo  
(p = 0.006) 
 
Placebo (p = 0.001) 
Statin (p = 0.034) 
Anaesthesia + Statin  
(p = 0.019) 
− 
Summary table of the TFC results.  
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Chapter 4 Morris Water Maze study 
4.1 Introduction 
In response to the inconsistent results of the TFC study, a second, smaller study was performed 
using the MWM, a water navigation task234,235 well validated as a laboratory tool in the 
investigation of hippocampal dependent memory.236   
4.2 Aims of the MWM study 
The MWM study was performed to answer the following questions:   
1: Learning:  Is the ability of APP23 and WT to learn a MWM task the same?   
2: Memory:  Does the modifiable risk factor have an impact on hippocampal dependent 
memory in APP23 and WT that have undergone learning in the MWM, and does 
perioperative atorvastatin have an effect on this?   
3: New learning:  Does the modifiable risk factor have an impact on new learning in the MWM, 
and does perioperative atorvastatin affect this?   
4: New memory:  Does the modifiable risk factor have an effect on the memory of new learning 
and does atorvastatin affect this?   
4.3 The study protocol timeline 
The assessment of learning (training) in the MWM began on d -6, and continued to d -2.   
Daily statin (atorvastatin 10 mg / kg) or placebo (tap water at 0.01 ml / g) intervention by oral 
gavage was introduced from d -5.   
The acquisition probe (assessment of memory before the modifiable risk) was on d -1, and the 
modifiable risk was introduced on d 0.   
Retention probes (the assessment of memory after introducing the modifiable risk) were repeated 
on d 3, 7 and 14 in the same cohort of mice.   
New learning began on d 15 and was assessed on d 17 in Young and d 19 in Old.   
A schematic of the MWM study time line and how it interacts with the Y maze study is illustrated 
in Figure 4-3, and further detailed in Table 3-8.  Groups in the MWM are described in Table 4-1.   
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4.4 The population studied using MWM 
This study was performed using a cohort of Young APP23 and Young WT mice (performed in 2 
mixed cohorts of APP23 and WT littermates), and also in a separate cohort of Old APP23.  
Duration of the study was over 3 months, with population statistics at the time of starting training 
for each group detailed in Table 4-2, Table 4-3, and Table 4-4.   
Mice used in the MWM study were older than those in the TFC study, but for consistency the 
same nomenclature was used for group identification.  No Statin, Anaesthesia + Statin or 
Anaesthesia + Placebo groups were included in order to simplify the study and its analysis.  There 
was no Old WT group either.   
The same mice were used in the MWM and Y maze studies and the two studies were performed 
simultaneously.   
4.5 Materials and Methods 
4.5.1 The data collected 
Evidence of learning and memory in the MWM is quantified using several measures that describe 
how the mouse navigates a pool during a 60 sec exploration.  These measures are described in 
Table 4-5.  In the MWM study, ‘trial’ is an episode for the assessment of learning and ‘probe’ an 
assessment of memory.   
The proforma used for manual data collection during both assessment of learning (trial) and 
memory (probe) are in the appendix.   
4.5.2 The MWM apparatus 
A pool of internal diameter 110 cm and depth 59 cm was used as the MWM.  Constructed of 
polyacrylamide, the pool and the external cues are illustrated in the Figure 4-1.  The pool was 
filled with warm tap water rendered opaque by the addition of non-toxic water based white paint, 
to a depth 0.5 cm above the surface of the submerged platform.  Surrounding the pool were fixed 
external cues and overhead a concealed video camera connected to a computer that ran the 
behaviour analysis software.   
Mice were acclimatised to swimming on d -7 during two 60 sec swims where the submerged 
platform was made visible (cued) by a black identifier flag (as illustrated in Figure 4-2).   
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4.5.3 The assessment of learning using MWM 
From d -6 to d -2 mice were trained by repeated exposure, to locate a submerged platform in the 
northeast quadrant of the pool.  All mice received three trials each d, start-point was entry into the 
pool and end-point was climbing onto the submerged platform and staying there.  The maximum 
time from start-point to end-point was 60 sec, when the mouse was manually moved onto the 
platform.  Once on the platform the animal remained there for 10 sec before being removed from 
the apparatus.   
Mice entered the pool at one of four positions (north, east, south or west), with three different 
entry points a day, determined semi-randomly.   
Between trials mice were held in a warm air box for at least 15 min, to dry and prevent 
hypothermia.   
Young mice were trained over 5 d.  An analysis of the mean latency to platform was performed 
at the end of each d, using data collected that d, so as to identify when the mice were consistent 
and comparable in their performance within genotype.  In Young APP23 and WT this was after 5 
d (when mean latency to platform edge was 15 sec).  Old APP23 required an additional 2 d 
training to reach a similar level of performance and received 7 d training in total.   
Statin or placebo was administered from the second d of training in all intervention groups.   
4.5.4 The assessment of memory using MWM 
An assessment of acquisition of the task was made on d -1 (termed ‘Before’) and assessments 
of retention were performed on d 3, 7 and 14 (termed ‘After’).   
Both acquisition and retention assessments involved a 60 sec probe with the platform removed.  
Time points of the MWM study are detailed in Table 3-8 and illustrated in Figure 4-3.   
The platform edge and the platform quadrant described throughout the analysis of the data are 
illustrated in Figure 4-4 and Figure 4-5.   
New learning 
Learning a new task in the MWM requires both the ability to learn a new platform position, and 
also to recognise, retain and recall that the old platform position is no longer is relevant.  This is 
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quantified using measures that reflect quadrant preference and swimming direction during a 
single probe, and is a reflection of cognitive flexibility.   
After the d 14 probe, the ability of Young and Old mice to learn a new task was assessed.  The 
hidden platform was moved from northeast to southwest quadrant and, using three 60 sec trials 
per d, mice were taught to locate the platform in its new position.  This ability to acquire the new 
task is an assessment of new learning and occurred over two d training in Young and four d 
training in Old, after which time all mice in the cohort displayed comparable levels of performance 
in the new task.   
New memory 
Memory of the new task was assessed during a single 60 sec probe in a pool without a submerged 
platform.  This was performed the day after comparable performance in the new task was 
achieved.  Three measures used to assess new memory are:   
- Time in old (NE) compared to new (SW) platform quadrants (% time Old vs. New, Delta NE vs. 
SW) 
- Latency to new platform edge 
- Number of new platform crossings 
The ‘new platform quadrant’, described throughout the analysis of new learning data, is illustrated 
in Figure 4-6.   
MWM housekeeping 
Water temperature was kept constant throughout the experiment (27.5 ± 1 oC), as well as external 
visual and acoustic cues.  Mice were placed in the pool facing the wall and were always gently 
lowered into the water.  Animals were observed throughout their swim via a video screen.  One 
APP23 female mouse drowned in the MWM during the conduct of this study.   
During initial learning the submerged platform was in the northeast quadrant.   
During new learning the submerged platform was in the southwest quadrant.   
The pool was cleaned of any floating debris between each mouse, which underwent training and 
assessment trials in the same sequential order within a batch.  Gloves were changed between 
each batch of cages.   
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Analysis of data 
Digital video recordings taken during training and assessments were analysed for mouse position 
in the pool using EthovisionXT software.  The outcome data used in analysis are detailed in Table 
4-5.   
4.6 Results 
4.6.1 The assessment of learning 
All mice learnt the new task, as shown by reduced latency to reach the hidden platform edge with 
repeated exposure to the task.   
Data are illustrated in Figure 4-7, Figure 4-8, and Figure 4-9.   
4.6.2 The assessment of memory  
Memory of the MWM task was assessed using 6 quantifiable analyses:   
4.6.3 Measure 1:  Latency to platform edge 
Young APP23 
When compared to performance on d -1, the latency to platform edge was longer on d 3, 7 and 
14 in all groups.  This difference reached statistical significance only in Control, when p = 0.021 
on d 3 and p = 0.026 on d 7.   
Data are illustrated in Figure 4-10.   
Young WT   
Longer latency to platform edge was seen in both surgery groups on d 3, reaching statistical 
significance in Surgery + Placebo (p = 0.007).  Longer latency persisted in Surgery + Statin group 
on d 7 (p = 0.01), whereas Surgery + Placebo was returned toward d -1 latency.  All groups 
showed similar latency by d 14.   
Longer latency persisted in Surgery + Statin but not in Surgery + Placebo.   
Data are illustrated in Figure 4-11.   
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Old APP23   
Performance of all groups was similar on d -1, with longer latency to platform on d 3, 7 and 14 in 
all groups.  On d 7, Surgery + Statin performed significantly worse than d -1.  Latency peaked on 
d 7 in all groups, the Control and Surgery + Placebo then improved by d 14, but Surgery + Statin 
did not.  Surgery + Statin performed significantly worse on d 7 (p = 0.004) and d 14 (p = 0.014) 
than on d -1.   
Data are illustrated in Figure 4-12.   
4.6.4 Measure 2:  % time in platform quadrant 
Young APP23   
Surgery + Statin group spent less time in the platform quadrant on d 3, 7 and 14 (p = 0.011, 0.017 
and 0.005 respectively) than on d -1.  Control group did the same on d 7 and 14 (p = 0.048 and 
0.003, respectively).  There was no difference in the performance of Surgery + Placebo between 
the different time-points.   
Data are illustrated in Figure 4-13.   
Young WT 
No difference in percentage time in platform quadrant was seen within any time-point or when 
compared to d -1 in in any group of Young WT mice.  No effect of Surgery was detected.   
Data are illustrated in Figure 4-14.   
Old APP23 
The variances within the Old group were larger than with Young mice.  Control group performed 
better on d 3 than d -1 but both Surgery groups performed worse.  This change was statistically 
significant on d 7 in Surgery + Placebo (p = 0.04) and approached significance in Surgery + Statin 
(p = 0.056).  Surgery + Statin then returned to d -1 performance but Surgery + Placebo did not.   
Data are illustrated in Figure 4-15.   
4.6.5 Measure 3:  Mean Platform Score (MPS) 
MPS = mean percentage time in platform quadrant d 3, 7 and 14.   
  
262 
Young APP23 
Mice from all groups spent less time in the platform quadrant After introduction of the modifiable 
risk than Before.  This difference was statistically significant in Surgery + Statin (p = 0.005) and 
Control (p = 0.02).   
Data are illustrated in Figure 4-16.   
Young WT 
No Before and After difference was found, there was no detectable effect of modifiable risk or 
intervention.   
Data are illustrated in Figure 4-17.   
Old APP23 
No statistically significant Before and After difference was observed, but worse performance 
approaching significance was seen in Surgery + Placebo (p = 0.07).   
Data are illustrated in Figure 4-18.   
4.6.6 Measure 4:  Number of platform crossings 
Platform crossings were reduced in all mice after introducing the modifiable risk.   
Young APP23 
In Control this reduction approached statistical significance on d 3 (p = 0.08) and reached 
statistical significance on d 14 (p = 0.021).  Surgery + Placebo and Surgery + Statin showed no 
difference in performance at any time-points in this measure.   
Data are illustrated in Figure 4-19.   
Young WT 
In Surgery + Placebo this difference approached statistical significant on d 7 (p = 0.058) and 
reached statistical significance on d 14 (p = 0.03).  A similar shaped curve is seen with Surgery + 
Statin, but the difference in performance between time-points was not statistically significant.   
Data are illustrated in Figure 4-20.   
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Old APP23 
The reduction in platform crossings after introduction the modifiable risk factor reached statistical 
significance in all groups including Control.   
Data are illustrated in Figure 4-21.   
4.6.7 Measure 5:  Latency to cross the bigger platform edge 
These results describe an analysis performed on probe data using a platform twice the diameter 
of the original platform.  The latency to cross the edge of the bigger platform was smaller than the 
latency to cross the edge of the original platform in all analyses.   
Young APP23 
Surgery + Placebo showed higher latency on d 7 (p = 0.011) compared to d -1.   
Data are illustrated in Figure 4-22.   
Young WT 
Surgery + Statin showed a trend toward higher latency on d 14 (p = 0.055), having shown longer 
latency at each time point than the other groups.   
Data are illustrated in Figure 4-23.   
Old APP23 
Surgery + Placebo showed longer latency on d 14 (p = 0.04).   
Data are illustrated in Figure 4-24.   
4.6.8 Measure 6:  Number of platform crossings bigger platform 
Mice crossed the bigger platform more times during the probe than they did the original platform.   
Young APP23 
Control showed reduced number platform crossings d 14 (p = 0.03), having previously 
consistently been the best performers in this measure.   
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Similar data were seen in the Young WT mice and Old APP23 populations and there were no 
differences detected between groups.   
Data are illustrated in Figure 4-25, Figure 4-26 and Figure 4-27.   
4.6.9 New learning 
The assessment of new learning 
Young WT Control showed significant reduction in latency to new platform between d 15 and 16 
(p = 0.002).  This was not seen in any post-surgical group, or in any Young APP23 group.   
Data are illustrated in Figure 4-28, Figure 4-29 and Figure 4-30.   
4.6.10 The assessment of new memory 
Measure 1:  % time spent in Old vs. New platform quadrant:  Delta NE vs. SW  
Young APP23 
Surgery + Statin achieved a negative delta NE vs. SW value of -15.08 %.  They showed 
preference for New platform quadrant, spending more time in New platform quadrant than Old.  
This difference barely missed statistical significance (p = 0.065).   
Control also showed a negative delta of -17.24 % (p = 0.016).   
However Surgery + Placebo showed a delta = -1.95 %.  They did not show a preference for New 
platform quadrant and spent ca. the same % time in Old and New platform quadrants (p = 0.426).   
This data shows that Young APP23 Surgery + Statin and Control showed evidence of learning 
the new task.  Surgery + Placebo did not.   
Data are illustrated in Figure 4-31 A.   
Young WT 
Surgery + Statin achieved a negative delta NE vs. SW of – 17.39 %, showing preference for New 
vs. Old platform quadrant (p = 0.02).   
However Surgery + Placebo (delta = -2.17 %) and Control (delta = -6.36 %) showed no preference 
for New vs. Old platform quadrant (p = 0.685 and p = 0.191 respectively).   
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Surgery + Statin showed evidence of learning the new task.  Surgery + Placebo and Control did 
not.   
Data are illustrated in Figure 4-31 B.   
Old APP23 
Figure 4-34 shows that Control mice spent more time in the New platform quadrant than the Old 
platform quadrant.  Surgery + Statin spend the same amount of time in both quadrants, and 
Surgery + Placebo spend more time in New platform quadrant than Old.   
4.6.11 Measure 2:  Latency to New platform edge 
Young APP23 
There was no difference between groups in this measure.  There is positive skew in all groups, 
but the skew is more pronounced in Surgery + Placebo and Control than in Surgery + Statin.   
Young WT 
There was no difference between groups in this measure.  Again, a positive skew was seen in all 
groups, but skew and spread of the data was greater in Control and Surgery + Placebo than in 
Surgery + Statin.   
Data are illustrated in Figure 4-32, A and B.   
Old APP23 
The distribution of this data is very strange, and may be due to small n number per group.  
However, it may also reflect different grades of underlying pathology in this group of Old APP23 
mice, which might influence their response to both the modifiable risk and the intervention.   
Data are illustrated in Figure 4-35, in the left hand figure.   
4.6.12 Measure 3:  Number of new platform crossings 
Young APP23 
There was no difference between groups in this measure.   
  
266 
Young WT 
There was no visible suggestion of difference between groups in this measure, but the p value in 
the analysis comparing all 3 groups = 0.049.  This is likely due to the different distribution of data 
within the 3 groups.  Control showed a large range of data, Surgery + Statin no skew, and Surgery 
+ Placebo a positive skew.   
Data are illustrated in Figure 4-33 A and B.   
Old APP23 
Performance in all groups was similar in this measure.   
Data are illustrated in Figure 4-35, in the right hand figure.   
Weight change after introducing the modifiable risk 
Young and Old Control did not lose significant amounts of weight during MWM assessment.  
Statistically significant weight loss was observed in all mice that had Surgery.  There was no 
difference in the amount of weight loss seen in Surgery + Statin and Surgery + Placebo, and body 
weight had not returned to starting weight at the time of cull.  The CI are larger in Old APP23 than 
in Young mice, suggesting more variability in phenotype in older APP23 animals.     
Data are illustrated in Figure 4-36.   
4.6.13 Summary of the MWM behavioural findings 
All mice learnt the MWM task.  Old mice needed more repetitions of the task to achieve the same 
performance as Young mice.   
No statistically different differences were seen between any groups compared within any one-
time point.  The longitudinal analysis of groups across time-points did reveal consistent 
differences.   
Considering latency, Surgery + Placebo and Surgery + Statin displayed deterioration in their 
performance at different time-points.  The effect of surgery appeared to be delayed by Statin in 
Young WT.  In Old APP23, Surgery + Statin performed worst.   
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MPS was effective at detecting performance deficit in APP23.  In Young APP23, Surgery + 
Placebo intervention appeared to preserve performance, but in Old APP23 tended to worsen 
performance, when compared to the other groups.   
Latency to bigger platform detected memory deficit in APP23 Surgery + Placebo that were not 
seen in Surgery + Statin or Control.   
More statistically significant changes in performance were detected in APP23 than in WT in the 
longitudinal analysis of the data.   
Some measures generated data that show improved performance early after introduction of the 
modifiable risk.  Evidence of the natural process of forgetting is seen in the shape of some curves, 
with deteriorating performance over time.   
Some Control were the worst performers of all groups.   
All results are summarised in Table 4-6 and Table 4-7.   
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Figure 4-1: The MWM 
 
The apparatus and environment used for the assessment of learning and memory using the 
Morris mater maze.  Cues are fixed and external to the pool.  Each swim is video recorded to 
enable analysis of the path taken to the hidden platform.   
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Figure 4-2: MWM:  Cued platform 
 
Photograph of the working MWM with cued platform.   
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Figure 4-3: Timeline of the MWM and Y maze study protocol 
 
Schematic illustrating the time course of the MWM and Y maze study.  ‘Before’ Y maze 
assessment occurred before d -8.  ‘After’ Y maze assessment occurred on d 3 and 14 after 
introducing the modifiable risk on d 0.  The assessment of learning using MWM occurred from d 
-6, whilst mice were receiving daily Placebo or Statin.  The assessment of memory was performed 
on d 3, 7 and 14.  Assessment of new learning and of new memory occurred later.   
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Figure 4-4: MWM:  The hidden platform edge 
 
The working MWM with the edge of the cued platform highlighted.   
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Figure 4-5: MWM:  The platform quadrant 
 
The working MWM with the platform quadrant highlighted.   
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Figure 4-6: MWM:  The new platform quadrant 
 
The working MWM with the new platform quadrant highlighted.   
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Figure 4-7: Young APP23 learning:  Latency to platform 
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Line graph illustrating latency to platform in the MWM during the training of Young APP23 mice that took place before the introduction of 
modifiable risk factor (Anaesthesia + Surgery).  Control group received handling only.  Placebo group received water by gavage (0.01 ml / g) 
from d -5.  Statin group received atorvastatin (10 mg / kg) from d -5.   
The x-axis represents d of training and the y-axis latency to the platform in sec.   
All mice displayed learning, as reflected by reduced latency to find the hidden platform with repeated exposure to the task.   
All data presented as mean (95 % CI).  p value derived by linear mixed model.  n numbers are Control = 8, Placebo = 10, Statin = 10.   
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Figure 4-8: Young WT learning:  Latency to platform 
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Line graph illustrating latency to platform in the MWM during the training of Young WT mice that took place before the introduction of modifiable 
risk factor.  Intervention group and figure layout is the same as for Young APP23.   
All mice displayed learning, as reflected by reduced latency to find the hidden platform with repeated exposure to the task.   
All data presented as mean (95 % CI).  p value derived by linear mixed model.  n numbers are Control = 13, Placebo = 14, Statin = 13.   
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Figure 4-9: Old APP23 learning:  Latency to platform 
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Line graph illustrating latency to platform in the MWM the training of Old APP23 mice that took place before the introduction of modifiable risk 
factor.  Intervention group and figure layout is the same as for Young APP23.   
All mice displayed learning, as reflected by reduced latency to find the hidden platform with repeated exposure to the task.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Placebo = 8 and Statin = 8.   
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Figure 4-10: Young APP23 remembering measure 1:  Latency to platform edge 
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Line graph illustrating latency to platform in Young APP23 mice before (d -1) and on d 3, 7 and 14 after introduction of the modifiable risk factor 
with Placebo or Statin.  The x-axis represents d and the y-axis the latency to platform edge in sec.   
Latency to platform was longer in all groups after introduction of the modifiable risk.  This difference reached statistical significance in the Control 
group on d 3 (p = 0.021) and d 7 (p = 0.026).  There was no intervention dependent difference in latency to platform within any time point.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 4-11: Young WT remembering measure 1:  Latency to platform edge 
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Line graph illustrating latency to platform in Young WT mice before (d -1) and on d 3, 7 and 14 after introduction of the modifiable risk factor with 
Placebo or Statin.  The x-axis represents d and the y-axis the latency to platform edge in sec.   
When compared to latency to platform at d -1, difference in latency reached statistical significance in the Surgery + Placebo group on d 3 (p = 
0.007) and in Surgery + Statin group on d 7 (p = 0.01).   
There was no intervention dependent difference in latency to platform within any time point.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 4-12: Old APP23 remembering measure 1:  Latency to platform edge 
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Line graph illustrating latency to platform in Old APP23 mice before (d -1) and on d 3, 7 and 14 after introduction of the modifiable risk factor 
with Placebo or Statin.  The x-axis represents d and the y-axis the latency to platform in sec.   
Latency to platform was longer in both Surgery groups after introduction of the modifiable risk.  When compared to latency to platform at d -1, 
difference in latency reached statistical significance in the Surgery + Statin group on d 7 (p = 0.004) with non-statistically significant trend toward 
longer latency in both Control and Surgery + Placebo.  On d 14 latency was reduced to near baseline in Control and Placebo, but remained 
significantly longer than d -1 in Surgery + Statin (p = 0.014).   
There was no intervention dependent difference in latency to platform within any time point.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 4-13: Young APP23 remembering measure 2:  % time in platform quadrant 
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Line graph illustrating % time spent in the platform quadrant during a 60 second probe in Young APP23 mice before (d -1) and on d 3, 7 and 14 
after introduction of the modifiable risk factor with Placebo or Statin.  The x-axis represents d and the y-axis the % time in platform quadrant in 
%.   
Surgery + Statin group spent less time in platform quadrant on d 3 (p = 0.011), 7 (p = 0.017) and 14 (p = 0.005) than on d -1.  Control did the 
same on d 7 (p = 0.048) and 14 (p = 0.005).   
There was no intervention dependent difference in latency to platform within any time point.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 4-14: Young WT remembering measure 2:  % time in platform quadrant 
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Line graph illustrating % time spent in the platform quadrant during a 60 second probe in Young WT mice before (d -1) and on d 3, 7 and 14 
after introduction of the modifiable risk factor with Placebo or Statin.  The x-axis represents d and the y-axis the % time in platform quadrant in 
%.   
No difference was seen within time-points or when compared to performance on d -1.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 4-15: Old APP23 remembering measure 2:  % time in platform quadrant 
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Line graph illustrating % time spent in the platform quadrant during a 60 second probe in Old APP23 mice before (d -1) and on d 3, 7 and 14 
after introduction of the modifiable risk factor with Placebo or Statin.  The x-axis represents d and the y-axis the % time in platform quadrant in 
%.   
Maximal difference to performance in this measure on d -1 was seen on d 7 in both Surgery + Placebo (p = 0.041) and Surgery + Statin groups 
(p = 0.056).  There was no intervention dependent difference in latency to platform within any time point.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 4-16: Young APP23 remembering measure 3:  % time NE quadrant and Mean Platform Score 
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Line graph illustrating comparison of % time in platform quadrant on d -1 (Before) with mean platform score (= mean % time in platform quadrant 
d 3, 7 and 14) (After) in Young APP23 mice.  The x-axis represents the Before or After introduction of the modifiable risk and the y-axis the % 
time in platform quadrant in %.   
Less time was spent in the platform quadrant After than was spend Before in Surgery + Statin group (p = 0.005) and Control (p = 0.02) groups.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 4-17: Young WT remembering measure 3:  % time NE quadrant and Mean Platform Score 
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Line graph illustrating comparison of % time in platform quadrant on d -1 (Before) with mean platform score (= mean % time in platform quadrant 
d 3, 7 and 14) (After) in Young WT mice.  The x-axis represents the Before or After introduction of the modifiable risk and the y-axis the % time 
in platform quadrant in %.   
No differences were observed between groups in this analysis.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 4-18: Old APP23 remembering measure 3:  % time NE quadrant and Mean Platform Score 
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Line graph illustrating comparison of % time in platform quadrant on d -1 (Before) with mean platform score (= mean % time in platform quadrant 
d 3, 7 and 14) (After) in Old APP23 mice.  The x-axis represents the Before or After introduction of the modifiable risk and the y-axis the % time 
in platform quadrant in %.   
A difference approaching statistical significance is seen in the Surgery + Placebo group (p = 0.07).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 4-19: Young APP23 remembering measure 4:  Number of platform crossings  
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Line graph illustrating number of platform crossings on d -1, 3, 7 and 14 during a 60 second probe in Young APP23 mice.  The x-axis represents 
d and the y-axis the number of platform crossings.   
On d 14, number platform crossings by Control was reduced (p = 0.021).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 4-20: Young WT remembering measure 4:  Number of platform crossings 
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Line graph illustrating number of platform crossings on d -1, 3, 7 and 14 during a 60 second probe in Young WT mice.  The x-axis represents d 
and the y-axis the number of platform crossings.   
On d 14 Surgery + Placebo number platform crossings was reduced (p = 0.03).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 4-21: Old APP23 remembering measure 4:  Number of platform crossings 
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Line graph illustrating number of platform crossings on d -1, 3, 7 and 14 during a 60 second probe in Old WT mice.  The x-axis represents d and 
the y-axis the number of platform crossings.   
All groups crossed the platform less times during probes on d 3, 7 and 14 than on d -1.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 4-22: Young APP23 remembering measure 5:  Bigger platform, latency to platform edge 
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Line graph illustrating latency to the platform edge of a bigger platform in Young APP23 mice before (d -1) and on d 3, 7 and 14 after introduction 
of the modifiable risk factor with Placebo or Statin.  The x-axis represents d and the y-axis the latency to platform in sec.   
Only Surgery + Placebo showed longer latency, on d 7.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 4-23: Young WT remembering measure 5:  Bigger platform, latency to platform edge 
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Line graph illustrating latency to platform edge of a bigger platform in Young WT mice before (d -1) and on d 3, 7 and 14 after introduction of the 
modifiable risk factor with Placebo or Statin.  The x-axis represents the d and the y-axis the latency to platform in sec.   
No differences reaching statistical significance were observed between groups in this analysis.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 4-24: Old APP23 remembering measure 5:  Bigger platform, latency to platform edge 
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Line graph illustrating latency to platform edge of a bigger platform in Old APP23 mice before (d -1) and on d 3, 7 and 14 after introduction of 
the modifiable risk factor with Placebo or Statin.  The x-axis represents the d and the y-axis the latency to platform in sec.   
Only Surgery + Placebo showed longer latency, on d 14.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 4-25: Young APP23 remembering measure 6:  Number of bigger platform crossings 
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Line graph illustrating number of platform crossings of a bigger platform on d -1, 3, 7 and 14 during a 60 second probe in Young APP23 mice.  
The x-axis represents the d and the y-axis the number of platform crossings.   
Control showed longer number of crossings, on d 14 (p = 0.031).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 4-26: Young WT remembering measure 6:  Number of bigger platform crossings 
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Line graph illustrating number of platform crossings of a bigger platform on d -1, 3, 7 and 14 during a 60 second probe in Young WT mice.  The 
x-axis represents d and the y-axis the number of platform crossings.   
No differences were observed between groups in this analysis.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 4-27: Old APP23 remembering measure 6:  Number of bigger platform crossings  
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Line graph illustrating number of platform crossings of a bigger platform on d -1, 3, 7 and 14 during a 60 second probe in Old APP23 mice.  The 
x-axis represents d and the y-axis the number of platform crossings.   
No differences were observed between groups in this analysis.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 4-28: New learning in Young APP23:  Latency to new platform  
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Line graph illustrating New learning Young APP23 mice that took place after the introduction of modifiable risk factor.  Control received handling 
only Surgery + Placebo group received water by gavage (0.01 ml / g) from d -5.  Surgery + Statin group received atorvastatin (10 mg / kg) from 
d -5.   
The x-axis represents d of training and the y-axis latency to the platform in sec.   
All groups showed a similar performance on both training d.   
All data presented as mean (95 % CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 9, Surgery + 
Statin = 10.   
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Figure 4-29: New learning in Young WT:  Latency to new platform  
 
  
3
2
1
 
Line graph illustrating New learning Young WT mice that took place after the introduction of modifiable risk factor.  Group intervention and figure 
layout is the same as for Young APP23 New learning.   
Latency in Control was significantly different on the second training d than the first (p = 0.002).  This difference was not seen in either post-
surgery group.   
All data presented as mean (95 % CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 13, Surgery + 
Statin = 9.   
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Figure 4-30: New learning in Old APP23:  Latency to new platform  
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Line graph illustrating New learning Old APP23 mice that took place after the introduction of modifiable risk factor.  Old mice received four d 
training in the new task.  Group intervention and figure layout is the same as for Young APP23 New learning.   
All groups showed a similar performance on all training d.   
All data presented as mean (95 % CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 5, Surgery + 
Statin = 6.   
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Figure 4-31: New learning in Young APP23 and WT measure 1:  % time in Old vs. New platform quadrant 
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Box and whisker plots illustrating % time in Old vs. New platform quadrant in Young APP23 and WT during a single probe after 2 d learning the 
new task.  The x-axis represents the group and the y-axis the mean difference in time spent in the Old vs. New platform (delta Old vs. New).  
APP23 are illustrated in the left hand figure, WT in the figure on the right.   
A:  Young APP23 
This figure illustrates that Surgery + Statin showed preference for New platform quadrant, spending more time in New platform quadrant than 
Old platform quadrant.  This difference barely missed statistical significance (p = 0.065).   
Control also showed preference for New vs. Old platform quadrant (p = 0.016).   
However Surgery + Placebo did not show a preference for New platform quadrant and spent ca. the same % time in Old and New (p = 0.426).   
This shows that Young APP23 Surgery + Statin and Control showed evidence of learning the new task.  Surgery + Placebo did not.   
B:  Young WT 
This figure illustrates that Surgery + Statin showed preference for New vs. Old platform quadrant, spending more time in New platform quadrant 
than Old platform quadrant (p = 0.02).   
However Surgery + Placebo and Control showed no preference for New vs. Old platform quadrant (p = 0.685 and p = 0.191).   
Surgery + Statin showed evidence of learning the new task.  Surgery + Placebo and Control did not.   
Box and whiskers illustrate:  bar = median, diamond = mean, box = lower and upper quartiles, whiskers min and max values.  p value derived 
using Wilcoxon signed rank test.  Summary statistics are displayed in the figure.  n numbers are APP23:  Control = 8, Surgery + Placebo = 9, 
Surgery + Statin = 10, WT Control = 13, Surgery + Placebo = 13, Surgery + Statin = 9.   
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Figure 4-32: New learning in Young APP23 and WT measure 2:  Latency to New platform edge 
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Box and whisker plots illustrating Latency to New platform edge in Young APP23 and WT during a single probe after 2 d learning the new task.  
The x-axis represents the group and the y-axis the latency to new platform edge in sec.  APP23 are illustrated in the left hand figure, WT in the 
figure on the right.   
A:  Young APP23 
This figure illustrates that there was no difference between groups in this measure.  There is positive skew in all groups, but the skew is more 
pronounced in Surgery + Placebo and Control than in Surgery + Statin.   
B:  Young WT 
This figure illustrates that there was no difference between groups in this measure.  Again, there is positive skew in all groups, but skew and 
spread of the data is greater in Control and Surgery + Placebo than in Surgery + Statin.   
Box and whiskers illustrate:  bar = median, diamond = mean, box = lower and upper quartiles, whiskers min and max values.  A:  p = 0.157; B:  
p = 0.167.  p value derived using Kruskal-Wallis test.  Summary statistics are displayed in the figure.  n numbers are APP23:  Control = 8, 
Placebo = 9, Statin = 10, WT Control = 13, Surgery + Placebo = 13, Surgery + Statin = 9.   
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Figure 4-33: New learning in Young APP23 and WT measure 3:  Number of New platform crossings 
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Box and whisker plots illustrating number of platform crossings in Young APP23 and WT during a single probe after 2 d learning the new task.  
The x-axis represents the group and the y-axis the number of New platform crossings.  APP23 are illustrated in the left hand figure, WT in the 
figure on the right.   
A:  Young APP23 
This figure illustrates that there was no difference between groups in this measure.   
B:  Young WT:  There was no visible suggestion of difference between groups in this measure, but the p value in the analysis comparing all 3 
groups = 0.049.   
Box and whiskers illustrate:  bar = median, diamond = mean, box = lower and upper quartiles, whiskers min and max values.  A:  p = 0.270; B:  
p = 0.049.  p value derived using Kruskal-Wallis test.  Summary statistics are displayed in the figure.  n numbers are APP23:  Control = 8, 
Placebo = 9, Statin = 10, WT Control = 13, Surgery + Placebo = 13, Surgery + Statin = 9.   
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Figure 4-34: New learning in Old APP23 measure 1:  % time in Old vs. New platform quadrants 
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Box and whisker plots illustrating % time in Old vs. New platform quadrant in Old APP23 during a single probe after 4 d learning the new task.  
The x-axis represents the group and the y-axis the mean difference in time spent in the Old vs. New platform (delta Old vs. New), and are to 
different scale.  The Old platform quadrant is illustrated in the left hand figure and the New platform quadrant on the right.   
This figure shows that Control spent more time in the New than Old platform quadrant.  Surgery + Statin spend the same amount of time in both 
quadrants, and Surgery + Placebo spend more time in New platform quadrant than Old.   
Box and whiskers illustrate:  bar = mean, diamond = median, box = lower and upper quartiles, whiskers min and max values.  p value data was 
not available at the time of submission.  n numbers are Control = 4, Surgery + Placebo = 5, Surgery + Statin = 6.   
  
  
3
3
2
 
Figure 4-35: New learning in Old APP23 measures 2 and 3 
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Box and whisker plots illustrating Latency to New platform data in Old APP23 during a single probe after 4 d learning the new task.  Latency to 
new platform edge is shown on the right and Number of New platform crossings on the left.  The x-axis represents group in both figures.  On the 
left the y-axis represents the latency to new platform edge in sec and on the right the number of new platform crossings.   
Latency to new platform edge:  The distribution of the data is anomalous.   
Number if New platform crossings:  No difference between groups 
Box and whiskers illustrate:  bar = mean, diamond = median, box = lower and upper quartiles, whiskers min and max values.  p value data was 
not available at the time of submission.  n numbers are Control = 4, Surgery + Placebo = 5, Surgery + Statin = 6.   
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Figure 4-36: Weight change after introducing the modifiable risk  
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This plate of 3 figures illustrates weight change as a % of weight at the start of the experiment in 
mice during the period of starting the daily gavage (Start Intervention), through MWM training, 
introduction of the modifiable risk (MR) and post-surgery d 3, 7 and 14 to cull.  The x-axis 
represents the d of the protocol and the y-axis the change in mouse body weight as a % of weight 
at the start of the experiment.   
A:   Line graph illustrating data for Young APP23.  Control did not lose weight during the 
experiment.  Surgery caused statistically significant amounts of weight loss, but no 
difference was seen between Placebo and Statin.  Pattern of weight recovery was similar in 
both Statin and Placebo but body weight had not returned to starting weight at the time of 
cull in either group (24 – 32 d after Surgery).   
B:   Line graph illustrating data for Young WT.  WT lost weight between the start of the 
experiment and the start of daily gavage but weight stayed the same later.  Again, Surgery 
caused significant weight loss and Statin or Placebo did no differ in their pattern of weight 
recovery, which remained below starting weight.   
C:   Line graph illustrating data for Old APP23.  The pattern of results is similar to Young APP23 
but more variance is seen in Control.   
All data are presented as mean (95% CI).  A:  Interaction:  F10 131= 5.15, p = < 0.0001; Group:     
F2 131= 27.95, p = < 0.0001; d F5 131= 14.66, p = < 0.0001.  n numbers are Control = 8, Surgery 
+ Placebo = 10, Surgery + Statin = 10.  B:  Interaction F10 200= 6.85, p < 0.0001; Group F2 200= 
79.48, p = < 0.0001; d F5 200= 21.0, p = < 0.0001.  n numbers are Control = 13, Surgery + 
Placebo = 14, Surgery + Statin = 13.  C:  Interaction F10 85= 2.93, p = 0.0033; Group F2 85= 21.70, 
p = < 0.0001; d F 5 85 = 13.04, p = < 0.0001.  n numbers are Control = 4, Surgery + Placebo = 
8, Surgery + Statin = 8.  p values derived from two-way ANOVA.   
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Table 4-1:  Groups in the MWM and Y maze study 
Group 
 
Drug intervention and modifiable risk  
Control 
 
 
5 d placebo by oral gavage with daily handling  
Surgery + Placebo 
 
5 d placebo by oral gavage, general anaesthesia 
and unilateral nephrectomy surgery on d 0, + daily 
handling 
Surgery + Statin 5 d atorvastatin by oral gavage, general 
anaesthesia and unilateral nephrectomy surgery 
on d 0, + daily handling 
Groups in the water and Y maze studies.  Littermates were randomly allocated to groups at the 
start.   
 
Table 4-2:  Characteristics of the MWM and Y maze study population:  Young APP23 
  Control Placebo Statin ANOVA p = 
n = 28  8 10 10  
Sex 
 
Male 
Female 
5 
3 
5 
5 
5 
5 
 
Age 
 
Male  
Female 
250 (200 –
300) 
257 (92 – 422) 
234 (152 –
315) 
257 (185 –
328) 
313 (293 –
332) 
292 (269 –
315) 
0.04, F2 12= 4.2 
0.47, F2 10= 
0.81 
Weight (start 
of training) 
Male  
Female 
32 (28 – 36) 
23 (21 – 25) 
27 (21 – 32) 
24 (19 – 28) 
29 (26 – 32) 
24 (20 – 27) 
0.09, F2 12= 2.9 
0.95, F2 10= 
0.05 
Population statistics of Young APP23 mice that underwent the assessment of learning and 
memory using MWM and Y maze.  Age in d, weight in g, quoted as mean (95 % CI).  p value, F 
and df calculated by one-way ANOVA.   
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Table 4-3:  Characteristics of the MWM and Y maze study population:  Young WT 
  Control Placebo Statin ANOVA p =  
n = 40  13 14 13  
Sex 
 
Male 
Female 
6 
7 
7 
7 
7 
6 
 
Age  
 
Male  
 
Female 
222 (178 –
266) 
207 (182 –
233) 
218 (197 –
239) 
200 (179 –
221) 
273 (242 –
304) 
279 (263 –
294) 
0.01, F2 17= 5.8 
 
< 0.0001, F2 
17= 23.6 
Weight (start 
of training) 
Male  
 
Female 
35 (29 – 41) 
 
29 (24 – 34) 
36 (34 – 38) 
 
29 (25 – 34) 
37 (32 – 41) 
 
33 (31 – 35) 
0.069, F2 17= 
0.38 
0.18, F2 17= 
1.88 
Population statistics of Young WT mice that underwent the assessment of learning and memory 
using MWM and Y maze.  Age in d, weight in g, quoted as mean (95 % CI).  p value, F and df 
calculated by one-way ANOVA.   
 
Table 4-4:  Characteristics of the MWM and Y maze study population:  Old APP23 
  Control Placebo Statin 
n = 21  4 8 8 
Sex 
 
Male 
Female 
2 
2 
4 
4 
3 
6 
Age  
 
Male  
Female 
442 
434 
442 (333 – 550) 
436 (299 – 572) 
500 (499 – 502) 
416 (375 – 457) 
Weight (start of 
training) 
Male  
Female 
39  
27 
32 (27 – 38) 
26 (21 – 30) 
35 (28 – 41) 
26 (23 – 29) 
Population statistics of Young APP23, Young WT and Old APP23 mice that underwent the 
assessment of learning and memory using MWM and Y maze.  Age in d, weight in g, quoted as 
mean (95 % CI).  ANOVA p values not quoted due to small numbers in Control.   
Comparing Placebo to Statin:  Male weight t = 0.88, df = 5, p = 0.42; female weight t = 0.1, df = 
8, p = 0.92; Male age t = 1.46, df = 5, p = 0.2; Female age t = 0.49, df = 8, p = 0.6.  p value, F and 
df calculated by two-tailed t test.   
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Table 4-5:  Quantifiable measures in MWM work 
Indices of learning 
 
Indices of memory Indices of new learning 
Latency to platform  Latency to platform edge Latency to platform 
 % time in NE (platform) 
quadrant  
% time in new vs. Old platform 
quadrant 
 Mean platform score237  
 
Number platform crossings 
 Number platform crossings  
Quantifiable indices of learning, memory and new learning used in the analysis of MWM behavior 
data collected during the study.  Mean platform score = mean latency to platform edge achieved 
during assessments on d 3, 7 and 14.  Latency in sec, % time in %.   
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Table 4-6:  MWM results summary table 
 Young APP23 Young WT Old APP23 
 Control Surgery 
+ 
Placebo 
Surgery 
+ Statin 
Control Surgery 
+ 
Placebo 
Surgery 
+ Statin 
Control Surgery 
+ 
Placebo 
Surgery 
+ Statin 
Learning  all groups  all groups  all groups 
 
Latency  
 
− − −  3  3 + 7 − Trend  
 7 
 
7 + 14 
 Longer in Control  Longer latency persisted in 
Surgery + Statin 
Longer latency persisted in 
Surgery + Statin 
% quad  
7, 14 
−  
3, 7, 14 
− − − −  
7 
 
7 
MPS  −  − − − − Trend 
 
− 
Number 
crossing 
 − − − − −    
Big plat 
latency 
−  − − − Trend  
 14 
−  14 − 
Big plat 
cross 
 − Trend  − − − − − − 
Summary table of the MWM results.  Number is d post introduction modifiable risk.  - means no 
difference.   
 
Table 4-7:  MWM results summary table:  New learning 
 Young APP23 Young WT Old APP23 
 Control Surgery 
+  
Statin 
Surgery 
+ 
Placebo 
Control Surgery 
+  
Statin 
Surgery 
+ 
Placebo 
Control Surgery 
+  
Statin 
Surgery 
+ 
Placebo 
New 
learning:   
Latency 
− 
 
 − − − 
 
 No difference between 
groups 
Significant reduction in 
latency seen in Control 
No difference between groups 
Delta Old 
vs. New 
= - 
17.24 
= -
15.08 
=  -1.95 = -6.36 = - 
17.39 
= -2.18 Negative − 
 
Negative 
Latency Skew Less 
Skew 
Skew Skew Less 
skew 
Skew − 
 
− 
 
− 
 
Number 
cross 
No difference between 
groups 
Difference between groups No difference between groups 
Summary table of new learning in the MWM.  - means no difference.   
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Chapter 5 Y Maze study 
5.1 Introduction 
The Y maze238 is a rudimentary assessment of spatial working memory,239,240 which describes a 
dynamic, highly active memory system that transiently holds information so that it can be used to 
guide immediate behaviour, but may then be rapidly forgotten.  The assessment made is of 
memory functional only within the task, and not between tasks,241 and involves active 
manipulation of recent acquired information by the subject.  Several brain regions and 
neurotransmitter systems play a role in holding this transitory information, including the 
hippocampus242 and prefrontal cortex243 in rodents.  In the Y maze the task is an assessment of 
alternation, utilising instinctive behaviour not to re-explored immediately territory that was recently 
explored.  Working memory is actively using information of recent exploration to guide future 
exploration.   
5.2 Aims of the Y maze study  
The Y maze was used to answer the following questions:   
1: Working Memory:  Does the modifiable risk factor have an impact on working memory in 
the APP23 and WT mice that are allowed to freely explore the Y maze, and does 
perioperative atorvastatin have an effect on this?   
2: Exploratory drive:  Does genotype and the modifiable risk factor have an impact on 
motivation and exploratory drive displayed within the Y maze task, and is it influenced by 
atorvastatin?   
3: Anxiety:  Does genotype and the modifiable risk factor have an effect on the anxiety 
behaviours displayed by mice in the Y maze, and is it influenced by atorvastatin?   
5.3 The Y maze study protocol timeline 
A schematic of the Y maze study time line and how it interacted with the MWM study is illustrated 
in Figure 4-3.   
5.4 The population studied using Y maze 
The study population and logistics are the same as described in 4.4.   
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5.5 Materials and Methods 
5.5.1 Data collected in the Y maze study 
Exploration of the Y maze during the 7 min trial was observed via video link and the following data 
was recorded:   
- The sequence of arms explored 
- The time taken to initiate exploration 
- The number of faecal pellets and urinations 
Mice were allowed to freely explore the Y maze for 7 minutes on 3 occasions:   
1: Before:  Between 7 and 24 d before starting intervention with daily statin or placebo by oral 
gavage, and introduction of the modifiable risk factor, anaesthesia with surgery.   
2: Day 3:  3 d after introduction of the modifiable risk factor with or without statin or placebo.   
3: Day 14:  14 d after introduction of the modifiable risk factor with or without statin or placebo.   
Trial time-points are detailed in Table 3-8.   
Repeated exposure to the Y maze was shown previously not to affect future performance in the 
task in C57B/6.244   
5.5.2 The Y maze apparatus 
A white coloured, featureless acrylic Y maze was custom made for the laboratory, with 3 open 
arms of 35 cm length (illustrated in Figure 5-1).  Placed on a platform positioned within the empty 
MWM tank and surrounded by a featureless white environment, exploration of the Y maze was 
relayed from the camera above to a monitor, where it was documented in real time.  The Y maze 
data collection sheet is provided in the appendix.   
Definitions 
Entry into an arm was defined as all 4 paws at least 4 cm along the arm from the centre of the 
maze.  Exit from the arm was defined as all 4 paws within the 4 cm of the arm nearest the centre.   
The following indices were used to describe the raw data for behavioural analysis:   
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Spontaneous Alternation Performance (SAP) 
Exploration of arms sequentially, from A to B to C to A….  This is SAP, an index of normal 
instinctive search pattern moving spontaneously from arm A to arm B to arm C….   
SAP = No. sequential alternations / (No. of total arm entries) - 2) x 100 
Alternate Arm Return performance (AAR) 
This is an index of abnormal search pattern, moving spontaneously from arm A to arm B but then 
returning to arm A….   
Same Arm Return performance (SAR)  
This is an index of abnormal search pattern, exiting arm A but then returning to enter arm A….   
How the data was analysed 
The sequence of arm entry data was analysed as ‘triplet events’.  A ‘triplet event’ was defined as 
a three consecutive arm entries.  The first triplet event started with the first arm entry, the second 
triplet event with the second arm entry etc.  The entire sequence of arm entries that described the 
exploration of the maze during the trial was translated into triplet events, each triplet event being 
classified as one of the indices SAP, AAR or SAR.  The total number of triplet events = 100 %.   
As a single SAR was represented in two consecutive triplet events it would be double represented 
in this final percentage analysis.  To compensate for this double representation a correction factor 
was introduced where the sum of SAR triplets was halved before being used to calculate the 
percentage triplet events that were SAP, AAR and SAR.  Following this correction:   
 % SAP + % AAR + % SAR = 100 % of all triplet events, and this percentage value of SAP, AAR 
and SAR was used to describe performance in this analysis.   
Also examined were:   
- Indices of exploratory drive and motivation:  Latency to exit the arm of entry and total number of 
arm entries.   
- Indices of anxiety:  Total number of faecal pellets and total number urination found within the 
maze at the end of the trial.   
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Y maze housekeeping 
Before use, the Y maze was set up in a standard orientation and levelled using a spirit level.  The 
tank beneath the maze was empty of water.  White plastic sheets were suspended around the 
maze to conceal external cues, making the environment consistent and featureless.  Each mouse 
was placed in the maze facing the end wall of arm B.  If the mouse climbed out of the maze during 
the trial it was immediately returned to the maze at its point of exit.  The maze was cleaned and 
allowed to air dry between each trial.   
Analysis of data in the Y maze study 
Young APP23, Young WT and Old APP23 data were analysed separately to be consistent with 
the analysis used in TFC.   
5.6 Molecular analysis of brain tissue by immunochemistry 
All samples used for immunochemistry analysis were from mice between 130 – 160 d of age.  
The number of mice per group, the brain regions of interest and the number of brain slices 
analysed are described here for each POI.   
5.6.1 Materials and methods 
Synaptophysin 
The staining described below was performed on 30 µm frozen section brain tissue slices from 
female mice that had undergone the assessment of learning and memory using the MWM and Y 
maze.   
Immunochemistry and DAB staining was performed (as described in 2.10) on the brain tissue of 
Old APP23.  Brains from two groups were analysed at d 30 after introducing the modifiable risk:   
-  Control 
-  Surgery + Placebo 
These groups were chosen as they were considered most likely to show a difference in 
synaptophysin intensity in view of the nil effect seen at d 3 and 14 for the same POI following 
TFC.   
All specimens used for immunochemistry analysis were between 371 – 500 d of age.  3 – 4 mice 
were used per group (detailed in Table 5-2), with images analysed of 3 brain slices per mouse.  
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Two discreet hippocampal areas of interest were manually outlined on the TIFF image using the 
ImageJ selection tool and quantified for MPI:   
1:  CA-1 
2:  DG 
5.7 Results   
5.7.1 The assessment of working memory 
The data do not reveal any differences between any groups at any one time-point in any genotype.  
However longitudinal analysis did show differences between time-points within group.   
5.7.2 Measure 1:  SAP    
Young APP23  
Repeated exposures to the Y maze increased SAP in Control at d 14 (p = 0.004).  This increase 
in SAP was not seen in either Young APP23 Surgery + Statin or Surgery + Placebo.   
Data are illustrated in Figure 5-2.   
Young WT 
Repeated exposures to the Y maze had no effect on SAP performance in Young WT.  SAP 
percentage showed a trend toward increase on d 14 in the Surgery + Placebo group (p = 0.056) 
but not in Surgery + Statin (p = 0.2).   
Data are illustrated in Figure 5-3.   
Old APP23   
No differences were found in this analysis of Old APP23.   
Data are illustrated in Figure 5-4.   
5.7.3 Measure 2:  AAR performance   
Young APP23, Young WT and Old APP23 
The large variances within each data point mean there was no statistical significance found in any 
analysis using AAR as a measure of working memory.   
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Data are illustrated in Figure 5-5, Figure 5-6 and Figure 5-7.   
5.7.4 Measure 3:  SAR performance 
Young APP23 
Repeated exposure to the Y maze produced a statistically significant reduction in SAR 
performance in Control (d 3 p = 0.025 and d 14 p = 0.016.  This correlates with the increase in 
SAP seen in this population of Young APP23).  Introduction of the modifiable risk factor with statin 
or placebo had no effect on SAR performance in Young APP23.   
Data are illustrated in Figure 5-8.   
Young WT 
A statistically significant reduction in SAR performance was seen in Surgery + Statin on both d 3 
(p = 0.019) and d 14 (p = 0.019), when compared to performance before introduction of the 
modifiable risk.  This reduction was not seen in Control or Surgery + Placebo.   
Data are illustrated in Figure 5-9.   
Old APP23 
No difference between groups was seen in this analysis of Old APP23 SAR performance in the 
Y maze.   
Data are illustrated in Figure 5-10.   
5.8 Measuring exploratory drive 
5.8.1 Measure 1:  Latency to exit the arm of entry 
Young APP23 
Although a much longer latency to exit the arm of entry was seen in Surgery + Statin, this did not 
achieve statistical significance when analysed longitudinally using a linear mixed method (p = 
0.13 and 0.16 on d 3 and 14 respectively).   
Data are illustrated in Figure 5-11.   
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Young WT 
Graphically, Surgery + Statin show longer latency.  However the analysis does not reveal 
statistical significance between different time-points for any group.   
Data are illustrated in Figure 5-12.   
Old APP23  
In Old APP23 an opposite effect was observed, with reduced latency to exit the arm of entry 
observed in all groups with repeated exposure to the Y maze.  Compared to performance before 
introduction of the modifiable risk, on d 14 the difference achieved statistical significance in 
Surgery + Placebo (p = 0.006) and Surgery + Statin (p = 0.01) but not in the Control.   
Data are illustrated in Figure 5-13.   
5.8.2 Measure 2:  Total number arm entries 
Young APP23 
A trend toward increase in total number arm entries was seen in Control (p = 0.11) and Surgery 
+ Placebo (p = 0.12), but no such trend in Surgery + Statin.   
Data are illustrated in Figure 5-14.   
Young WT 
In Young WT, a statistically significant increase in total number arm entries was seen in Control 
(p = 0.0003) on d 3.  However, in Surgery + Statin, a decrease was seen on both d 3 (p = 0.0356) 
and d 14 (p = 0.0306) as compared to Before.  This effect was not observed in the Surgery + 
Placebo group.   
Data are illustrated in Figure 5-15.   
Old APP23 
No difference between groups was seen in this analysis of Old APP23.   
Data are illustrated in Figure 5-16.   
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5.8.3 Measure Anxiety:  Number faecal pellets 
Young APP23 
Surgery + Placebo showed statistically significant reduction in number of faecal pellets on both d 
3 (p = <0.001) and d 14 (p = 0.002).  No difference was seen in other groups.   
Data are illustrated in Figure 5-17.   
Young WT and Old APP23 
No difference between groups was seen in this analysis in both Young WT and Old APP23.   
Data are illustrated in Figure 5-18 and Figure 5-19.   
There were an inadequate number of urinations observed to perform valid comparison.   
5.8.4 Summary of Y maze behavioural findings 
Working memory and exploratory drive were affected by both repeated exposure to the Y maze 
and by the introduction of the modifiable risk factor with statin or placebo.  There were wide 
variances in the data making interpretation difficult.   
Young mice showed more changes in Y maze behaviour than Old mice.   
Instinctive SAP exploration of the maze was enhanced in Young APP23 Control by repeated 
exposure to the maze.  This occurred along with a corresponding reduction in abnormal 
exploration (SAR performance).   
In Young WT, repeat exposure to the task did not improve SAP performance in Control, as has 
been previously reported.   
Latency to exit the arm of entry was a very interesting measure.  Statin + Surgery showed longer 
latency in both Young APP23 and WT.   
In Young WT Control, motivation was increased by repeat exposure to the maze, as reflected in 
total number arm entries.  However, Surgery + Statin showed reduced motivation, as reflected in 
a strong trend toward increased latency to exit the arm of entry, and reduced total number of arm 
entries, in both Young APP23 and WT.   
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This was contrary to the finding suggesting increased motivation in Old APP23 Surgery + Statin, 
with reduced latency to exit arm of entry.   
AAR did not reveal any differences in any group investigated.   
Exceptional performance Before contributed to the findings of significant differences, such as in 
Young APP23 and WT SAR.   
All finding are summarized in Table 5-1.   
5.9 Results:  Molecular analysis of brain tissue by immunochemistry 
5.9.1 Immunochemistry for synaptophysin 
Summary descriptions of groups, age and sex data for mouse brain analysed for synaptophysin 
after the maze study are presented in Table 5-2.   
The MPI of synaptophysin in APP23 Control and APP23 Surgery + Placebo was not different in 
either the CA-1 or DG at d 30 after introduction of the modifiable risk.   
In view of this, no further groups were analysed.   
Immunochemistry data are illustrated in Figure 5-20 with results for the MWM and Y maze study 
immunochemistry work summarised in Table 5-3.  Representative images of the staining are 
presented in Figure 3-44.   
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Figure 5-1: The Y maze 
 
Photograph of the featureless Y maze.  The illustration describes how performance in the maze 
was analysed:  Spontaneous Alternation Performance (SAP), Alternate Arm Return (AAR) and 
Same Arm Return (SAR).   
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Figure 5-2: Young APP23 measure 1:  SAP 
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This line graph illustrates SAP in Young APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor with Statin or 
Placebo.  The x-axis represents the d and the y-axis the % SAP of total events during the exploration.   
Repeat exposure to the task increased SAP in Control (p = 0.004 on d 14).  This increase in SAP was not seen in after introduction of the 
modifiable risk with either Statin or Placebo.  There was no intervention dependent difference in SAP within any time point.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 5-3: Young WT measure 1:  SAP 
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This line graph illustrates SAP in Young WT mice Before and on d 3 and 14 after introduction of the modifiable risk factor with Statin or Placebo.  
The x-axis represents the d and the y-axis the % SAP of total events during the exploration.   
Repeated exposure and modifiable risk had no detectable effect on SAP in Young WT.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 5-4: Old APP23 measure 1:  SAP 
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This line graph illustrates SAP in Old APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor with Statin or Placebo.  
The x-axis represents the d and the y-axis the % SAP of total events during the exploration.   
Repeated exposure and modifiable risk had no detectable effect on SAP.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 5-5: Young APP23 measure 2:  AAR   
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This line graph illustrates AAR in Young APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor with Statin or 
Placebo.  The x-axis represents the d and the y-axis the % AAR of total events during the exploration.   
No difference in performance was detected in this analysis of Young APP23.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 5-6: Young WT measure 2:  AAR   
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This line graph illustrates AAR performance in Young WT mice Before and on d 3 and 14 after introduction of the modifiable risk factor with 
Statin or Placebo.  The x-axis represents the d and the y-axis the % AAR of total events during the exploration.   
Repeated exposure, modifiable risk and Statin or Placebo had no detectable effect on AAR in Young WT.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 5-7: Old APP23 measure 2:  AAR   
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This line graph illustrates AAR in Old APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor with Statin or Placebo.  
The x-axis represents the d and the y-axis the % AAR of total events during the exploration.   
Repeated exposure and modifiable risk had no detectable effect on SAP.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 5-8: Young APP23 measure 3:  SAR   
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This line graph illustrates SAR in Young APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor with Statin or 
Placebo.  The x-axis represents the d and the y-axis the % SAR of total events during the exploration.   
Control displayed statistically significant reduction in SAR on repeated exposure to the maze (d 3 p = 0.025, d 14 p = 0.016).  This was not seen 
in the other groups.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 5-9: Young WT measure 3:  SAR   
 
  
3
6
7
 
This line graph illustrates SAR performance in Young WT mice Before and on d 3 and 14 after introduction of the modifiable risk factor with 
Statin or Placebo.  The x-axis represents the d and the y-axis the % SAR of total events during the exploration.   
In Young WT, when compared to performance of the group Before introduction of the modifiable risk, Statin produced a statistically significant 
reduction in SAR performance on both d 3 (p = 0.019 compared to Before) and d 14 (p = 0.019 compared to Before).   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 5-10: Old APP23 measure 3:  SAR  
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This line graph illustrates SAR in Old APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor with Statin or Placebo.  
The x-axis represents the d and the y-axis the % SAR of total events during the exploration.   
In Old APP23, when compared to performance of the group Before introduction of the modifiable risk, Statin produced a trend toward reduction 
in SAR performance d 14 (p = 0.08 compared to Before).  This strong trend was not seen in either of the other groups.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 5-11: Young APP23 exploratory drive measure 1:  Latency to exit arm of entry 
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This line graph illustrates latency to leave the arm of entry in Young APP23 mice Before and on d 3 and 14 after introduction of the modifiable 
risk factor with Statin or Placebo.  This is an index of exploratory drive.  The x-axis represents the d and the y-axis the latency to leave the arm 
of entry.   
A longer latency was seen after introduction of the modifiable risk factor in Statin, but this did not achieve statistical significance (p = 0.13 and 
0.16 on d 3 and 14 respectively) and was not different to the other groups investigated.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 5-12: Young WT exploratory drive measure 1:  Latency to exit arm of entry 
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This line graph illustrates latency to leave the arm of entry in Young WT mice Before and on d 3 and 14 after introduction of the modifiable risk 
factor with Statin or Placebo.  This is an index of exploratory drive.  The x-axis represents the d and the y-axis the latency to leave the arm of 
entry.   
In Young WT, a similar trend was seen after introduction of the modifiable risk factor, with longer latency to leave the arm of entry seen in Statin 
when compared to performance Before (p = 0.14).  This trend was not seen in the other groups investigated.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 5-13: Old APP23 exploratory drive measure 1:  Latency to exit arm of entry 
 
  
3
7
5
 
This line graph illustrates latency to leave the arm of entry in Old APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk 
factor with Statin or Placebo.  This is an index of exploratory drive.  The x-axis represents the d and the y-axis the latency to leave the arm of 
entry.   
In Old APP23 the opposite effect was observed, with reduced latency to leave the arm of entry seen after introduction of the modifiable risk in 
Statin.  Compared to performance of the groups Before introduction of the modifiable risk, the difference observed on d 14 achieved statistical 
significance in Placebo (p = 0.006) and Statin (p = 0.01) but not in Control.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 5-14: Young APP23 exploratory drive measure 2:  Total number arm entries 
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This line graph illustrates total number arm entries in Young APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor 
with Statin or Placebo.  This is an index of exploratory drive.  The x-axis represents the d and the y-axis the total number of arm entries.   
On d 3 a trend toward increased number of entries was seen in Control  (p = 0.1186) and Placebo (p = 0.1261) groups, but not in Statin.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 5-15: Young WT exploratory drive measure 2:  Total number arm entries 
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This line graph illustrates total number arm entries in Young WT mice Before and on d 3 and 14 after introduction of the modifiable risk factor 
with Statin or Placebo.  This is an index of exploratory drive.  The x-axis represents the d and the y-axis the total number of arm entries.   
In Young WT, a statistically significant increase in total arm entries was seen in Control (p = 0.0003) on d 3 after introduction of the modifiable 
risk.  However, in Statin, a reduced number of total arm entries were seen on both d 3 (p = 0.0356) and d 14 (p = 0.0306).  This effect was not 
observed in Placebo.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 5-16: Old APP23 exploratory drive measure 2:  Total number arm entries 
 
  
3
8
1
 
This line graph illustrates total number of arm entries in Old APP23 mice Before and on d 3 and 14 after introduction of the modifiable risk factor 
with Statin or Placebo.  This is an index of exploratory drive.  The x-axis represents the d and the y-axis the total number of arm entries.   
No difference between groups was seen in this analysis of Old APP23.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 5-17: Young APP23 anxiety:  Number faecal pellets 
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This line graph illustrates total number of faecal pellets left after exploration of the Y maze by Young APP23 mice Before and on d 3 and 14 after 
introduction of the modifiable risk factor with Statin or Placebo.  This is an index of anxiety.  The x-axis represents the d and the y-axis the total 
number of faecal pellets.   
Placebo showed reduced number of faecal pellets on both d 3 (p = <0.001) and d 14 (p = 0.002) as compared to the number left Before 
introduction of the modifiable risk factor.  A similar trend was seen in Control but not in Statin.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 8, Surgery + Placebo = 10 and 
Surgery + Statin = 10.   
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Figure 5-18: Young WT anxiety:  Number faecal pellets 
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This line graph illustrates total number of faecal pellets left after exploration of the Y maze by Young WT mice Before and on d 3 and 14 after 
introduction of the modifiable risk factor with Statin or Placebo.  This is an index of anxiety.  The x-axis represents the d and the y-axis the total 
number of faecal pellets.   
No differences were observed between the groups compared.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 13, Surgery + Placebo = 14 and 
Surgery + Statin = 13.   
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Figure 5-19: Old APP23 anxiety:  Number faecal pellets 
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This line graph illustrates total number of faecal pellets left after exploration of the Y maze by Old APP23 mice Before and on d 3 and 14 after 
introduction of the modifiable risk factor with Statin or Placebo.  This is an index of anxiety.  The x-axis represents the d and the y-axis the total 
number of faecal pellets.   
No differences were observed between the groups compared.   
All data are presented as mean (95% CI).  p value derived by linear mixed model.  n numbers are Control = 4, Surgery + Placebo = 8 and 
Surgery + Statin = 8.   
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Figure 5-20: Synaptophysin in CA-1 and DG, d 30 
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This figure illustrates immunochemistry using DAB for synaptophysin in hippocampus of brain from Old APP23 mice 371 – 500 d of age that had 
undergone the assessment of learning and memory using the MWM and Y maze.  The mice were killed d 30 after introduction of the modifiable 
risk factor.  The x-axis represents the group and brain region analysed and the y-axis represents the MPI.   
The left hand side of the figure illustrates data from the CA1 region of the hippocampus in Control and Surgery + Placebo mice.  The right hand 
side of the figure illustrates data from the DG in the same mice.   
No difference was found in the MPI of synaptophysin in either APP23 Control or Surgery + Placebo d mice 30 after introduction of the modifiable 
risk in either CA1 or DG.   
Data are illustrated as mean (95% CI).  CA1:  t = 1.050, df = 4, p = 0.35; DG:  t = 0.2148, df = 6, p = 0.84.  p value derived from unpaired t test.  
n = 3 – 4 mice per group, with 3 brain slices per mouse.   
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Chapter 5  Tables 
Table 5-1:  Y maze results summary table 
 Young APP23 Young WT Old APP23 
 Control Surgery 
+ 
Placebo 
Surgery 
+ Statin 
Control Surgery 
+ 
Placebo 
Surgery 
+ Statin 
Control Surgery 
+ 
Placebo 
Surgery 
+ Statin 
SAP  − − −  − − − − 
AAR − − − − − − − − − 
SAR  − − − −  − − − 
Latency 
to leave 
− − Trend  
 
p = 0.13 
− − Trend  
 
p =0.14 
− −  
Number 
arm 
changes 
− − −  −  − − − 
Number 
faecal 
Pellets 
− −  − Trend  
 
p = 0.07 
− − − − 
Summary table of the Y maze results.  Number is day post introduction modifiable risk.  - means 
no difference.   
Table 5-2:  Mouse brain analysed for synaptophysin after the maze study 
 APP23  
Group Control Surgery + Placebo  
Sex 2 M 1 F 2 M 2 F  
Age 397 (383 – 500) 396 (374 – 476)  P = 0.72, U = 4.5 
Details of group, sex and age of APP23 mouse brain used for synaptophysin quantification on d 
30 after introduction of the modifiable risk factor.  Age in day, quoted as median (IQR).  M means 
male, F means female.  p value calculated by Mann-Whitney U test.   
Table 5-3:  In vivo immunochemistry results summary table 
POI Technique Result of any experiment performed 
IBA-1 Immunochemistry 
(Fluorescent indirect 
antibody) 
− 
Thioflavin-S Immunochemistry 
(Fluorescent stain) 
− 
Synaptophysin 
(7H12) 
Immunochemistry 
(DAB stain) 
− 
This table summarises the results of the APP23 and WT brain immunochemistry data.   
− means the no difference.   
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Chapter 6 Discussion 
6.1 Aims of the investigation 
This thesis aims to report work performed to investigate:   
In vitro 
1. The effect of anaesthetic agents on the A molecule in solution.   
2. The response of healthy neurones to A in the presence of anaesthetic agents.   
3. The response of immortal APP over-expressing cells to the presence of anaesthetic agents.   
In vivo 
1. The phenotype of APP23 mice and their distinction from WT littermates.   
2. Learning in APP23 and WT littermates using multiple methods.   
3. Changes in memory associated with the introduction of the modifiable risk factor 
(anaesthesia and surgery), assessing hippocampal dependent, non-hippocampal 
dependent, working memory and motivation.   
4. Neuropathological changes associated with these behavioural findings.   
5. If and how atorvastatin applied acutely during the perioperative period affects any of these 
findings.   
6.2 Cell free assay 
To begin the investigation we examined the effect of anaesthetic agents on the A molecule using 
different molecular species within the starting solutions of pure, synthetic A (monomer and 
ADDL).   
This work showed that the proportion of each A oligomer species in the end solution was 
dependent on both the starting A solution and the anaesthetic agent.  When comparing end 
products within any A oligomer species, the composition of the post-exposure solution was, in 
most cases, different after anaesthetic exposure to that seen after control conditions.  Also, in 
several cases, the proportion of each end product was different when comparing any two 
anaesthetic agents directly.   
It is interesting that xenon, considered the most neuroprotective218 anaesthetic agent of all those 
tested, consistently revealed the highest proportions of monomer and LMW molecules in the post-
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exposure solution.  These small oligomers are considered the most synaptotoxic forms of A.  
This was seen both when starting with monomeric A and with ADDL and suggests a degree of 
interaction with A that is surprising considering the inert nature of the noble gases.   
An explanation for the differing effects of anaesthetic agents on A remains unclear.  It would be 
interesting to explore these interactions further by developing the cell free assay model, for 
example, by introducing rudimentary lipids to mimic the cell membrane, with which both A and 
the anaesthetic agent may react.  This may modulate the interactions observed by changing 
molecular conformations and the availability of binding sites.   
Beyond this laboratory, emerging computer aided modelling technology holds potential for in silica 
investigation of anaesthetic-A interactions.  Tiwari et al. showed, using their computed model, 
that A aggregation propensity and the cell toxicities of Aβ variants were well described by their 
in silica system, suggesting a direct relationship between aggregation propensity and cell 
toxicity.245  This may be a suitable model to examine and understand anaesthetic-A interactions 
in much more detail, to predict consequences and to model ways of reducing aggregation 
propensities by molecular intervention, targeting specific molecular conformational changes.   
6.3 In vitro 
Neonatal WT mouse primary neurones in pure culture were used as a model to examine the 
concentration-dependent effects of A on cell viability, producing several findings worthy of 
discussion.   
Comparing this model with those previously published in the literature, we have demonstrated A 
toxicity at lower concentration, and after a shorter duration of exposure, than that previously 
described in a comparable in vitro model.  For example, Eckenhoff et al. used a 15 μM for 72 h 
exposure model, whereas here we used 0.8 μM for 24 h.  This exemplifies the benefits to 
experimental design of comprehensive concentration-response data.   
The sigmoidal shape of the concentration-response curve, relating the magnitude of the stressor 
(A concentration) to the endpoint (cell viability), follows the shape of a receptor-binding curve.  
This suggests that the mechanism of A neurotoxicity may be receptor-mediated in this model.  
Several biological steps may be required to cause A’s biological effect on cell viability, but this 
shape of concentration-response curve suggests that here, each messenger binds to one 
receptor according to the law of mass action.  Many receptors are implicated in the neurotoxic 
effects mediated by A, including the acetylcholine (ACh) receptor in basal forebrain cholinergic 
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neurones,246 the oxidative stress sensing calcium-permeable channel Transient Receptor 
Potential Melastatin 2247 and several others.248   
The threshold effect (concentration of A below which no change in cell viability is detectable) 
seen in the concentration-response curve possibly reflects metabolism and clearance of A by 
the primary neuronal culture at concentrations below this threshold, consistent with the existence 
of a normal, physiological role for A.  The maximal effect suggests these neurones may have 
differing sensitivity to the agonist effects of the molecule e.g. due to differences in receptor sub-
type expression, or are in possession of more established compensatory mechanisms, such as 
those that resolve oxidative stress and maintain calcium homeostasis.   
It should be noted that the effect of A on cell viability in vivo, and the values for threshold, ED50 
and maximal effect observed, apply only to this in vitro system and may not apply in other in vitro 
and in vivo models.  Of note, these d 7 ex vivo (DIV 7) pure neuronal cultures are immature and 
represent at best a neonatal laboratory model.  These cells have distinct expression of surface 
and cytoplasmic markers, receptors and ion channels, and possess different differentiation 
potential to neurones at another ex vivo age.  It would be interesting to repeat the work using 
neurones of higher DIV that may better represent the mature neurones of the ageing brain, which 
are difficult to mimic experimentally.  Fundamental differences include the degree of 
morphological maturation, differing receptor and ion channel expression and function (notably of 
potassium channel subtypes), and more mature cell-to-cell communication and interaction.  The 
use of hippocampal-derived neurones or those grown in glial co-culture249 would be an interesting 
avenue to explore.   
The data illustrating concentration dependent effects of anaesthetic agents on cell viability in A 
supplemented media, is consistent with the literature, as toxicity of anaesthetic agents is known 
to be concentration dependent.  An investigation as to how combinations of agents at sub-toxic 
levels affect the toxic potency and maximal effect of A is possible future work.   
Initial H4 cell line experiments were performed in order to validate the in vitro model against that 
already described in the literature.114,116  These authors compared H4-APP in both control and 
anaesthetic exposed conditions, whereas here we present data comparing both H4 and H4-APP 
(non-transfected and transfected) control with anaesthetic exposed H4-APP.   
The absence of any difference in APP expression in H4 and H4-APP is a significant confounder.  
This WB data shows that H4-APP were not over-expressing WT human APP-Full length, and that 
its expression in both H4 and H4-APP was the same.  This is despite H4-APP being stably 
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transfected and of young passage.  Several lines of evidence suggest that these H4-APP were 
not over expressing APP, and the significance of this finding was not adequately appreciated 
during the conduct of the investigation.   
Stable transfection involves the long-term introduction of DNA into cells, which is passed onto 
progeny through incorporation into the genome or through the stable inheritance of non-genomic 
(episome) DNA.  This relies on both effective DNA delivery into a suitable host, and the efficient 
selection of cells that possess the transfection.  Selection is achieved through the co-transfection 
of selectable marker genes along with the primary transfection.  Candidate genes for co-
transfection include those encoding aminoglycoside phosphotransferase (conferred by neo gene 
transfection), which render the cell resistant to aminoglycoside toxicity.  H4 cells are considered 
suitable transfection hosts and an appropriate selection pressure (resistance to G418 disulphate 
aminoglycoside antibiotic)250 was consistently employed.  However, we appear to have lost 
activity of the primary transfection whilst retaining that of the co-transfection, which is feasible as 
the two genes are not co-localised and need not share a promoter.   
Loss of transfection is a known problem when using any transfected cell line, being less frequent 
at low passage and with stable transfection.  Expression levels can decline acutely or gradually 
for several reasons including promoter gene suppression by factors such as DNA methylation, or 
due to a reorganisation of the integrated plasmid sequence by the clone.  This is generally 
overcome by the use of low passage cells.  A further possibility is that the increase in A produced 
early after initial transfection was cytotoxic to those cells.  This is significant in that stable 
integration of plasmid DNA into a genome is a rare event achieved in only 1 x 104 cells.  Loss of 
a small proportion of those with stable DNA integration through A toxicity would have significant 
effect on later A production.   
These H4-APP cells were transfected elsewhere and should have been better characterised in 
this laboratory to confirm their phenotype prior to use.  Data using their parent clone have been 
widely published in the literature however,114-116,119-121,125 and certainly some of those findings are 
consistent with data presented here.114,116,120  Despite not detecting a difference in APP-FL, these 
H4-APP do secrete more A into media than H4, as confirmed by the ELISA work.  However, the 
magnitude of the over expression appears to be lacking.   
The overall findings of the in vitro investigation were consistent with those described previously 
for up-regulation of cleaved caspase-3, decreased -CTFs and increased A production following 
isoflurane 2% exposure.  However, the quantity of A 1-42 detected in media, as reported by Xie 
et al. was 7-fold higher than that detected in the presented experiments, both being quantified 
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using an ELISA technique.  This is likely due to either a different sensitivity of the ELISA kit used, 
or to a real reduction in A production, secondary to transfection failure.   
To validate the present experimental model, N2aSwe cells were used in proof of concept -CTF 
quantification experiments.  N2aSwe over-express the pathological human APP Swedish 
mutation, as opposed to the physiologically normal, non-mutant APP expressed by H4-APP.   
The N2aSwe data are consistent with those previously published, the fall in -CTF observed in 
Isoflurane 2% reflecting reduced BACE-1 activity as CTF levels “are good indicators of the activity 
of the secretases.”224   
 
The expression of anti-apoptotic BCL-2 in H4-APP produced interesting findings.  BCL-2 
expression was reduced in H4-APP as compared to H4, which was not reduced further by 
isoflurane exposure (in contrast to that described previously by Xie et al.,120) and was rescued to 
H4 levels by exposure to xenon.  This anti-apoptotic effect of xenon is consistent with the reduced 
expression of cleaved caspase-3.  A xenon anti-apoptotic effect has been described previously,251 
where it again reduced caspase-3 expression.   
Isoflurane induced modulation of A synthesis is known to be caspase and apoptosis 
dependent116 and it would be interesting to further explore whether the neuroprotective and anti-
apoptotic effects of xenon share a common mechanism involving CTFs and A.   
6.4 In vivo 
The assessment of learning and memory 
Three different behavioural techniques were employed in this investigation in order to assess 
different facets of memory.  Similar to human AD, behaviour deficits in APP mouse models evolve 
in a progressive manner over time, with spatial working memory (MWM) being the first to reveal 
deficit, followed by working and associative memory changes (Y maze and TFC).   
6.4.1 Trace Fear Conditioning  
We proceeded to a TFC study in light of the positive data from WT mice observed previously 
using this model.150   
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6.4.1.1 The assessment of learning  
Learning was confirmed in both APP23 and WT mice using TFC.  An interaction analysis of the 
assessment of learning data showed a statistical interaction between genotype and % freezing in 
TFC.  As a consequence, comparisons of changes in performance across genotype were not 
made and each genotype was analysed separately.   
However, to establish that learning in APP23 and WT littermates was different, cross genotype 
comparisons were initially made.  When comparing this data to that previously published from the 
parent mouse colony,252 Katsouri et al. showed that APP23 had higher maximal performance than 
WT during their assessment of learning in TFC, both during Tone and Trace components, using 
an identical single training session.  This was in 9-month-old mice, both male and female, and is 
contrary to data presented here, where APP23 showed lower maximal performance than WT 
littermates during Tone, both in Young and Old mice.  Data of maximal performance during Trace 
is more consistent with that of Katsouri et al.   
Female mice tended to show higher maximal performance in TFC during the assessment of 
learning, notably in APP23 during Trace.  Sex dependent performance in TFC has been described 
in mice previously but is not widely reported in the literature, which lacks detailed analyses of sex 
dependent data.253  The differences observed here may represent sex dependent differences 
within the brain centres operating during discreet intervals of the training.   
6.4.1.2 The assessment of memory 
Anaesthesia + Placebo appear to protect hippocampal independent memory on d 3 after 
exposure in both genotypes, an effect reduced by the introduction of statin or surgery.  This 
augmented learning joins a growing body of published literature showing that isoflurane may 
protect certain facets of learning and memory254 but is contrary to some of the literature.100  
Indeed, the finding of reduced hippocampal synaptic function99,255 in response to isoflurane is also 
disputed.105  This result may be an effect of the non-gender specific analysis combining male and 
female animal data.256  Alternatively, it may be due to a neuroprotective effect of isoflurane in non-
hippocampal brain regions, including those associated with fear responses, such as the 
amygdala, where isoflurane-induced alterations in gene expression are described.257  A reduction 
in this augmented memory with statin intervention may be induced by a disruption of inflammatory 
processes underlying memory formation.104   
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An increased freezing on d 14 correlates with the increased anxiety observed in Y maze in the 
Surgery + Statin group.  The contribution of acute anxiety causing freezing behaviour cannot be 
separated from freezing due to memory of the Tone-Shock association.   
In this analysis of TFC, the subtle effects of anaesthesia are the most prominent.  The addition of 
surgery to anaesthesia did not produce a clear memory dysfunction in the mice.  However, sex, 
modifiable risk and intervention dependent differences in pain thresholds may have disguised an 
effect of surgery on memory function detectable by TFC.  Sex difference in nociception in APP23 
is a remarkable finding and may contribute to the negative result of the analysis.   
6.4.2 Morris Water Maze 
We proceeded to MWM and Y maze investigation in light of the equivocal TFC results, thinking 
these well-described behavioural methods may have the sensitivity required to detect memory 
deficit caused by anaesthesia with surgery.   
6.4.2.1 The assessment of learning 
Analysis showed a strong genotype dependent effect on learning in the MWM,258 as has been 
long established.   
All mice showed evidence of learning, which was unaffected by the administration of placebo or 
statin.  In the statin treated group, the rate of improvement in performance appears different at 
the start and end of training, with a steeper gradient observed at the start, reflecting a higher rate 
of learning.  However, variation in the rate of acquisition is typical of normal biological variation.  
Performance at the end of training was comparable between all groups within genotype.  An effect 
of ageing was evident as Old APP mice required 2 additional d training to reach uniform 
performance in the task.   
A review of the literature shows that this APP23 colony out-performed other APP23 colonies in 
MWM acquisition,259 both in latency to platform and % time in platform quadrant measures of 
performance.  This is despite a shorter duration and smaller number of training sessions here.  
Performance data from the Old APP23 mice (14 – 16.5 months of age) better replicate the data 
previously published for 6-month-old APP23,259 suggesting the pathology of this colony was not 
typical of APP23 in age-matched colonies elsewhere.   
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6.4.2.2 The assessment of memory 
The broad variance seen within the data makes it impossible to draw robust conclusions, as the 
95% CI intervals broadly overlap.  A further confounding effect was outstanding performance in 
one group during the d -1 probe, which distorted the assessment of later retention.  Also, control 
mice were the worst performers in certain measures.  This occurred most often in Young APP23 
and may be due to performance benefits derived from subtle, unintentional differences in handling 
and husbandry between the experimental groups.   
Confirming a surgery effect on memory 
A surgery effect was detectable in the MWM data only in the more sensitive measures of 
performance, such as MPS, in Young and Old APP23.   
Genotype effect 
No strong genotype effect on the impact of the modifiable risk on memory is evident in the data.   
Age effect 
Old mice developed more memory deficits after surgery than Young mice; the effect of surgery 
on memory is more evident in the Old mouse data.  This is consistent with the older brain being 
more vulnerable to the detrimental effects of the modifiable risk.   
Statin effect 
There is no clear effect of statins in this data.   
Atorvastatin appears to have effect in some measures, but this is not consistent.  % time in 
platform quadrant, MPS and latency to bigger platform reveal an effect of surgery that appears 
reduced by atorvastatin.   
One clear trend in the data is that memory deficit seen after surgery is longer lasting in statin 
treated mice.  In Old APP23, Surgery + Statin performed worst in latency to platform, and were 
still worse performing on d 14, when the performance of other groups had recovered.   
The effect of surgery with statin or placebo appears to be age sensitive in this analysis.  
Considering that the MWM is most sensitive at detecting hippocampal memory deficits, this 
makes the inconclusive results of the TFC and Y maze studies unsurprising.   
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6.4.2.3 Omnibus analysis: taking a step back from the data 
Although there were differences in learning and in pathology, no robust effect of surgery was 
seen, either in the WT or APP23 genotype.  When analysing longitudinal performance in the MWM 
in aggregate; genotype and age dependent differences do appear, in terms of gross numbers of 
significant differences compared to performance on d -1.  I shall term this summary of the data 
an omnibus analysis, as detailed in Table 6-1.   
When comparing pre- and post-modifiable risk factor performance in MWM, all differences 
approaching or achieving statistical significance were negative changes in performance.  That is, 
all mice displayed a poorer performance in the task, or forgetting, over time.  This was regardless 
of group.   
Old APP23 
Old APP23 displayed the most forgetting, in terms of the highest number of comparisons made 
that approached or achieved statistically significant difference.  In Old APP23 mice, these were 
seen in 17 of a possible 54 comparisons.   
The order, from poorest performance to best performance in Old APP23 was: 
Surgery + Placebo > Surgery + Statin > Control.   
In Old mice, Surgery + Placebo showed the greatest impairment in this analysis, outperformed 
by Surgery + Statin.  Statin appears to have ameliorated the surgery effect on memory when 
taking an overview of the data in summary, but the effect was not detectable when the data was 
placed under closer scrutiny.   
Young APP23 
Young APP23 showed differences achieving or approaching significance in 15 of a possible 54 
comparisons: 
The order, from poorest performance to best performance in Young APP23 was: 
Control > Surgery + Statin > Surgery + Placebo.   
It is unclear why Control performed poorest, but the result suggests that Surgery did not cause a 
significant effect on memory in Young APP23, or indeed may have improved performance.   
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Young WT 
Young WT showed differences achieving or approaching significance in 6 of a possible 54 
comparisons.   
The order, from poorest performance to best performance in Young WT was: 
Surgery + Placebo > Surgery + Statin > Control.   
There was no instance of statistically significant difference in the performance of Control mice.   
Overall, genotype and age- dependent effects emerge from the data using this omnibus analysis, 
and the effect of statin was variable.  Old APP23 mice benefited from statin during the 
perioperative period, Young APP23 mice that received statin appeared harmed.   
This suggests an age dependent effect of statin.   
Sensitivities of each measure 
Several analyses of the data reveal that some measures were more sensitive than others in 
detecting the memory deficit caused by surgery.   
MPS, a measure designed to accommodate the inherent memory deficits of APP transgenic 
mice,260 providing a longer-term overview of performance, picked up a surgery effect in APP23 
only.   
Retention deficits or forgetting? 
Retention deficits in the MWM can occur for several reasons: a failure to encode and store 
information into long-term memory, failure to consolidate or failure to retrieve.261  This is 
particularly relevant in AD mouse models with inherent memory deficits.  Forgetting occurs due 
to a deficit of consolidation or interference from other learning.  APP23 appear to have steeper 
rates of forgetting than do WT, but the effect of surgery on forgetting was inconsistent.   
6.4.2.4 New learning and new memory 
New learning, caused by platform relocation, is an index of cognitive flexibility in the MWM.262   
The data for APP23 mice is interesting in that Young and Old show different features.   
A detrimental effect of surgery on new learning is evident in young APP23.  Statin attenuates this.   
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Similarly, in Young WT, an effect of surgery is demonstrated, attenuated by statin.  This may be 
a group size or an atorvastatin effect.  A statin effect on new learning has previously been 
demonstrated in this laboratory in WT mice.150  Disappointingly, Control showed no evidence of 
having learnt the new task.   
In Old mice the skew of the data in Control and Surgery + Placebo is marked.  This skew is absent 
in Surgery + Statin.  Statin use was making performance in the group more uniform.  On a 
neuronal level, this effect is typically seen in drugs with major CNS action, such as major 
tranquilizers.  Statin mechanism is potentially both cholesterol modifying in the brain and also 
pleiotropic elsewhere, possibly filtering down to neurotransmitter pathways that are modified.  
Statins are not a class of drug normally associated with psychoactive properties, although 
memory and mood side effects are some of the most commonly reported by human consumers,263 
and antidepressant effects are reported in animals.193,195   
6.4.3 Y maze 
APP23 develop working memory deficits only in old age127,264 where deficits are minimal when 
compared to age matched WT controls.   
In this study, SAP was improved in APP23 Control on repeated exposure to the maze.  In APP23, 
the benefit of practice effect may have improved performance.  Its absence in both surgery groups 
suggests an effect of surgery on working memory that was not affected by statin use.   
Previous experience of the Y maze task has not been shown to improve performance in WT 
C57BL/6 mice.244  However, reversible improvement in working memory performance in 5 month 
male WT C57BL/6 has been described up to d 7 after isoflurane105 in the visuospatial hole board 
test of working memory.  These better performing mice showed increased LTP in CA-1 that was 
secondary to selective up-regulation of the NR2B NMDA receptor subunit.  In a Guinea Pig study 
investigating the effects of long term statin use on memory, both atorvastatin and simvastatin 
were associated with deficits in working memory,265 but this was detected using a modified MWM 
protocol.   
SAP performance in WT mice approached statistically significant improvement in Surgery + 
Placebo.  Atorvastatin is dose-dependently neuroprotective of primary cortical neurones exposed 
to both NMDA266 and Glutamate267 in vitro after several d treatment.  This suggests that in WT 
mice the lack of improvement in Surgery + Statin was not due to neurotoxicity linked to NMDA, 
but due to a deficit in one of the many other neurotransmitter systems operating during working 
memory.   
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A strong and persistent reduction in exploratory drive was seen in WT Surgery + Statin in two 
measures: 1] increased latency to leave the arm of entry; and, 2] reduction in total number of arm 
entries.  This decrease in total number of arm entries has been reported previously in albino mice 
treated with the same dose of atorvastatin.194  Increase in anxiety behaviours have been reported 
after atorvastatin in other species including Guinea Pigs, where 6-week atorvastatin treatment 
had no effect on reference memory but increased thigmotaxis during the assessment of working 
memory in the MWM.265  Reduced motivation was less likely due to depression as atorvastatin 
has been reported as an antidepressant in male Swiss mice,195 but at 100th of the daily dose.   
6.5 Was APP23 fit for purpose? 
Mice do not develop AD; they have no comparable diagnosis that causes neurodegeneration.  
Consequently, the use of animal models in AD, despite their complexity and usefulness, has 
significant inherent limitations.   
APP23, in common with most existing animal models, are based on the over-expression of mutant 
proteins found in familial AD, making APP23 a model of familial AD aetiology.  Most clinical AD 
in humans is sporadic.   
The contribution of background strain will always be significant and can affect phenotype in subtle 
ways that only emerge on close scrutiny.  C57BL/6 is a widely used inbred mouse background 
strain.  However, the prolonged isolation of C57BL/6 breeding colonies has generated distinct 
genetic sub strains.  These mice were of C57BL/6N background, sourced from Harlan, UK, whose 
colony was originally derived from the National Institutes of Health, USA.  Differences in rotarod, 
hot plate and TFC performance have been reported previously in sub strains of C57BL/6.268   
A consistent rearing environment limited the effect of differing chronic stress on the behavioural 
variability observed,269 but already this colony revealed TFC differences compared to their parent 
colony.   
Genetic drift was limited throughout the conduct of this study by introducing young C57B/6 
breeding females sourced direct from the supplier approximately every 5 generations.  This colony 
should be considered a sub-strain as the breeding room was declared mouse parvovirus positive 
mid-study, changing the health status of all the mice within the room.  This virus is not reported 
to cause behavioural changes in mice.   
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6.5.1 Was this colony typical of APP23? 
These mice displayed several described features typical of APP23: 
6.5.1.1 Phenotypic 
Features observed were classic of the model:128 
1. Reduced weight in the context of increased feed consumption232 
2. Increased tonic clonic seizure activity126  
3. Stereotyped myoclonic jumping (thought related to 5HT over activity)127 
4. Increased aggression270  
5. Increased mortality of unknown cause (thought related to advanced cerebral amyloid 
angiopathy)271 
Considering weight, 8-month weight data from these mice are comparable to that previously 
published258 but suggest female APP23 in my colony may have been underweight.  The finding 
of greater feed consumption in female APP23 is novel.  Likewise, the finding of altered 
nociception.   
6.5.1.2 Behavioural 
MWM deficits are described at 3 – 5 months in APP23259 but their performance in TFC is not 
widely published and the age of onset of deficits could not be established.   
6.5.1.3 Biochemical 
Initial WB showed soluble A over-expression to be present from at least infancy and is in keeping 
with the literature.272   
6.5.1.4 Neuropathology 
Why was plaque pathology absent in > 6 month old APP23 mice? 
The balance of evidence suggests that this colony was not typical of the APP23 described in the 
literature,233 and were not developing the pathology at the normal rate.   
The absence of A has several contributing factors:  
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1. The majority of mice used in this investigation were reared in an enriched environment from 
birth, which is considered a non-pharmacological intervention known to influence A burden 
and reverse MWM deficits in APP23 mice of similar age.273  Environmental enrichment was 
introduced into cages early during the conduct of the TFC study.  This may have influenced 
the data in the interim analysis.  At the time, enrichment was not considered to have any 
therapeutic potential.   
2. The colony may have been atypical in its over-expression of APP.  Positive control samples 
used in immunochemistry were of oldest old APP23 retired breeding stock, ca. 24 months 
of age.  Pathology in positive control females was considerably more advanced than in 
positive control males of the same age.  Females had large cortical and hippocampal 
plaques with surrounding bright IBA-1 staining, whereas males showed only sparse, small 
specks of plaque in the hippocampus surrounded by reactive gliosis.  Representative female 
positive control staining is presented in Figure 3-45 and of male in the appendix.   
The colony was certainly transgenic, as proven by genotyping and clear distinctions in phenotype.  
The oldest old mice developed severe cerebral amyloid pathology, notably in female mice, with 
robust neuroinflammation and cerebral amyloid angiopathy.   
6.5.2 Why was no surgery effect detected? 
Interestingly, Xie et al. showed both Contextual and Conditioned response deficits in 10-week-
old C57BL/6 after isoflurane alone, and in the same paper showed Il-6 to be increased after 
isoflurane in adult rats.104  Exaggerated Il-6 levels are in seen in the APP23 brain after peripheral 
LPS, when compared to WT,158 making this lack of effect of surgery even more confusing, as a 
surgical insult should compound the anaesthetic effect, not ameliorate it.  However, isoflurane 
has been shown to improve cognitive performance in young and old APP23.254  Furthermore, less 
invasive surgical insult but longer anaesthetic exposure has shown behaviour effects in TFC at d 
14 in young C57BL/6 WT mice,274 a deficit reversed by an enriched environment, which preserved 
hippocampal Brain Derived Neurotrophic Factor (BDNF) and enhanced neurogenesis.   
In the absence of A plaque, younger APP23 showed strong effects of surgery on 
immunochemistry early in the study.  GFAP expression in the hippocampal fissure showed a 
difference in the rate of resolution of neuroinflammation between APP23 and WT.  A small batch 
of samples also showed marked increase in A pathology after Surgery + Placebo that was not 
seen after Surgery + Statin.  Representative images are presented in the appendix.   
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Was the surgical stimulus inadequate?  Possibly, although the model of surgery has shown strong 
behavioural effects previously, in young150 and older WT mice,275 as has isoflurane anaesthesia 
alone, both in WT123 and APP23.122  Unilateral nephrectomy as a surgical model for the 
assessment of perioperative behavioural changes in mice is, however, not widely published in the 
literature.  In this laboratory, permanent behavioural deficits in MWM performance using this 
model of surgery have been shown (H. Watts, in press), but only in the oldest old mice.   
Furthermore, the severe and persisting weight loss of up to 20% seen after surgery in both 
genotypes indicates that the physiological impact of the modifiable risk was severe and long 
lasting.   
Both male and female mice were used in this study, in keeping with the principles of 3 Rs.  The 
distribution of male and female sex was balanced between groups, but most literature reports 
only work on male mice, due to concerns regarding variability introduced by hormonal cycles in 
females.  Endogenous oestrogens are known to reduce microglial activation in female APP23.276   
6.5.3 Why was the interim data different?   
The number of specimens analysed during an early interim, proof of principle analysis, was far 
too small for anything but speculation.  Optimisation of surgical technique and practice effect may 
also have changed the strength of the surgical stimulus as the study progressed.  Images from 
the interim analysis are presented in the appendix.   
6.5.3.1 Could good perioperative care be implicated?  
Possible contributing factors are the many refinements adopted during the conduct of this 
investigation, which may have weakened the surgical stimulus.  Several small but significant 
modifications to the protocol occurred in light of the interim A data and the need for long 
postoperative survival of the mice.  These refinements aimed to ensure the absence of 
perioperative hypothermia and hypoxia, good analgesia, aggressive intraoperative resuscitation 
and close attention to sterility.  Each of these factors has been shown to impact cognitive 
outcomes in humans after surgery, and were optimised in this protocol.  The evidence suggests 
that by optimising brain oxygenation and depth of anaesthesia, POCD is minimised in humans 
under 65 years of age.23   
Possibly, the ‘enhanced recovery’ these mice received positively modified the neuroinflammatory 
response to the modifiable risk, and its effect was cleared before d 14.  The shape of the MWM 
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data suggests that behavioural effects appear to peak in the early postoperative period, MWM 
being the most sensitive behavioural technique used.   
The stronger effect of surgery in old APP23 may be due to a better resolution of 
neuroinflammation in young mice.   
6.5.4 Trial design and methodology 
6.5.4.1 The study population may have been too young 
Cognitive effects of surgery have been demonstrated in young adult humans but are far more 
common in those > 65 years old.  An older population of mice might have revealed the effects of 
the modifiable risk factor and the intervention more strongly in this model.  However, using young 
mice to mimic preclinical AD was part of the study rationale.  Old groups in this study were smaller 
than the Young groups; too small to show any difference.   
6.5.4.2 Were we looking at the correct time points?   
We used time points that are often used in the literature and possibly the d 14 time point may 
have been too far from the stimulus.  Wan et al.30 showed gliosis on d 3 and increased A 1-42 
on d 7 after partial hepatectomy under chloral hydrate general anaesthesia in old mice.  If there 
was substantial gliosis and an increase in A, then we should have detected its signal.   
6.5.4.3 The study was under-powered 
Mouse numbers of at least 10 per group were estimated to be adequate to show a difference 
between groups in the TFC study.  This estimate was based on group numbers used in similar 
previous studies in this laboratory, and on group numbers frequently described in similar work 
throughout the literature.   
However, this sample size estimate was inadequate.  A careful retrospective power calculation 
based on previous work published from this laboratory150 calculates the equal sample size of both 
groups to achieve power of 0.9 with significance level 0.05, to be 26 mice per group.  This large 
number is partly due to a skew in the distribution of the data on which the power calculation is 
based.   
Larger group size would have been easier to achieve had the number of groups been smaller; 
the TFC study had too many groups.   
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6.6 Was the model fit for purpose?  
The appealing feature of APP23 was the early onset of learning defects that are detectable 
months before the onset of classical AD pathology.  Subtle, late onset cholinergic neuronal 
damage and deficit,277 strong cerebral amyloid angiopathy, strong gliosis and the spontaneous 
phosphorylation of 278 are common to both APP23 and human AD pathology.279  These opened 
several potential avenues for inquiry that could be explored.  Further, the multiple phenotypic and 
behavioural features shared with sporadic AD suggest a sophistication in APP23 that is absent in 
stronger AD mouse models.  I consider APP23 to best mirror the clinical syndrome of AD in 
humans at a preclinical stage of disease, potentially susceptible to the impact of modifiable risks 
and intervention.   
Any link connecting anaesthesia, surgery and AD is subtle and no one model can fully replicate 
all aspects of clinical disease, different mouse models providing different behavioural and 
neuropathological insights.   
6.6.1 What could have been done differently? 
6.6.1.1 The importance of detecting a memory lesion 
Only late in the TFC study was it recognised that at no point had a surgical effect on behaviour 
been confirmed after the introduction of the modifiable risk, in this colony and by this author.  We 
should have confirmed this early in the study.   
6.6.1.2 ‘Non-specific binding’ problems 
Immunochemistry work was delayed by apparent ‘non-specific binding’ of antibodies, notably for 
synaptophysin.  Several protocols were designed and tested in an attempt to eliminate this, each 
taking time to develop and refine.  This ‘non-specific binding’ turned out to be a problem with the 
filters on the local microscope and was not seen when the specimens were examined off-site.  
Additional cross checking when data was unusual or unexpected would have saved considerable 
time.   
6.6.1.3 The pitfalls of amyloidosis in APP23 
The absence of strong A pathology in these young APP23 meant that quantifiable cortical 
changes in neuronal density and structure were limited as neuronal loss is spontaneous in APP23 
hippocampus280 but in cortex, it is secondary to A deposition.277   
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6.6.1.4 Statistical analysis  
An independent academic statistician performed all statistical analyses of the assessment of 
learning and memory data using a modified repeated measures method applied longitudinally 
(linear mixed model).  The emphasis was to use the strongest statistical method possible to 
compare the data, which also overcame any loss of data due to the higher mortality caused by 
surgery.  All error bars illustrated in the figures are 95% CI, and clearly illustrate how no within-
time-point difference between groups is present in the data.   
The spread and large variances seen within both the in vitro and in vivo data reflect biological 
variation.  Some vulnerable mice did suffer an impact of surgery on memory using this model, 
and some may have been affected by the intervention with statin.   
6.6.1.5 Methodological issues 
The age of the animals at the time of the experiment was too inconsistent and introduced 
unnecessary variability in the model.  Closer attention should have been paid to making mouse 
age at experiment more uniform.   
Mice were allocated randomly to groups throughout the conduct of this investigation.  For part of 
the study, the randomisation scheme was generated using www.randomization.com, but some 
was performed blindly by the investigator and may have been open to unconscious bias.   
6.7 Future work 
Work that is planned in this investigation, but not yet performed include: 
6.7.1.1 Tau imaging 
This work was deferred following the publication of data showing that sevoflurane, a halogenated 
ether general anaesthetic agent in common use, induced  hyperphosphorylation in C57BL/6 
mice under normothermic conditions.  This is seen in both WT281 and AD282 mouse models and 
was associated with deficits in spatial learning using the MWM.   
6.7.1.2 Hippocampal volume estimation 
In humans, hippocampal volume loss occurs in AD, and reduced hippocampal volume is 
associated with POCD.106  In mice, Bedhwar et al. performed post mortem MRI measurement of 
anatomical brain structures in 6-month old male J20, a double APP mutation AD model.  They 
showed average overall brain volume to be larger in J20 when compared to age-matched WT 
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controls, as was hippocampal and cortical volume (including dentate gyrus, CA1 – 3, and cortical 
structures involved in memory processing).283  However, memory induced neuroanatomical 
plasticity (change in brain structure size after learning) was attenuated in the J20, as was spatial 
learning in MWM.  Measurement of hippocampal and cortical thickness and estimation of 
hippocampal volume might reveal group differences in this investigation.   
6.7.1.3 Peripheral cytokine quantification  
It would be of interest to examine for differences in central and peripheral cytokine responses to 
the modifiable risk.  Exaggerated brain Il-6 response after peripheral LPS has been described in 
APP23,158 associated with worse BBB leakage of FITC-labelled albumin.  No genotype difference 
in brain interstitial soluble A or TNF-was described in that study, and both groups showed the 
same plasma Il-6 and TNF- response.   
We should determine if acute atorvastatin has a stabilising effect on BBB function during the 
perioperative period.   
6.7.1.4 Epigenetics 
Epigenetic techniques could be used to analyse changes in gene expression targeting several 
genes that regulate both AD and inflammation with far greater sensitivity than that achieved here.  
This could be used to compare regional differences in gene expression, using the isolated brain 
structures already prepared during this investigation.   
6.7.2 Further analyses 
WB of samples would achieve increased detection sensitivity compared to that of 
immunochemistry.  This might have been a more suitable technique for the semi-quantification of 
synaptic proteins.   
6.7.2.1 Analysis of mortality data 
It would be interesting to examine if mortality data changed during the course of the study.  
Several factors might influence this beyond practice effect and protocol optimisation.  Phenotypic 
differences that were genotype dependent may have affected surgical complexity, and therefore 
outcome.  Physiological, inflammatory and immune responses might also have genotype 
dependent effects on perioperative mortality.  Although surgical mortality rates were not formally 
analysed, contemporaneous records kept during the course of the investigation indicate no large 
change in mortality rate during the 3-year time course of the study, consistently standing at around 
10%.  This rate was observed in both genotypes.   
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6.7.2.2 Other neuropathology 
Altered A processing: Examining APP  
Intra-neuronal APP accumulation occurs in APP23 and inversely correlates with dendritic spine 
generation and density.284  This is in keeping with our proof of concept experiments showing that 
APP expression and distribution in H4-APP was changed by exposure to A and isoflurane 
(representative images are shown in the appendix).  Effects on APP distribution and expression 
could be further characterised in these study animals.   
Cerebral amyloid angiopathy   
This describes the deposition of A in blood vessel walls leading to micro and macroscopic 
changes in cerebral perfusion, aneurism formation, haemorrhage, and vasculitis.  APP23 is an 
excellent model of cerebral amyloid angiopathy,279 which develops from the age of 12 months.  
Preliminary data, illustrated in Figure 6-1, suggest that this was accelerated by Surgery and more 
focus should have been placed on investigating this unique feature of APP23.   
Neurogenesis 
Effects on neurogenesis may be a more sensitive index of the consequences of modifiable risk 
and intervention, notably in the context of introducing exercise and novelty to mice bred in the 
laboratory cage.  These mice had little access to novelty until their introduction into the 
experimental protocol.  Enrichment of the environment, novelty and exercise are known to 
stimulate neurogenesis.  Consequently, the process of handling, dosing, behavioural 
characterisation and the assessment of learning will have had an effect on neurogenic activity 
within the hippocampus and already altered cell populations, growth factor expression and 
neuronal plasticity.  Acute exercise-induced neurogenesis has previously been speculated to 
enhance cognitive performance in spatial tasks.285-288   
Altered neurogenesis is described in AD affected humans289 and in APP23.290  Interestingly, 
Ermini et al. showed, using a bromodeoxyuridine incorporation and doublecortin staining 
technique, the rate of hippocampal neurogenesis in the granule cell layer of the hippocampus 
was the same in both WT and APP23 age matched littermates at 5 months of age, but was 
significantly higher in APP23 at 25 months.  Other AD mouse models however showed reduced 
neurogenesis in age matched adult mice.  Neurogenesis must have been present in these APP23 
as it is required for gains in spatial learning performance in the MWM, but is not required for gains 
in performance in TFC.291   
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Acute activity of senescent adult and old male C57BL/6 is associated with enhanced 
neurogenesis in DG.292  Altered hippocampal neurogenesis and trophic factors, in the context of 
the methods of this investigation, may have more clearly revealed the impact of the modifiable 
risks and interventions.  The gliosis identified in preliminary work indicates that a hippocampal 
insult is possible in this model.   
Cholinergic fibre length and dendritic spines 
Cholinergic fibre length and dendritic spine formation, density and turnover, as correlates of 
learning and memory, would have been another, dynamic index of neuronal health we could have 
examined.   
Characterising activated microglia 
Peripherally derived macrophages clear A from the brain.  Macrophage recruitment from bone 
marrow is necessary for hippocampal neuroinflammation293 and has been described in APP23 by 
Stalder et al.294  We showed, using confocal microscopy performed during the interim analysis, 
endocytosis of Thioflavin-S stained plaque by activated IBA-1 staining cells, in both the CA-1 and 
subiculum (representative images are shown in the appendix).  Further work to establish the origin 
of these IBA-1 staining cells, characterising their interaction with A plaque and the temporal 
relationship between their activation and the modifiable risks, might prove fruitful. 
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6.8 Clinical implications 
The main clinical implication of this study is the reassurance that anaesthesia with surgery, 
performed well and in the absence of strong risk factors for cognitive change, can be free of gross 
cognitive repercussions.  Main risk factors addressed as part of the evolution of this study were 
the meticulous surgical technique, the absence of hypothermia and hypoxia, good fluid 
resuscitation and good analgesia.   
Anaesthesia with surgery does cause subtle deficits in new learning.  These are attenuated by 
the acute perioperative use of atorvastatin.   
Clinical research should focus on the adequate assessment and recording of cognitive function 
in patients prior to sterile elective surgery, and push to improve the clinical utility of these tools.  
Only with sound baseline data can we proceed to randomised controlled trials of perioperative 
statin use, both acute and chronic, that examine their effect on new learning and mood.  Studies 
should adopt a unified approach to intervention so that a large, comparable body of evidence can 
be gathered and used in meta-analyses.  Perioperative discontinuation of statins, causing a statin 
withdrawal state associated with poorer cardiovascular outcome after major surgery in 
humans,295,296 should also be more closely scrutinised for cognitive effects.   
Further laboratory research to investigate the beneficial effects of statins on new learning is 
warranted.  Any future studies should be adequately powered and focus on more sensitive 
markers of animal behavioural and neuronal dysfunction than those employed here.   
Statins do show perioperative cognitive benefits, but only in subtle measures.  Far more evident 
in this investigation, however, were their potential cognitive side effects.   
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Figure 6-1: Cerebral amyloid angiopathy in APP23:  representative images of the staining 
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This plate of images illustrates representative immunochemistry staining on brain slices from 
female WT and APP23 mice.  The left column shows IBA-1 staining of microglia (red channel), 
the center column Thioflavin-S staining of A plaque (green channel) and the right column a 
composite image of IBA-1 and Thioflavin-S staining (merged).  Row:  
A = WT Control 
B = APP23 Control  
C = APP23 Surgery + Placebo d 1 
D = APP23 Surgery + Placebo d 3  
E = APP23 Surgery + Statin d 14.   
All mice were Young, mean age (95% CI) = 138.4 (115.5 – 161.3) d.   
Vessel wall IBA-1 and Thioflavin-S staining intensity is comparable between Young WT and 
APP23.  An increase in intensity is seen in blood vessel walls d 1 and 3 after Surgery in APP23, 
which had resolved by d14 in Surgery + Statin.  
This pattern of staining is consistent with Cerebral amyloid angiopathy.   
All images at x40 magnification.    
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Table 6-1: Omnibus data:  MWM error rates in longitudinal analysis 
Measure Group Young APP23 Young WT Old APP23 
1:  Latency Control 3 0 1 
Surgery + 
Placebo 
0 2 1 
Surgery + Statin 0 1 2 
% of all possible comparisons 33 33 44 
 
2:  % time in 
platform quadrant 
Control 2 0 0 
Surgery + 
Placebo 
0 0 2 
Surgery + Statin 3 0 1 
% of all possible comparisons 55 0 33 
 
3:  MPS Control 1 0 0 
Surgery + 
Placebo 
0 0 1 
Surgery + Statin 1 0 0 
% of all possible comparisons 22 0 11 
 
4:  No. platform 
crossings 
Control 2 0 3 
Surgery + 
Placebo 
0 2 2 
Surgery + Statin 0 0 2 
% of all possible comparisons 22 22 78 
 
5:  Latency to 
bigger platform 
Control 0 0 0 
Surgery + 
Placebo 
1 0 2 
Surgery + Statin 0 1 0 
% of all possible comparisons 11 11 22 
 
6:  Latency to 
bigger platform 
crossings 
Control 1 0 0 
Surgery + 
Placebo 
0 0 0 
Surgery + Statin 1 0 0 
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% of all possible comparisons 22  0 0 
 
Grand Total  
(% of all possible comparisons) 
15 of 54 
(28) 
6 of 54 
(11) 
17 of 54 
(31) 
This table shows sum of performance comparisons that approached or statistical significance 
during the analysis of longitudinal data from MWM using linear mixed model.  An age, genotype 
and surgery effect is observed, where comparison is possible, and the effect of statin is variable.   
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Appendix 14:  Positive control immunochemistry 
This plate of images illustrates immunochemistry using IBA-1 antibody (red) co-
stained with Thioflavin-S (green) in brain slices of oldest old male APP23 mice used 
as positive control tissue during immunochemistry experiments.  The top panel 
illustrates Thioflavin-S staining (green channel) and the lower panel a merged image 
with IBA-1 (red channel).  The paucity of A plaque and reactive gliosis in this oldest 
old male APP23 mouse brain is remarkable, and is strikingly different to female APP23 
positive control brain tissue, illustrated in Figure 3-45.  A mixture of oldest old male 
and female brain slices was used as positive control in every immunochemistry 
experiment performed on tissues derived from the TFC, MWM and Y maze studies.  
All images at x40 magnification.     
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Appendix 15: Microglial activation in APP23 and WT hippocampus  
 
This plate of images illustrates immunochemistry using IBA-1 antibody (co-stained 
with Hoechst) on hippocampal slices of male APP23 and WT mice 16 – 18 weeks of 
age on d 7 after Surgery.  The left panel shows APP23 Control, the centre panel 
APP23 (lower) and WT (top) Surgery d 7 at x20 and the right panel x40 detail of part 
of the same image.  
The figure illustrates that at d 7 APP23 Surgery show higher IBA-1 expression than 
WT Surgery, and the microglia show a more activated phenotype.  
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Appendix 16: Astrocyte activation in APP23 and WT hippocampus 
 
This plate of images illustrates immunochemistry using GFAP antibody (co-stained 
with PECAM and Hoechst) on hippocampal slices of male APP23 and WT mice 16 – 
18 weeks of age on d 1 and d 7 after Surgery.  The left panel shows WT Control, the 
right panel shows APP23 Surgery (bottom) and WT Surgery (top) on d 1 and 7.   
The figure illustrates in WT Control astrocyte processes surrounding a blood vessel.  
After Surgery, in WT the processes retain a fine, slender morphology on both d 1 and 
7.  In APP23 GFAP signal is brighter overall and the astrocyte processes are fine on 
d 1 but thickened on d 7 (arrowed). 
All images at x20 magnification. 
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Appendix 17: A expression in APP23 and WT hippocampus 
 
This plate of images illustrates immunochemistry using 6E10 antibody on hippocampal 
slices of male APP23 and WT mice 16 – 18 weeks of age.  The top row shows WT 
and APP23 Control and the bottom row APP23 Surgery on d 1 and 7.   
The figure illustrates the low 6E10 signal in WT Control and a stronger signal in APP23 
Control.  After Surgery signal is much brighter in APP23 on d 1, and on d 7 is reduced 
but appears more speckled, and plaque like. 
All images at x20 magnification. 
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Appendix 18: A plaque and microglia in APP23 hippocampus 
 
This plate of images illustrates immunochemistry using IBA-1 antibody (red) co-
stained with Thioflavin-S (green) on hippocampal slices of male APP23 mice 16 – 18 
weeks of age.  The right column shows APP23 Control, the centre column APP23 
Surgery d 7 and the right column a detail of the central image. The top row shows CA-
1 region and the bottom row subiculum. 
The figure illustrates that Aβ plaque and microglia are seen in both CA-1 and 
subiculum in APP23 Control.  The amount of plaque is much increased in APP23 
Surgery d 7.  White arrows point to microglia which show an activated phenotype and 
are in close proximity to the Aβ plaque which they have endocytosed.  Blue arrow 
points to dark areas occupied by unstained neuronal bodies. 
Images taken on confocal microscope with digital magnification + x20 or x40. 
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Appendix 19: Cytochrome c expression in mouse brain after Surgery using 
the early model 
 
  
  
490 
This figure illustrates normalised WB for protein of tissue lysates from mouse brain 
with cytochrome c antibody.  Mice were killed 24 h after either Anaesthesia or Surgery.  
The x-axis represents the group and the y-axis the fold change in MPI compared to 
genotype specific Control.  A illustrates data from females and B data from males. 
A downward trend in cytochrome c was seen in WT female and APP23 male after both 
Anaesthesia and Surgery.  This was thought to be secondary to inadvertent 
perioperative hypothermia.  
Data are presented as Mean ± SD. n numbers per group are illustrated in the figure.  
Statistical analysis was not performed due to the small n numbers. 
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Appendix 20: Cox 2 expression in mouse brain after Surgery using the early model. 
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This figure illustrates normalised WB for protein of tissue lysates from mouse brain with COX-2 antibody.  Mice were killed 24 h after either 
Anaesthesia or Surgery.  The x-axis represents the group and the y-axis the fold change in MPI compared to genotype specific Control. 
In both Anaesthesia and Surgery a reduction in Cox 2 expression was seen in both APP23 and WT.  This was thought to be secondary to 
inadvertent perioperative hypothermia.  
Data are presented as Mean ± SD, F5 16= 5, p = 0.0059. ** means p < 0.0059, derived using one-way ANOVA. n numbers per group are 
illustrated in the figure.    
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Appendix 21: GFAP immunofluoresence in the hippocampal fissure after surgery 
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This figure illustrates MPI of GFAP antibody immunochemistry in APP23 and WT mouse hippocampal fissure.  The x-axis represents the day 
post modifiable risk factor and the y-axis the MPI for GFAP 
The trend lines illustrate that GFAP expression in the Hippocampal fissure is increased in both APP23 (continuous line) and WT (dotted line) at 
d 1 post modifiable risk factor.  At d 7, expression has resolved to baseline in WT, but continues to increase in APP23 (AUC WT = 86, AUC 
APP23 = 110). 
Illustrative immunochemistry images show major branch vessels emanating from the hippocampal fissure (PECAM, red).  Arrows contrast the 
fine astrocyte processes (GFAP, green) surrounding the blood vessels in APP23 brain on d 1 with the thickened processes seen on d 7. 
Data are presented as mean ± SEM, n = 3 per data point.   All at x20 magnification. 
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Appendix 22: Soluble A in APP23 Males 
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This figure illustrates WB for protein from whole brain homogenate of male APP23 13 – 18 weeks of age using 6E10 antibody.  Mice were killed 
24 hours after exposure to the modifiable risk.  The x-axis represents the group and the y-axis represents MPI.  AW means active warming.   
This scatter dot plot illustrates a downward trend in amyloid beta expression after introduction of the modified risk.  
All data presented and mean ± SD. p value not calculated due to small group numbers, n numbers per group are illustrated in the figure. 
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Appendix 23: 6E10 and Thioflavin quantification:  early data 
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This figure illustrates A quantification in mouse brain using A:  WB of mouse brain cortex lysates 
with 6E10 Antibody, and B:  Thioflavin staining of mouse hippocampus. 
A: The x-axis represents the group (genotype and intervention) and the y-axis represents the 
mean change in pixel intensity compared to genotype specific Control. 
B: The x-axis represents the group and the y-axis Thioflavin stain as % subiculum area. 
A: This scatter plot illustrates that in mice killed at 24 hour after introducing the modifiable risk 
factor using the early model, exposure to anaesthesia and to the modifiable risk factor 
(Anaesthesia + Surgery) reduced the mean amount of A detected using 6E10 antibody in 
both APP23 and WT, when compared to Control. 
B: This scatter plot illustrates that in APP23 mice killed at d 7 and 14 using the early model, 
the % subiculum stained by Thioflavin is increased.  This % subiculum stained by Thioflavin 
at d 14 after introducing the modifiable risk factor in mice receiving Statin is similar to Control. 
Data are presented as mean ± SD, A:  F5 13= 5, p = 0.0088; B:  F3 9= 22, p = 0.0002.  p values 
derived using one-way ANOVA with post hoc Bonferroni's Multiple Comparison Test. * means p 
< 0.05 and ** means p < 0.01. n numbers per group are illustrated in the figure.    
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Appendix 24: APP expression in H4-APP cells 
 
This plate of images illustrates immunochemistry on H4-APP cells after 6 h 
exposure to 0.8 μM Aβ with 2% isoflurane.  The left column represents Control 
and the right Aβ+Isoflurane.  The top row shows greyscale and the bottom row 
colour versions of the same image.   
The figure illustrates that the distribution and intensity of the APP signal is 
different after exposure to Aβ+Isoflurane.   
 
Magnification x20.  
